

=> fil reg; d stat que 17; d que nos 115; fil capl; s 115; fil uspatf; s 115
FILE 'REGISTRY' ENTERED AT 14:39:04 ON 30 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 29 APR 2002 HIGHEST RN 409058-68-0
DICTIONARY FILE UPDATES: 29 APR 2002 HIGHEST RN 409058-68-0

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L4

STR



L4 STR
L7 771 SEA FILE=REGISTRY SSS FUL L4
L9 1916 SEA FILE=REGISTRY ABB=ON C18H18N2O3/MF OR C18H18N2O3.BRH/MF
L10 1973 SEA FILE=REGISTRY ABB=ON C18H18N2O3.CLH/MF OR C18H18N2O3.K/MF
OR C18H18N2O3.NA/MF OR L9
L11 14 SEA FILE=REGISTRY ABB=ON L7 AND L10
L12 3074 SEA FILE=REGISTRY ABB=ON 1H PYRROLE 3 PROPANOIC ACID
L13 9 SEA FILE=REGISTRY ABB=ON L11 AND L12
L14 70130 SEA FILE=REGISTRY ABB=ON 2 4 DIMETHYL
L15 3 SEA FILE=REGISTRY ABB=ON L13 AND L14



FILE 'CAPLUS' ENTERED AT 14:39:05 ON 30 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Apr 2002 VOL 136 ISS 18
FILE LAST UPDATED: 29 Apr 2002 (20020429/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

L16 10 L15

FILE 'USPATFULL' ENTERED AT 14:39:05 ON 30 APR 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 25 Apr 2002 (20020425/PD)
FILE LAST UPDATED: 25 Apr 2002 (20020425/ED)
HIGHEST GRANTED PATENT NUMBER: US6378132
HIGHEST APPLICATION PUBLICATION NUMBER: US2002049999
CA INDEXING IS CURRENT THROUGH 25 Apr 2002 (20020425/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 25 Apr 2002 (20020425/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2002
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2002

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<

>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

L17 6 L15

=> dup rem l16,l17
FILE 'CAPLUS' ENTERED AT 14:39:14 ON 30 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:39:14 ON 30 APR 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L16
PROCESSING COMPLETED FOR L17

L18 16 DUP REM L16 L17 (0 DUPLICATES REMOVED)
ANSWERS '1-10' FROM FILE CAPLUS
ANSWERS '11-16' FROM FILE USPATFULL

=> d ibib abs hitstr l18 1-16; fil cao; s l15

L18 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:184907 CAPLUS
DOCUMENT NUMBER: 136:241643
TITLE: Exemestane as chemopreventing agent
INVENTOR(S): Di Salle, Enrico; Piscitelli, Gabriella; Massimini,
Giorgio; Purandare, Dinesh; Martini, Alessandro;
Muggetti, Lorena
PATENT ASSIGNEE(S): Pharmacia + Upjohn S.p.A., Italy; Pharmacia + Upjohn
Company
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|---|----------|-----------------|----------|
| WO 2002020020 | A1 | 20020314 | WO 2001-EP10172 | 20010831 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, | | | |

US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-658052 A 20000908


AB The present invention concerns the use of aromatase inhibitor exemestane, either alone or in combination with other therapeutic agents, in the chemoprevention of estrogen dependent cancer in mammals, including humans, at increased risk of the disease. Exemestane treatment (4, 20 or 100 mg/kg/wk, IM), started 1 wk after dimethylbenzanthracene (DMBA) exposure (20 mg/rat, PO) and continued for 19 wk, significantly decreased tumor incidence from 85 % in vehicle treated rats to 13.6 % in the 100 mg/kg treated group. Moreover, exemestane at 100 mg/kg reduced significantly the tumor multiplicity, being 2.55 the no. of tumors/rat in the control groups vs. 0.27 in the treated group. No signs of toxicity were obsd.

IT 245036-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination; exemestane as chemopreventing agent for estrogen-dependent cancer)

RN 245036-27-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:89818 CAPLUS

DOCUMENT NUMBER: 136:139851

TITLE: Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs

INVENTOR(S): Gao, Ping; Morozowich, Walter; Shenoy, Narmada

PATENT ASSIGNEE(S): Pharmacia + Upjohn Company, USA; Sugen, Inc.

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2002007712 | A2 | 20020131 | WO 2001-US23140 | 20010720 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |

PRIORITY APPLN. INFO.: US 2000-220376P P 20000724
OTHER SOURCE(S): MARPAT 136:139851
AB A self-emulsifying drug delivery system for extremely water-insol.,
lipophilic compds. is disclosed. Self-emulsifying drug delivery systems
contg. PVP achieved 10-15% oral bioavailability of 3-[(2,4-dimethylpyrrol-
5-yl)methylene]-2-indolinone compared to tablet and oil suspension
formulations showing only 0-1% bioavailability.
IT 245036-27-5
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(self-emulsifying drug delivery systems for extremely water-insol.
lipophilic drugs)
RN 245036-27-5 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L18 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:868449 CAPLUS
DOCUMENT NUMBER: 136:5902
TITLE: Preparation of prodrugs of 3-(pyrrol-2-ylmethylidene)-
2-indolinones as ~~modulators of protein kinase~~
~~activity.~~
INVENTOR(S): Moon, Malcolm Wilson; Morozowich, Walter; Gao, Ping;
Koenig, Marcel
PATENT ASSIGNEE(S): Sugen, Inc., USA; Pharmacia + Upjohn Company
SOURCE: PCT-Int.-Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------------------------|-----------------|----------|
| WO 2001090103 | A2 | 20011129 | WO 2001-US16741 | 20010524 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2002032204 | A1 | 20020314 | US 2001-863804 | 20010524 |
| US 2002035140 | A1 | 20020321 | US 2001-863905 | 20010524 |
| US 2002037878 | A1 | 20020328 | US 2001-863819 | 20010524 |
| PRIORITY APPLN. INFO.: | | US 2000-207000P P 20000524 | | |
| | | US 2000-225045P P 20000811 | | |
| OTHER SOURCE(S): | | MARPAT 136:5902 | | |
| GI | | | | |



I

AB Title compds. [I; R3-R6 = H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, OH, alkoxy, aryloxy, SH, alkylthio, arylthio, etc.; .gtoreq.2 of R3-R6 = H; R3R4, R4R5, R5R6 = atoms to form aryl ring, OCH2O, OCH2OCH2; R7 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, OH, alkoxy, aryloxy, etc.; R8-R10 = H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, OH, alkoxy, aryloxy, SH, arylthio, etc.; Q = CHR11OR21, COR51, OP(O)(ORa)(ORb); R11 = H, alkyl; R21 = H, alkyl, aralkyl, acyl; R51 = alkyl; Ra, Rb = H, alkyl], were prep'd. as prodrugs for modulators of protein kinase activity (no data). Thus, 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylidene)-1,3-dihydroindol-2-one was stirred 1 h with aq. H2CO and Et3N in DMF to give (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1-hydroxymethyl-1,3-dihydro-2H-indol-2-one.


IT 210644-62-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinones as modulators of protein kinase activity)

RN 210644-62-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L18 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:507531 CAPLUS

DOCUMENT NUMBER: 135:107247

TITLE: Preparation of 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

INVENTOR(S): Langecker, Peter J.; Shawver, Laura K.; Tang, Peng C.; Sun, Li

PATENT ASSIGNEE(S): Sugan, Inc., USA

SOURCE: PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| WO 2001049287 | A1 | 20010712 | WO 2000-US18058 | 20000630 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| WO 2000038519 | A1 | 20000706 | WO 1999-US31232 | 19991230 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRIORITY APPLN. INFO.: | | | US 1999-476232 | A 19991230 |
| | | | WO 1999-US31232 | A 19991230 |
| | | | US 2000-569545 | A 20000512 |
| | | | US 1998-114313P | P 19981231 |

OTHER SOURCE(S): MARPAT 135:107247
GI



AB The present invention relates to 3-heteroarylidene-2-indolinone compds. [I; R1 = H, alkyl; R2 = O, S; R3 = H; R4, R5, R6, R7 = H, alkyl, alkoxy, aryl, aryloxy, alkaryloxy, halo, trihalomethyl, S(O)R, SO2NRR', SO3R, SR, NO2, NRR', OH, cyano, COR, O2CR, (CH2)nCO2R, CONRR'; A = a five membered heteroaryl selected from (un)substituted thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3,4-oxatriazole, 1,2,3,5-oxatriazole, 1,2,3-thiadiazole, etc.; n = 0-3; R, R' = H, alkyl, aryl] or physiol. acceptable salts or prodrugs thereof are prepd. These compds. modulate the enzymic activity of protein kinases such as receptor protein tyrosine kinase, cellular tyrosine kinase, and serine threonine kinase and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. Furthermore, these compds. are expected to enhance the efficacy of other chemotherapeutic agents, in particular, fluorinated pyrimidines, in the treatment of cancer. In a cellular-based assay for inhibiting the receptor phosphorylation, 3-[(2,4-dimethylpyrrol-5-yl)methylidene]-2-indolinone (II) inhibited Flk-1-autophosphorylation with IC50 of .apprx.1 .mu.M. II in vitro inhibited proliferation of endothelial cells induced

by VEGF with IC50 of .apprx.0.07 .mu.M. Although II in vitro had no direct inhibitory effect on a variety of tumor cell lines at concn. up to 50 .mu.M, it in vivo demonstrated a significant suppression of tumor growth against a broad spectrum of tumor types s.c. implanted into immunocompromised mice and whose growth are driven by various growth factors such as PDGF, EGF, and Her2.


IT 245036-27-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 3-heteroarylidenyl-2-indolinone compds. for modulating protein kinase activity for cancer chemotherapy)

RN 245036-27-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:472477 CAPLUS

DOCUMENT NUMBER: 135:56059

TITLE: Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds

INVENTOR(S): Lipson, Ken; McMahon, Gerald

PATENT ASSIGNEE(S): Sugén, Inc., USA

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2001045689 | A2 | 20010628 | WO 2000-US35009 | 20001222 |
| WO 2001045689 | A3 | 20020103 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002010203 A1 20020124 US 2000-741842 20001222

PRIORITY APPLN. INFO.: US 1999-171693P P 19991222

OTHER SOURCE(S): MARPAT 135:56059

AB The invention concerns indolinone compds. and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity of c-kit kinase.


IT 245036-27-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(indolinone derivs. for c-kit tyrosine protein kinase function modulation)

RN 245036-27-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L18 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:396655 CAPLUS

DOCUMENT NUMBER: 135:19549

TITLE: Preparation of pyrrole substituted 2-indolinones as antitumor agents

INVENTOR(S): Shenoy, Narmada; Sorasuchart, Waranush

PATENT ASSIGNEE(S): Sugen, Inc., USA

SOURCE: PCT Int. Appl., 249 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2001037820 | A2 | 20010531 | WO 2000-US32277 | 20001122 |
| WO 2001037820 | A3 | 20011213 | | |


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-167544P A1 19991124

OTHER SOURCE(S): MARPAT 135:19549

GI



I

AB The title compds. [I; R1 = H, alkyl, alkenyl, etc.; R2 = H, halo, alkyl, etc.; R3-R6 = H, alkyl, trihaloalkyl, etc.; R3 and R4, R4 and R5, R5 and R6 may combine to form a six membered aryl ring, OCH2O, OCH2CH2O; R7 = H, alkyl, cycloalkyl, etc.; R8-R10 = H, alkyl, trihaloalkyl, etc.] were prepd. and formulated. E.g., a multi-step synthesis of I [R1-R7 = H; R8, R10 = Me; R9 = (CH2)2CO2H] which showed 79-86% inhibition of tumor growth of Calu-6 cells in mice at 75 and 100 mg/kg/day, was given. The present invention features formulations of indolinones which compds. are ionizable as free acids or free bases. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an ionizable substituted indolinone, and a pharmaceutically acceptable carrier therefor. ~~The term "ionizable substituted indolinone" includes pyrrole substituted 2-indolinones I which, in addn. to being otherwise optionally substituted on both the pyrrole and 2-indolinone portions of the compd., are necessarily substituted on the pyrrole moiety with one or more hydrocarbon chains which themselves are substituted with at least one polar group.~~


IT 245036-27-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

(prepn. of pyrrole substituted 2-indolinones as antitumor agents)

RN 245036-27-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




IT 251356-54-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrrole substituted 2-indolinones as antitumor agents)

RN 251356-54-4 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na

L18 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:456819 CAPLUS

DOCUMENT NUMBER: 133:84238

TITLE: 3-heteroarylidenyl-2-indolinone compounds for
modulating protein kinase activity and for use in
cancer chemotherapyINVENTOR(S): Langecker, Peter J.; Shawver, Laura Kay; Tang, Peng
Cho; Sun, Li

PATENT ASSIGNEE(S): Sugan, Inc., USA

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2000038519 | A1 | 20000706 | WO 1999-US31232 | 19991230 |
| W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| BR 9916735 | A | 20010925 | BR 1999-16735 | 19991230 |
| EP 1139754 | A1 | 20011010 | EP 1999-966725 | 19991230 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |
| WO 2001049287 | A1 | 20010712 | WO 2000-US18058 | 20000630 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| PRIORITY APPLN. INFO.: | | | US 1998-114313P | P 19981231 |
| | | | US 1999-476232 | A 19991230 |
| | | | WO 1999-US31232 | W 19991230 |
| | | | US 2000-569545 | A 20000512 |

OTHER SOURCE(S): MARPAT 133:84238

AB 3-Heteroarylidenyl-2-indolinone compds. are provided that modulate the
enzymic activity of protein kinases and therefore are expected to be

useful in the prevention and treatment of protein kinase-related cellular disorders, e.g. cancer. Furthermore, these compds. are expected to enhance the efficacy of other chemotherapeutic agents, in particular, fluorinated pyrimidines, in the treatment of cancer.


IT 245036-27-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(heteroarylidenylindolinone derivs. for modulating protein kinase activity and in cancer chemotherapy)

RN 245036-27-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:764021 CAPLUS

DOCUMENT NUMBER: 132:12257

TITLE: Preparation of pyrrole substituted-2-indolinone protein kinase inhibitors

INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald

PATENT ASSIGNEE(S): Sugen, Inc., USA

SOURCE: PCT Int. Appl., 240 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 9961422 | A1 | 19991202 | WO 1999-US12069 | 19990528 |
| W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2314156 | AA | 19991202 | CA 1999-2314156 | 19990528 |
| AU 9944102 | A1 | 19991213 | AU 1999-44102 | 19990528 |
| EP 1082305 | A1 | 20010314 | EP 1999-927120 | 19990528 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |
| BR 9910792 | A | 20020129 | BR 1999-10792 | 19990528 |
| NO 2000005916 | A | 20010129 | NO 2000-5916 | 20001122 |
| PRIORITY APPLN. INFO.: | | | US 1998-87310P | P 19980529 |
| | | | US 1999-116106P | P 19990115 |
| | | | WO 1999-US12069 | W 19990528 |

OTHER SOURCE(S): MARPAT 132:12257

GI



I



II


AB The present invention relates to 5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-ylalkanoic acid derivs. (I) [where R1 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, aryl, OH, alkoxy, carboxy, acetyl, (thio)amido, (trihalomethane)sulfonyl, etc.; R2 = H, halo, (cyclo)alkyl, (hetero)aryl, or heteroalicyclic; R3, R4, R5, R6, R8, R9, R10 = independently H, (cyclo)alkyl, trihaloalkyl, alkenyl, alkynyl, (hetero)aryl(oxy), heteroalicyclic, OH, alkoxy, SH, alkylthio, arylthio, sulfinyl, sulfonyl, sulfonamido, carbonyl, carboxy, amido, CN, NO2, halo, (thio)carbonyl, (un)substituted amino, etc.] which modulate the activity of protein kinases and are useful in the prevention and treatment of protein kinase related cellular disorders, such as cancer. Thus, 2,4-dimethyl-5-ethoxycarbonyl-3-(2-ethoxycarbonylethyl)pyrrole was deprotected using NaOH to form 3-(2-carboxyethyl)-2,4-dimethylpyrrole (100%) and the product C-5 formylated (two methods given for 86% and 90% yield, resp.). Reaction with 2-oxindole in EtOH and pyrrolidine or in aq. NaOH yielded II (88% and 91%, resp.), which reduced the av. size of C6 human glioma and melanoma tumors s.c. implanted in mice by 80-85%. II, when administered orally, demonstrated notably superior efficacy compared to structurally similar analogs.

IT 245036-27-5P 251356-54-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of 5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-ylalkanoic acid protein kinase inhibitors as antitumor agents)

RN 245036-27-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 251356-54-4 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:626172 CAPLUS

DOCUMENT NUMBER: 131:257441

TITLE: Heterocyclic families of compounds [tricyclic-based indolinones and pyrazolecarboxylic acid amides] for the modulation of tyrosine protein kinase

INVENTOR(S): Fong, Annie; Hannah, Alison; Harris, David G.; Hirth, Peter; Hubbard, Steven R.; Langecker, Peter; Liang, Congxin; McMahon, Gerald; Mohammadi, Moosa; Schlessinger, Joseph; Shawver, Laura K.; Sun, Li; Tang, Peng C.; Ullrich, Axel

PATENT ASSIGNEE(S): Sugen, Inc., USA; New York University; Max-Planck Institut fur Biochemie

SOURCE: PCT Int. Appl., 269 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|----------|-----------------|----------|
| WO 9948868 | A2 | 19990930 | WO 1999-US6468 | 19990326 |
| WO 9948868 | A3 | 20000224 | | |

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|------------|----|----------|-----------------|----------|
| CA 2325935 | AA | 19990930 | CA 1999-2325935 | 19990326 |
| AU 9933635 | A1 | 19991018 | AU 1999-33635 | 19990326 |
| EP 1066257 | A2 | 20010110 | EP 1999-915018 | 19990326 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

| | | | | |
|---------------|----|----------|----------------|----------|
| JP 2002507598 | T2 | 20020312 | JP 2000-537851 | 19990326 |
|---------------|----|----------|----------------|----------|

PRIORITY APPLN. INFO.:

| | | |
|----------------|---|----------|
| US 1998-79713P | P | 19980326 |
| US 1998-80422P | P | 19980402 |
| US 1998-81792P | P | 19980415 |
| US 1998-82056P | P | 19980416 |
| US 1998-89397P | P | 19980615 |
| US 1998-89521P | P | 19980616 |
| US 1998-98783P | P | 19980901 |
| WO 1999-US6468 | W | 19990326 |

OTHER SOURCE(S): MARPAT 131:257441
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to certain ~~indolinone-based and pyrazolylamide-based~~ compds., I and II, their method of ~~synthesis, and combinatorial libraries~~ consisting of the compds. [wherein AB = atoms to make up 1-2 fused and/or connected rings; R = arom. or heteroarom. ring which may form an addnl. ring by cyclization to the methylene group; R1, R2 = H, alkyl, (hetero)aryl or -aliph. ring, amino, NO2, halo, etc.; R3 = (un)substituted Ph; Z = (un)substituted (CH2)0-3; R4, R5 = H, alkyl, (hetero)aryl or -aliph., amine, ketone, etc.]. The invention also relates to methods of modulating the function of protein kinases using these compds., and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways. Data for prepn. and/or biol. activity are given, as well as the prepn. of various oxindole intermediates. For instance, the pyrazolecarboxamide deriv. III gave up to 70% inhibition of growth of Calu-6 human lung carcinoma cells as a xenograft in mice. As another example, the indolinone deriv. IV was prepd. by condensation of 6-(4-methoxyphenyl)-2-oxindole with 3,5-dimethyl-1H-pyrrole-2-carboxaldehyde in the presence of piperidine. Extensive tests of a few selected compds. against a variety of protein kinases are described.

IT 245036-27-5P, 3-[2,4-Dimethyl-5-[(2-oxo-1,2-dihydroindol-3-ylidene)methyl]-1H-pyrrol-3-yl]propionic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of pyrazolecarboxylic acid amides and (arylmethylene)indolinones as protein tyrosine kinase modulators)

RN 245036-27-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L18 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:757553 CAPLUS

DOCUMENT NUMBER: 132:137242

TITLE: Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases

AUTHOR(S): Sun, Li; Tran, Ngoc; Liang, Congxin; Tang, Flora; Rice, Audie; Schreck, Randall; Waltz, Kara; Shawver, Laura K.; McMahon, Gerald; Tang, Cho

CORPORATE SOURCE: SUGEN Inc., South San Francisco, CA, 94080-4811, USA

SOURCE: Journal of Medicinal Chemistry (1999), 42(25), 5120-5130

CODEN: JCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB ~~Receptor tyrosine kinases (RTKs) were implicated as therapeutic targets for the treatment of human diseases including cancers, inflammatory diseases, cardiovascular diseases including arterial restenosis, and fibrotic diseases of the lung, liver, and kidney.~~ Three classes of 3-substituted 2-indolinones contg. propanoic acid functionality attached to the pyrrole ring at the C-3 position of the core were identified as catalytic inhibitors of the vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) RTKs. Some of the compds. were found to inhibit the tyrosine kinase activity assocd. with isolated vascular endothelial growth factor receptor 2 (VEGF-R2) [fetal liver tyrosine kinase 1 (Flk-1)/kinase insert domain-contg. receptor (KDR)], fibroblast growth factor receptor (FGF-R), and platelet-derived growth factor receptor (PDGF-R) tyrosine kinase with IC50 values at nanomolar level. Thus, SU 5402 [5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-Pyrrole-3-propanoic acid] showed inhibition against VEGF-R2 (Flk-1/KDR) and FGF-R1 tyrosine kinase activity with IC50 values of 20 and 30 nM, resp., while 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid inhibited the PDGF-R tyrosine kinase activity with IC50 value of 10 nM. Structural models and structure-activity relationship anal. of these compds. for the target receptors are discussed. The cellular activities of these compds. were profiled using cellular proliferation assays as measured by bromodeoxyuridine (BrdU) incorporation. Specific and potent inhibition of cell growth was obsd. for some of these compds. These data provide evidence that these compds. can be used to inhibit the function of these target receptors.


IT 245036-27-5P, 5-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-Pyrrole-3-propanoic acid

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and evaluation of [(dihydrooxoindolylidene)methyl]pyrrolepropanoic acid as tyrosine kinase inhibitors)

RN 245036-27-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 16 USPATFULL

ACCESSION NUMBER: 2002:17323 USPATFULL
TITLE: Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
INVENTOR(S): Lipson, Ken, San Mateo, CA, UNITED STATES
McMahon, Gerald, Kenwood, CA, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2002010203 | A1 | 20020124 |
| APPLICATION INFO.: | US 2000-741842 | A1 | 20001222 (9) |


| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 1999-171693P | 19991122 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | John P. Isacson, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109 | |

NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1762
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 245036-27-5
(indolinone derivs. for c-kit tyrosine protein kinase function modulation)
RN 245036-27-5 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



*Dwayne,
Answers 12-16 are
très bizarre. I've
asked the STN Help
Desk about it. Will
forward their reply, didn't
want to hold up results*

L18 ANSWER 12 OF 16 USPATFULL

ACCESSION NUMBER: 2001:83308 USPATFULL
TITLE: Monolithic 3D radial power
INVENTOR(S): Stones, David I., Torrance,
Lee, Alfred E., Torrance,
PATENT ASSIGNEE(S): TRW Inc., Redondo Beach,
corporation)

*writing for reply.
(What do canopy beds
& protein kinase
modulators have in
common? !?)*

| NUMBER | KIND |
|--------|------|
| | Barb |


PATENT INFORMATION: US 6242984 B1 20010605
APPLICATION INFO.: US 1998-80422 19980518 (9)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lee, Benny
LEGAL REPRESENTATIVE: Yatsko, Michael S.
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1,2,3,4
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 500

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An SSPA module in accordance with the present invention comprises a signal input (102), and a ~~radial~~ splitter (100) connected to the signal input (102) comprising a plurality of radially extending splitter waveguides 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126. The SSPA module also includes a signal output (202), and a radial combiner (200) connected to the signal output (202) comprising a plurality of radially extending combiner waveguides 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226. Connections between the splitter (100) and combiner (200) are provided by a plurality of vertically extending waveguides 404, 406, 408, 410, 412, 414, 416, 418, 420, 422, 424, 426. The SSPA module also includes a plurality of processing circuits 304, 308, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, for example MMIC amplifiers, connected to the combiner waveguides 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226. A waveguide to microstrip transition (510) may also be used to connect signals propagating in the waveguides to and from microstrip lines connected to the processing circuitry (304-326). Generally, the transition (510) includes a waveguide section (512) with a top conducting layer (516) that defines a first slit (526) and a second slit (528) bounding a transition area (530) abutting a microstrip section (514) to form a waveguide to microstrip transition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 245036-27-5P, 3-[2,4-Dimethyl-5-[(2-oxo-1,2-dihydroindol-3-ylidene)methyl]-1H-pyrrol-3-yl]propionic acid
(target compd.; prepn. of pyrazolecarboxylic acid amides and (arylmethylene)indolinones as protein tyrosine kinase modulators)
RN 245036-27-5 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L18 ANSWER 13 OF 16 USPATFULL
ACCESSION NUMBER: 2001:15039 USPATFULL
TITLE: Variable delay circuit and semiconductor intergrated circuit device
INVENTOR(S): Yamazaki, Masafumi, Kawasaki, Japan
Tomita, Hiroyoshi, Kawasaki, Japan
PATENT ASSIGNEE(S): Fujitsu Limited, Kawasaki, Japan (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6181184 B1 20010130
APPLICATION INFO.: US 1998-89397 19980603 (9)

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | JP 1997-203315 | 19970729 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Cunningham, Terry D. | |
| ASSISTANT EXAMINER: | Tra, Quan | |
| LEGAL REPRESENTATIVE: | Armstrong, Westerman, Hattori, McLeland, & Naughton | |
| NUMBER OF CLAIMS: | 4 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 46 Drawing Figure(s); 44 Drawing Page(s) | |
| LINE COUNT: | 2911 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A variable delay circuit includes a load on a signal transfer line, at least one transistor connected to the signal transfer line. Each transistor is controlled by a gate voltage, thereof so that a signal on the signal transfer line is delayed in response to a magnitude of the gate capacitance connected thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 245036-27-5P, 3-[2,4-Dimethyl-5-[(2-oxo-1,2-dihydroindol-3-ylidene)methyl]-1H-pyrrol-3-yl]propionic acid
(target compd.; prepn. of pyrazolecarboxylic acid amides and (arylmethylene)indolinones as protein tyrosine kinase modulators)

RN 245036-27-5 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L18 ANSWER 14 OF 16 USPATFULL

ACCESSION NUMBER: 2000:90153 USPATFULL

TITLE: System for automatic inspection and ejection of cartons in a packaging machine

INVENTOR(S): Robinson, Glenn, Alpharetta, GA, United States
Potteiger, Thomas M., Powder Springs, GA, United States
Jacob, Jeffrey G., Gainesville, GA, United States

PATENT ASSIGNEE(S): The Mead Corporation, Dayton, OH, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 6088995 | | 20000718 |
| APPLICATION INFO.: | US 1998-98783 | | 19980617 (9) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Coan, James F. | | |
| LEGAL REPRESENTATIVE: | Drew, Michael V. | | |
| NUMBER OF CLAIMS: | 4 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 13 Drawing Figure(s); 8 Drawing Page(s) | | |

LINE COUNT: 355

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A system for automatic inspection and ejection of cartons in a packaging machine includes detection elements (20, 22) for determining whether a carton (C) has assumed a predetermined configuration at a predetermined point in its path of travel. Carton ejection elements include rollers (30, 32) which are actuated to eject a carton (C) when the detection elements (20) determine that the carton has not assumed the predetermined configuration at the predetermined point in its path of travel. A synchronous relationship between a flow of cartons (C) and a flow of groups of articles (G) to be packaged is preserved at and as cartons leave the carton inspection and ejection station of a packaging machine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 245036-27-5P, 3-[2,4-Dimethyl-5-[(2-oxo-1,2-dihydroindol-3-ylidene)methyl]-1H-pyrrol-3-yl]propionic acid
(target compd.; prepn. of pyrazolecarboxylic acid amides and (arylmethylene)indolinones as protein tyrosine kinase modulators)

RN 245036-27-5 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L18 ANSWER 15 OF 16 USPATFULL

ACCESSION NUMBER: 2000:79392 USPATFULL

TITLE: Valve-timing controller for an internal combustion engine

INVENTOR(S): Morikawa, Junya, Toyota, Japan

PATENT ASSIGNEE(S): Denso Corporation, Japan (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|---------------|------|--------------|
| PATENT INFORMATION: | US 6079381 | | 20000627 |
| APPLICATION INFO.: | US 1998-81792 | | 19980520 (9) |

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | JP 1997-131341 | 19970521 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Lo, Weilun | |
| LEGAL REPRESENTATIVE: | Nixon & Vanderhye PC | |
| NUMBER OF CLAIMS: | 21 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 18 Drawing Figure(s); 7 Drawing Page(s) | |
| LINE COUNT: | 734 | |


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A system and method for determining abnormality of a VVT (variable valve-timing control mechanism) and controlling the VVT on consideration of responsiveness thereof. When execution conditions for abnormality determination of the VVT are present, speed of change in angle of rotation ACSPD is calculated on a basis of transition in actual angle of

rotation of the VVT as a responsiveness-detection parameter. In the abnormality determination, if the speed of change in angle of rotation ACS PD is less than a programmed determination value, it is determined that followup of VVT operation is faulty, and an abnormality-determination flag XVTFail is set to "1" to indicate that some abnormality has occurred. Also, a warning light is placed in an illuminated state. Target relative angle of rotation of the VVT is appropriately established, and VVT operation is suppressed on the basis of this abnormality determination. As a result, drivability and emissions performance degradation can be suppressed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 245036-27-5P, 3-[2,4-Dimethyl-5-[(2-oxo-1,2-dihydroindol-3-ylidene)methyl]-1H-pyrrol-3-yl]propionic acid
(target compd.; prepn. of pyrazolecarboxylic acid amides and (arylmethylene)indolinones as protein tyrosine kinase modulators)
RN 245036-27-5 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



L18 ANSWER 16 OF 16 USPATFULL

ACCESSION NUMBER: 2000:6506 USPATFULL

TITLE: Fabric supporting ring fixtures for creating bed canopy and window drapery arrangements

INVENTOR(S): Harkinson, Greg, 12121 Veterans Memorial Dr., Ste. 2, Houston, TX, United States 77067

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 6015004 | | 20000118 |
| APPLICATION INFO.: | US 1998-87310 | | 19980529 (9) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Purol, David M. | | |
| LEGAL REPRESENTATIVE: | Roddy, Kenneth A. | | |
| NUMBER OF CLAIMS: | 9 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 14 Drawing Figure(s); 6 Drawing Page(s) | | |
| LINE COUNT: | 465 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Fabric supporting ring fixtures for use in creating bed canopy and window drapery arrangements. A corner ring fixture has a central body portion configured to be supported in a first plane from a support surface and a pair of fabric receiving ring elements each having an outer circumferential portion extending outwardly from the central body portion in a second plane different from the first plane. An intermediate ring fixture has a central body portion configured to be supported from a support surface and a fabric receiving ring element with an outer circumferential portion extending perpendicularly outward therefrom. The fabric receiving ring elements have a central circular opening sized to pass fabric and drapery materials therethrough and to support the fabric and drapery materials in decorative arrangements.

Typically, the corner ring fixtures are installed on a flat surface above a bed or window in spaced apart relation and allow a length of fabric material to be passed through its ring elements to selectively make a transition from a first horizontal plane to a second horizontal plane angularly offset therefrom or to make a transition from a horizontal plane to a vertical plane, and the intermediate ring fixtures are installed on a flat surface between the spaced apart corner ring fixtures to support lengths of fabric material passed through the corner ring fixtures.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 245036-27-5P 251356-54-4P

(target compd.; prepn. of 5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-ylalkanoic acid protein kinase inhibitors as antitumor agents)


RN 245036-27-5 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 251356-54-4 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na

FILE 'CAOLD' ENTERED AT 14:39:44 ON 30 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L19

0 L15

=> fil capl; d que nos 144; d que nos 145; s (144 or 145) not 116
FILE 'CAPLUS' ENTERED AT 14:53:38 ON 30 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Apr 2002 VOL 136 ISS 18
FILE LAST UPDATED: 29 Apr 2002 (20020429/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

L4 STR
L7 771 SEA FILE=REGISTRY SSS FUL L4
L8 78 SEA FILE=CAPLUS ABB=ON L7
L27 1718 SEA FILE=CAPLUS ABB=ON KAPOSI?
L30 75998 SEA FILE=CAPLUS ABB=ON AIDS OR HIV OR (ACQUIRED OR HUMAN) (W) (I
MMUNE DEFICIEN? OR IMMUNODEFICIEN?)
L31 34379 SEA FILE=CAPLUS ABB=ON ?ATHEROSCLERO?
L32 12544 SEA FILE=CAPLUS ABB=ON ?ARTERIOSCLERO?
L44 12 SEA FILE=CAPLUS ABB=ON L8 AND (L27 OR L30 OR L31 OR L32)

=> d que nos 159; d que nos 160; s (144 or 159 or 160) not 116
L4 STR
L7 771 SEA FILE=REGISTRY SSS FUL L4
L8 78 SEA FILE=CAPLUS ABB=ON L7
L23 90833 SEA FILE=CAPLUS ABB=ON PROTEIN(1W)KINASE#
L24 86890 SEA FILE=CAPLUS ABB=ON ?DIABET?
L25 128272 SEA FILE=CAPLUS ABB=ON ANTITUMOR AGENTS+OLD/CT
L26 221118 SEA FILE=CAPLUS ABB=ON NEOPLAS?/CW
L28 8039 SEA FILE=CAPLUS ABB=ON ?PSORIA?
L29 32754 SEA FILE=CAPLUS ABB=ON ?ARTHRIT?
L59 19 SEA FILE=CAPLUS ABB=ON L8 AND L23 AND (L24 OR L25 OR L26 OR
L28 OR L29)

L4 STR
L7 771 SEA FILE=REGISTRY SSS FUL L4
L8 78 SEA FILE=CAPLUS ABB=ON L7
L24 86890 SEA FILE=CAPLUS ABB=ON ?DIABET?
L25 128272 SEA FILE=CAPLUS ABB=ON ANTITUMOR AGENTS+OLD/CT
L26 221118 SEA FILE=CAPLUS ABB=ON NEOPLAS?/CW
L28 8039 SEA FILE=CAPLUS ABB=ON ?PSORIA?

L29 32754 SEA FILE=CAPLUS ABB=ON ?ARTHRIT?
L58 66 SEA FILE=CAPLUS ABB=ON L8(L) (THU OR BAC OR PAC OR DMA OR
PKT)/RL
L60 46 SEA FILE=CAPLUS ABB=ON L58 AND (L24 OR L25 OR L26 OR L28 OR
L29)

Roles
THU - Therapeutic use

BAC - Biological activity

PAC - pharmacological activity

PKT - pharmacokinetics

DMA - drug mechanism of action

L63 41 (L44 OR L59 OR L60) NOT L16 *previously printed*

=> fil uspatf; d que nos l56

FILE 'USPATFULL' ENTERED AT 15:01:48 ON 30 APR 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 25 Apr 2002 (20020425/PD)

FILE LAST UPDATED: 25 Apr 2002 (20020425/ED)

HIGHEST GRANTED PATENT NUMBER: US6378132

HIGHEST APPLICATION PUBLICATION NUMBER: US2002049999

CA INDEXING IS CURRENT THROUGH 25 Apr 2002 (20020425/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 25 Apr 2002 (20020425/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2002

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2002

>>> ~~USPAT2 is now available. USPATFULL contains full text of the~~ <<<
>>> ~~original, i.e., the earliest published granted patents or~~ <<<
>>> ~~applications. USPAT2 contains full text of the latest US~~ <<<
>>> ~~publications, starting in 2001, for the inventions covered in.~~ <<<
>>> ~~USPATFULL. A USPATFULL record contains not only the original~~ <<<
>>> ~~published document but also a list of any subsequent~~ <<<
>>> ~~publications. The publication number, patent kind code, and~~ <<<
>>> ~~publication date for all the US publications for an invention~~ <<<
>>> ~~are displayed in the PI (Patent Information) field of USPATFULL~~ <<<
>>> ~~records and may be searched in standard search fields, e.g., /PN,~~ <<<
>>> ~~/PK, etc.~~ <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

L4 STR
L7 771 SEA FILE=REGISTRY SSS FUL L4
L46 336 SEA FILE=REGISTRY ABB=ON L7 AND USPATFULL/LC
L47 40 SEA FILE=USPATFULL ABB=ON L46
L48 6553 SEA FILE=USPATFULL ABB=ON PROTEIN(1W)KINASE#
L49 22995 SEA FILE=USPATFULL ABB=ON ?DIABET?
L50 72810 SEA FILE=USPATFULL ABB=ON ?TUMOR? OR ?TUMOUR? OR KAPOS? OR
?NEOPLAS? OR ?SARCOMA? OR ?CANCER?
L51 10525 SEA FILE=USPATFULL ABB=ON ?PSORIA?
L52 22380 SEA FILE=USPATFULL ABB=ON ?ARTHRIT?
L53 117125 SEA FILE=USPATFULL ABB=ON AIDS OR HIV OR (ACQUIRED OR
HUMAN) (W) (IMMUNE DEFICIENCY) OR IMMUNODEFICIENCY?
L54 15773 SEA FILE=USPATFULL ABB=ON ?ATHEROSCLERO? OR ?ARTERIOSCLERO?
L56 31 SEA FILE=USPATFULL ABB=ON L47 AND L48 AND (L49 OR L50 OR L51
OR L52 OR L53 OR L54)

=> s 156 not 117

L64 30 L56 NOT (L17) *previously printed*

=> dup rem 163,164

FILE 'CAPLUS' ENTERED AT 15:02:04 ON 30 APR 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:02:04 ON 30 APR 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

PROCESSING COMPLETED FOR L63

PROCESSING COMPLETED FOR L64

L65 70 DUP REM L63 L64 (1 DUPLICATE REMOVED)

ANSWERS '1-41' FROM FILE CAPLUS

ANSWERS '42-70' FROM FILE USPATFULL

=> d ibib abs hitstr 165 1-70; fil hom

L65 ANSWER 1 OF 70 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1

ACCESSION NUMBER: 2000:622463 CAPLUS

DOCUMENT NUMBER: 133:217719.

TITLE: 3-(Cyclohexanoheteroarylidenyl)-2-indolinone

protein tyrosine kinase inhibitors,

and their therapeutic use

INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Blake, Robert A.

PATENT ASSIGNEE(S): Sugen, Inc., USA

SOURCE: U.S., 61 pp., Cont. -in-part of U.S. Ser. No. 99,842.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|-------------|
| US 6114371 | A | 20000905 | US 1998-190970 | 19981112 |
| US 6130238 | A | 20001010 | US 1998-99842 | 19980619 |
| PRIORITY APPLN. INFO.: | | | US 1997-50977P | P 19970620 |
| | | | US 1997-59384P | P 19970919 |
| | | | US 1998-99842 | A2 19980619 |
| | | | US 1997-59544P | P 19970919 |

OTHER SOURCE(S): CASREACT 133:217719; MARPAT 133:217719


AB 3-(Cyclohexano-heteroarylidenyl)-2-indolinone compds., and physiol. acceptable salts and prodrugs thereof, are disclosed which are expected to modulate the activity of **protein tyrosine kinases** and therefore to be useful in the prevention and treatment of **protein tyrosine kinase**-related cellular disorders (cancer, **arthritis**, restenosis, etc.).

IT 245035-93-2 245036-08-2 245036-22-0 290821-16-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclohexanoheteroarylidenyl indolinone **protein tyrosine kinase inhibitors**, and therapeutic use)


RN 245035-93-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-(3-methoxyphenyl)-3-[(4,5,6,7-tetrahydro-3-methyl-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 245036-08-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-(4-methoxyphenyl)-3-[(4,5,6,7-tetrahydro-3-methyl-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 245036-22-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-(2-methoxyphenyl)-3-[(4,5,6,7-tetrahydro-3-methyl-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 290821-16-8 CAPLUS

CN 2H-Indol-2-one, 6-bromo-1,3-dihydro-3-[(4,5,6,7-tetrahydro-3-methyl-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 2 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220379 CAPLUS

DOCUMENT NUMBER: 136:268137

TITLE: ~~Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals~~

INVENTOR(S): Muggetti, Lorena; Martini, Alessandro; Buzzi, Giovanni; Colombo, Paolo
PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2002022134 | A1 | 20020321 | WO 2001-EP10398 | 20010907 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |

PRIORITY APPLN. INFO.: IT 2000-MI1984 A 20000912


AB The present invention relates to the use of arginine and, more in particular, to the injectable formulations for i.v. use comprising it, in the prevention and treatment of the side effects assocd. with the extravasation of drugs administered by i.v. route. A salt of estramustine phosphate with arginine was prepd.

IT 204005-46-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arginine in prepn. of a medicament for prevention and treatment of side effects assocd. with i.v. administration of pharmaceuticals)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 3 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:31440 CAPLUS

DOCUMENT NUMBER: 136:102386

TITLE: Preparation and use of 4-heteroaryl-3-heteroarylidényl-2-indolinones and their use as protein kinase inhibitors

INVENTOR(S): Tang, Peng Cho; Wei, Chung Chen; Huang, Ping; Cui, Jingron

PATENT ASSIGNEE(S): Sugan, Inc., USA

SOURCE: PCT Int. Appl., 164 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2002002551 | A1 | 20020110 | WO 2001-US20768 | 20010629 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.:

US 2000-215654P P 20000630


OTHER SOURCE(S):

MARPAT 136:102386

GI



I



II

AB Title compds. I [R1-2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, etc.; Het = (un)substituted arom. heterocycle contg. at least one and not more than two N atoms, tetrahydro(thio)pyranyl, (thio)morpholino, piperidinyl, piperazinyl, tetrazolyl, etc.; Q = (un)substituted arom. heterocycle contg. not more than two N atoms, 5-membered ring (un)substituted heterocycle contg. N, O or S, e.g., imidazolyl, pyrrolyl, indolyl, etc.] with some exceptions, were prepd. Included are 75 synthetic examples and results for several **protein tyrosine kinase** assays for those compds. For instance, 4-bromoindole was coupled to bis(pinacolato)diborane (DMSO, KOAc, PdCl2(dppf).bul.CH2Cl2, 80.degree.C, 22 h). The resulting dioxaborolane was coupled to 4-bromopyridine.bul.HCl (THF, Pd(PPh3)4, NaOH, 70.degree.C, 6 h) to give the indole which was treated with C5H5N.bul.Br3 (t-BuOH/EtOH/H2O, 1h) followed by zinc (stirred 1 addnl. hour) to give 4-(pyridin-4-yl)-1,3-dihydroindol-2-one as a yellow solid. Condensation of this intermediate with 5-methylimidazole-4-carboxaldehyde (EtOH, piperidine, 2 days) afforded II. II had IC50 = 4.88 mM for FGFR-1 tyrosine kinase and 0.03 mM for cdk2/cyclin A tyrosine kinase. I are useful in treating cancer, immunol. disorders, etc.


IT 388116-44-7P 388116-47-0P 388116-50-5P
388116-51-6P 388116-52-7P 388116-54-9P
388116-55-0P 388116-56-1P 388116-57-2P,
3-(1H-Indol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
388116-60-7P 388116-61-8P 388116-64-1P
388116-65-2P 388116-66-3P 388116-68-5P
388116-73-2P 388116-74-3P 388116-76-5P
388116-80-1P, 3-[3-Methyl-4-((piperidin-1-yl)carbonyl)pyrrol-2-ylmethylene]-4-(piperidin-4-yl)-1,3-dihydroindol-2-one
388116-81-2P, 3-[3-Methyl-4-(morpholine-4-carbonyl)pyrrol-2-ylmethylene]-4-(piperidin-4-yl)-1,3-dihydroindol-2-one
388116-86-7P, 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-

(piperidin-4-yl)-1,3-dihydroindol-2-one 388116-87-8P
 388116-88-9P 388116-89-0P 388116-90-3P
 388116-91-4P 388116-92-5P 388116-93-6P,
 3-(1H-Indol-2-ylmethylene)-4-(piperidin-4-yl)-1,3-dihydroindol-2-one
 388116-96-9P 388116-97-0P 388116-99-2P
 388117-00-8P, 3-[(3-Methyl-5-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-(piperidin-4-yl)-1,3-dihydroindol-2-one 388117-01-9P 388117-02-0P 388117-05-3P
 388117-06-4P 388117-07-5P 388117-08-6P
 388117-10-0P 388117-12-2P 388117-14-4P
 388117-16-6P, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-2-yl-1,3-dihydroindol-2-one
 388117-17-7P, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyrimidin-5-yl-1,3-dihydroindol-2-one
 388117-18-8P, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-(thiazol-2-yl)-1,3-dihydroindol-2-one
 388117-19-9P 388117-20-2P 388117-21-3P
 388117-22-4P, 4-(6-Aminopyridin-3-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one
 388117-23-5P 388117-24-6P, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-3-yl-1,3-dihydroindol-2-one 388117-25-7P 388117-26-8P,
 5-[3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-2-oxo-2,3-dihydro-1H-indol-4-yl]nicotinic acid
 388117-28-0P 388117-29-1P, 4-(2-Aminopyrimidin-5-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one 388117-30-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(drug; prepn. and use of 4-heteroaryl-3-heteroarylidanyl-2-indolinones
 and their use as **protein kinase** inhibitors)

RN 388116-44-7 CAPLUS
 CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 388116-47-0 CAPLUS
 CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 388116-50-5 CAPLUS

CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 388116-51-6 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 388116-52-7 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-ethyl- (9CI) (CA INDEX NAME)




RN 388116-54-9 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 388116-55-0 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-56-1 CAPLUS


CN 1H-Pyrrole-3-acetic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-57-2 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-4-(4-pyridinyl)-

(9CI) (CA INDEX NAME)




RN 388116-60-7 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 388116-61-8 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 388116-64-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 388116-65-2 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 388116-66-3 CAPLUS
CN 2H-Isoindole-1-carboxylic acid, 3-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 388116-68-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 388116-73-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 388116-74-3 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 388116-76-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 388116-80-1 CAPLUS


CN Piperidine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 388116-81-2 CAPLUS
CN Morpholine, 4-[[5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 388116-86-7 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 388116-87-8 CAPLUS
CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 388116-88-9 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 388116-89-0 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-5-ethyl- (9CI) (CA INDEX NAME)




RN 388116-90-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 388116-91-4 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-4-(4-piperidiny1)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 388116-92-5 CAPLUS

CN 1H-Pyrrole-3-acetic acid, 5-[[1,2-dihydro-2-oxo-4-(4-piperidiny1)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 388116-93-6 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-4-(4-piperidiny1)- (9CI) (CA INDEX NAME)




RN 388116-96-9 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 388116-97-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-99-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 388117-00-8 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 388117-01-9 CAPLUS

CN 2H-Isoindole-1-carboxylic acid, 3-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-02-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 388117-05-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 388117-06-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-piperidiny)]-3H-indol-3-ylidene]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 388117-07-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-piperidiny)]-3H-indol-3-ylidene]methyl]-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-08-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidiny)]-3H-indol-3-ylidene]methyl]-4-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 388117-10-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 388117-12-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 388117-14-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, (9CI) (CA INDEX NAME)

ethyl ester (9CI) (CA INDEX NAME)




RN 388117-16-6 CAPLUS

CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 388117-17-7 CAPLUS


CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 388117-18-8 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-thiazolyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-19-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-20-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-thiazolyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-21-3 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-22-4 CAPLUS


CN Piperazine, 1-[[5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-23-5 CAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)

ethyl ester (9CI) (CA INDEX NAME)




RN 388117-24-6 CAPLUS

CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 388117-25-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[[4-(ethoxycarbonyl)-5-methyl-3-[3-(4-methyl-1-piperazinyl)propyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)




RN 388117-26-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)




RN 388117-28-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 388117-29-1 CAPLUS


CN Piperazine, 1-[[5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-30-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



IT 388116-49-2P, 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as **protein kinase** inhibitors)
 RN 388116-49-2 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L65 ANSWER 4 OF 70 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:43419 CAPLUS

DOCUMENT NUMBER: 136:259310
TITLE: ~~The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation~~
AUTHOR(S): Ning, Shoucheng; Laird, Douglas; Cherrington, Julie M.; Knox, Susan J.
CORPORATE SOURCE: Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA, 94305-5105, USA
SOURCE: ~~Radiation Research (2002), 157(1), 45-51~~
CODEN: RAREAE; ISSN: 0033-7587
PUBLISHER: Radiation Research Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Angiogenesis is crit. for tumor development, growth and metastasis. The vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) and their tyrosine kinase receptors are major regulators of angiogenesis. Radiation induces the prodn. of VEGF, FGF and PDGF in many tumor cells. We hypothesized that inhibition of the function of these growth factors could inhibit tumor angiogenesis and thereby enhance the efficacy of radiation therapy. To test this hypothesis, we used the small mol. inhibitors SU5416 (an inhibitor for Vegf receptor) and SU6668 (an inhibitor for Vegf, Fgf and Pdgf receptors) alone and in combination with fractionated irradiation to treat C3H mice bearing SCC VII carcinomas. The SCC VII tumors express Vegf, Fgf2 (also known as bFGF), Pdgf and their assocd. receptors. Animals were given either SU5416 or SU6668 daily before or after irradiation (2 Gy per fraction per day for 5 days). The results from these experiments demonstrate that administration of either SU5416 or SU6668 without radiation delayed tumor growth. Administration of SU5416 at a dose of 25 mg/kg per day (the max. tolerated ED) inhibited tumor growth by 17.9% on day 7 (P < 0.05 compared to untreated control mice) and produced an av. tumor growth delay time of 0.5-2.0 days. When combined with fractionated irradiation, administration of SU5416 increased the inhibition of tumor growth to 50-53% on day 7 and the tumor growth delay time to 5.7-6.5 days (P < 0.001 compared with SU5416 alone; P = 0.05 compared with radiation alone). SU6668 alone inhibited tumor growth in a dose-dependent manner. Administration of SU6668 at a dose of 75 mg/kg per day (a suboptimal dose) inhibited tumor growth by 36% on day 7 and produced an av. tumor growth delay time of 3.3 +/- 1.4 days. The combination of SU6668 with fractionated radiation increased inhibition of tumor growth to 66-70% and the tumor growth delay time from 3.3 days to 11.9 days (P < 0.001 compared with either radiation alone or SU6668 alone). Administration of these agents before or after irradiation produced similar results (P = 0.40 for SU5416; P = 0.98 for SU6668). SU5416 or SU6668 alone or in combination with radiation was very well tolerated with little or no toxicity. These results suggest that inhibition of Vegf, Fgf and Pdgf receptor function by SU5416 and SU6668 can enhance the efficacy of irradiation. The targeting of multiple tyrosine kinase receptors by SU6668 is more effective than inhibition of the Vegf receptor alone by SU5416 for the enhancement of tumor cell killing by fractionated irradiation.

IT 204005-46-9, SU5416
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiangiogenic agents SU5416 and SU6668 increase antitumor effects of fractionated irradiation.)

RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 5 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:904107 CAPLUS

DOCUMENT NUMBER: 136:37505

TITLE: Preparation of 3-(2-indolylmethylene)-2-indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases

INVENTOR(S): Tang, Peng Cho; Harris, G. Davis; Li, Xiaoyuan

PATENT ASSIGNEE(S): Sugen, Inc., USA

SOURCE: PCT Int. Appl., 199 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------|------|----------|-----------------|----------|
| WO 2001-094312 | A2 | 20011213 | WO 2001-US17961 | 20010604 |


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.: US 2000-209162P P 20000602

OTHER SOURCE(S): MARPAT 136:37505

GI



I



II


AB Title compds. I [wherein R4-R6 and R8-R10 = H; R1, R2, and R3 = independently H, halo, carboxylic acid, trihalomethyl, or (un)substituted ester, amide, alkyl, alkoxy, or (hetero)aryl; R7 = (un)substituted alkyl or alkoxy; or pharmaceutically acceptable salt thereof] were prepd. as modulators of the activity of **protein kinases** (PKs) and phosphatases. For example, 5-bromo-2-oxindole was coupled with 5-(3-diethylaminopropyl)-1H-indole-2-carbaldehyde (prepn. given) in the presence of piperidine in EtOH to afford II, which inhibited GST-FLK-1, EGF receptor kinase, and PDGF with IC50 values of 0.03 .mu.M, 2.87 .mu.M, and 0.38 .mu.M, resp. I are useful in treating disorders related to abnormal PK activity, such as blood vessel proliferative disorders, mesangial cell proliferative disorders, fibrotic disorders, cancer, **diabetes**, autoimmune disorders, hyperproliferation disorders, restenosis, fibrosis, **psoriasis**, von Heppel-Lindau disease, **osteoarthritis**, rheumatoid **arthritis**, angiogenesis, inflammatory disorders, immunol. disorders, and cardiovascular disorders (no data). Combinatorial libraries comprising at least five indolinone compds., formed by reacting oxindoles with aldehydes, are also claimed.

IT 258830-88-5P

RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of (indolylmethylene)indolinones as **protein kinase**/phosphatase inhibitors for treatment of proliferative diseases)

RN 258830-88-5 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



IT 258830-79-4P 380241-29-2P 380241-30-5P


380241-31-6P 380241-33-8P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(prepn. of (indolylmethylene)indolinones as **protein kinase**/phosphatase inhibitors for treatment of proliferative diseases)


RN 258830-79-4 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 380241-29-2 CAPLUS

CN 2H-Indol-2-one, 5-bromo-3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 380241-30-5 CAPLUS

CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)




RN 380241-31-6 CAPLUS

CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-5-phenyl- (9CI) (CA INDEX NAME)



RN 380241-33-8 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




IT 258830-66-9P 380242-44-4P 380242-45-5P
380242-46-6P 380242-47-7P 380242-48-8P
380242-49-9P 380242-50-2P 380242-51-3P
380242-52-4P 380242-53-5P 380242-54-6P
380242-55-7P 380242-56-8P 380242-57-9P
380242-58-0P 380242-59-1P 380242-60-4P
380242-61-5P 380242-62-6P 380242-63-7P
380242-64-8P 380242-65-9P 380242-66-0P
380242-67-1P 380242-68-2P 380242-69-3P
380242-70-6P 380242-71-7P 380242-72-8P
380242-73-9P 380363-16-6P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses) (prepn. of (indolylmethylene)indolinones as **protein kinase**/phosphatase inhibitors for treatment of proliferative diseases)


RN 258830-66-9 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-44-4 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-45-5 CAPLUS

CN Piperazine, 1-[[3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 380242-46-6 CAPLUS

CN Pyrrolidine, 1-[[3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 380242-47-7 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-(2-methoxyethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-48-8 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 380242-49-9 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-(2-methoxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-50-2 CAPLUS

CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-51-3 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-N-[(4-fluorophenyl)methyl]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-52-4 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-53-5 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-54-6 CAPLUS


CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 380242-55-7 CAPLUS
CN Pyrrolidine, 1-[[2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 380242-56-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N-(2-methoxyethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-57-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N-(2-methoxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-58-0 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-59-1 CAPLUS

CN 1H-Indole-5-sulfonamide, N-[(4-fluorophenyl)methyl]-2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-60-4 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-61-5 CAPLUS

CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 380242-62-6 CAPLUS

CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 380242-63-7 CAPLUS

CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 380242-64-8 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-65-9 CAPLUS

CN 2H-Indol-2-one, 6-bromo-3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 380242-66-0 CAPLUS

CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-67-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380242-68-2 CAPLUS

CN Glycine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 380242-69-3 CAPLUS

CN Glycine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 380242-70-6 CAPLUS

CN L-Alanine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 380242-71-7 CAPLUS

CN L-Valine, N-[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 380242-72-8 CAPLUS

CN L-Alanine, N-[[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 380242-73-9 CAPLUS


CN L-Valine, N-[[[2,3-dihydro-2-oxo-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 380363-16-6 CAPLUS

CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-6-(pyridinyl)- (9CI) (CA INDEX NAME)




IT 380242-01-3P

RL: CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of (indolylmethylene)indolinones as **protein kinase**/phosphatase inhibitors for treatment of proliferative diseases)

RN 380242-01-3 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-methoxy-1H-indol-2-yl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




IT 380241-13-4P 380241-14-5P 380241-15-6P
 380241-16-7P 380241-17-8P 380241-18-9P
 380241-19-0P 380241-20-3P 380241-21-4P
 380241-22-5P 380241-23-6P 380241-24-7P
 380241-25-8P 380241-26-9P 380241-27-0P
 380241-28-1P 380241-32-7P 380241-34-9P
 380241-35-0P 380241-36-1P 380241-37-2P
 380241-38-3P 380241-39-4P 380241-40-7P
 380241-41-8P 380241-42-9P 380241-43-0P
 380241-44-1P 380241-45-2P 380241-46-3P
 380241-47-4P 380241-48-5P 380241-49-6P
 380241-50-9P 380241-51-0P 380241-53-2P
 380241-54-3P 380241-56-5P 380241-59-8P
 380241-61-2P 380241-65-6P 380241-68-9P
 380241-71-4P 380241-74-7P 380241-78-1P
 380241-82-7P 380241-84-9P 380241-86-1P
 380241-88-3P 380241-90-7P 380241-91-8P
 380241-92-9P 380241-93-0P 380241-94-1P
 380241-95-2P 380241-96-3P 380241-97-4P
 380241-98-5P 380241-99-6P 380242-00-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (indolylmethylene)indolinones as **protein kinase**/phosphatase inhibitors for treatment of proliferative diseases)


RN 380241-13-4 CAPLUS

CN 2H-Indol-2-one, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 380241-14-5 CAPLUS

CN 2H-Indol-2-one, 5-bromo-3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 380241-15-6 CAPLUS

CN 2H-Indol-2-one, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)




RN 380241-16-7 CAPLUS

CN 2H-Indol-2-one, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 380241-17-8 CAPLUS

CN 2H-Indol-2-one, 3-[[5-[2-(dimethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 380241-18-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-phenyl-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-19-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-20-3 CAPLUS

CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-21-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-6-phenyl- (9CI) (CA INDEX NAME)




RN 380241-22-5 CAPLUS

2H-Indol-2-one, 3-[[5-[2-(dimethylamino)ethoxy]-1H-indol-2-yl]methylene]-
1,3-dihydro- (9CI) (CA INDEX NAME)




RN 380241-23-6 CAPLUS

CN 2H-Indol-2-one, 5-bromo-3-[[5-[2-(dimethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 380241-24-7 CAPLUS

CN 2H-Indol-2-one, 3-[[5-[2-(dimethylamino)ethoxy]-1H-indol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)




RN 380241-25-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-26-9 CAPLUS

CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-27-0 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-6-phenyl-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-28-1 CAPLUS


CN 2H-Indol-2-one, 3-[[5-[2-(diethylamino)ethoxy]-1H-indol-2-yl]methylene]-

1,3-dihydro- (9CI) (CA INDEX NAME)




RN 380241-32-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[3-(1-pyrrolidinyl)propyl]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-34-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-35-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-36-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(2-hydroxyethyl)-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-37-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-(3-pyridinyl)-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-38-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-(4-methoxyphenyl)-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-39-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-(3-methoxyphenyl)-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-40-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-(2-methoxyphenyl)-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-41-8 CAPLUS

CN 2H-Indol-2-one, 6-(4-fluorophenyl)-1,3-dihydro-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-42-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 380241-43-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 380241-44-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-5-phenyl- (9CI) (CA INDEX NAME)




RN 380241-45-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(2-hydroxyethyl)-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-46-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 380241-47-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-(4-methoxyphenyl)-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-48-5 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-(3-methoxyphenyl)-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-49-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-(2-methoxyphenyl)-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-50-9 CAPLUS

CN 2H-Indol-2-one, 6-(4-fluorophenyl)-1,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-51-0 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-53-2 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 380241-54-3 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-56-5 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-59-8 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-(1-methylethyl)-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-61-2 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-phenyl-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 380241-65-6 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-3-pyridinyl-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-68-9 CAPLUS


CN 1H-Indole, 1-[[2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-71-4 CAPLUS

CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-Cl

RN 380241-74-7 CAPLUS


CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-N-methyl-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)



RN 380241-78-1 CAPLUS

CN 1H-Indole-5-sulfonamide, N-(4-chloro-2-fluorophenyl)-2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Cl


RN 380241-82-7 CAPLUS

CN Quinoline, 1-[[2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]-1H-indol-5-yl]sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 380241-84-9 CAPLUS

CN Isoquinoline, 2-[[2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]-1H-indol-5-yl]sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 380241-86-1 CAPLUS

CN 1H-Indole, 5-bromo-1-[[2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl]methylene]-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 380241-88-3 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 380241-90-7 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 380241-91-8 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-(1-methylethyl)-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 380241-92-9 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)




RN 380241-93-0 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 380241-94-1 CAPLUS


CN 1H-Indole, 1-[[2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 380241-95-2 CAPLUS

CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 380241-96-3 CAPLUS

CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-N-methyl-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 380241-97-4 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(4-chloro-2-fluorophenyl)-2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




RN 380241-98-5 CAPLUS
CN Quinoline, 1-[[2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 380241-99-6 CAPLUS
CN Isoquinoline, 2-[[2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 380242-00-2 CAPLUS
CN 1H-Indole, 5-bromo-1-[[2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



L65 ANSWER 6 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:868450 CAPLUS

DOCUMENT NUMBER: 136:5903

TITLE: Preparation of 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinones as **protein kinase** activity modulators.INVENTOR(S): ~~Moon, Malcolm Wilson; Morozowich, Walter; Gao, Ping~~PATENT ASSIGNEE(S): ~~Pharmacia + Upjohn Company, USA~~

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2001090104 | A2 | 20011129 | WO 2001-US16756 | 20010524 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---------------|----|----------|----------------|----------|
| US 2002032204 | A1 | 20020314 | US 2001-863804 | 20010524 |
|---------------|----|----------|----------------|----------|

| | | | | |
|---------------|----|----------|----------------|----------|
| US 2002035140 | A1 | 20020321 | US 2001-863905 | 20010524 |
|---------------|----|----------|----------------|----------|


| | | | | |
|---------------|----|----------|----------------|----------|
| US 2002037878 | A1 | 20020328 | US 2001-863819 | 20010524 |
|---------------|----|----------|----------------|----------|

PRIORITY APPLN. INFO.: US 2000-207000P P 20000524

US 2000-225045P P 20000811

OTHER SOURCE(S): MARPAT 136:5903

GI



I

AB Title compds. [I; R3-R6 = H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, OH, alkoxy, SH, alkylthio, arylthio, etc.; .gtoreq.2 of R3-R6 = H; R7 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, OH, alkoxy, aryloxy, etc.; R8-R10 = H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, OH, alkoxy, aryloxy, SH, alkylthio, arylthio, etc.], were prepd. Thus, pyrrolidine was added to a mixt. of aq. H2CO and 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylidene)-1,3-dihydroindol-2-one in MeOH; after 15 min. the mixt. was cooled to 0.degree. and filtered to give (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1-(1-pyrrolidinylmethyl)-1,3-dihydro-2H-indol-2-one. The latter prodrug had a half life of 7.3 min. in dogs.


IT 375387-20-5P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrolidinylmethylpyrrolylmethylideneindolinones as protein kinase activity modulators)

RN 375387-20-5 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-(1-pyrrolidinylmethyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 204005-46-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyrrolidinylmethylpyrrolylmethylideneindolinones as protein kinase activity modulators)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L65 ANSWER 7 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:868415 CAPLUS

DOCUMENT NUMBER: 136:697

TITLE: Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

INVENTOR(S): Moon, Malcolm Wilson; Morozowich, Walter; Gao, Ping;

Searched by Barb O'Bryen, STIC 308-4291

PATENT ASSIGNEE(S): Tang, Peng Cho
SOURCE: Sugen, Inc., USA; Pharmacia + Upjohn Company
PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2001090068 | A2 | 20011129 | WO 2001-US16757 | 20010524 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2002032204 | A1 | 20020314 | US 2001-863804 | 20010524 |
| US 2002035140 | A1 | 20020321 | US 2001-863905 | 20010524 |
| US 2002037878 | A1 | 20020328 | US 2001-863819 | 20010524 |
| PRIORITY APPLN. INFO.: | | | US 2000-207000P | P 20000524 |
| | | | US 2000-225045P | P 20000811 |

OTHER SOURCE(S): MARPAT 136:697


AB The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs. that modulate the activity of **protein kinases** ("PKs"). Pharmaceutical compns. comprising these compds., methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compns. comprising these compds. and methods of prepg. them are also disclosed.

IT **375387-20-5P 375798-46-2P**
RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 375387-20-5 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-(1-pyrrolidinylmethyl)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-46-2 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(4-methyl-1-piperazinyl)methyl]-, dihydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● 2 HCl

IT 326914-13-0P 375798-54-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 326914-13-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-54-2 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-(hydroxymethyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 375798-45-1P 375798-47-3P 375798-48-4P

375798-49-5P 375798-50-8P 375798-51-9P

375798-52-0P 375798-53-1P 375798-55-3P


RL: SPN (Synthetic preparation); PREP (Preparation)

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone
derivs.)

RN 375798-45-1 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-
[(4-methyl-1-piperazinyl)methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-47-3 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-
[(2-hydroxy-1-pyrrolidinyl)methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-48-4 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-
[(2-methyl-1-pyrrolidinyl)methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-49-5 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-
[[2-(methoxymethyl)-1-pyrrolidinyl]methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-50-8 CAPLUS

CN L-Proline, 1-[(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-1-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 375798-51-9 CAPLUS

CN 2H-Indol-2-one, 1-[(3,5-dimethyl-1-piperazinyl)methyl]-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 375798-52-0 CAPLUS

CN 2H-Indol-2-one, 1-[[bis(2-methoxyethyl)amino]methyl]-3-[(3,5-dimethyl-1H-

pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-53-1 CAPLUS

CN Pyridinium, 1-[[[(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-1-yl)methyl]-4-methoxyphenyl]pyridinium, chloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● Cl⁻

RN 375798-55-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L65 ANSWER 8 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:617993 CAPLUS

DOCUMENT NUMBER: 135:195497

TITLE: Preparation of pyrrole substituted 2-indolinone
protein kinase inhibitors for
treatment of cancer

INVENTOR(S): Tang, Peng Cho; Miller, Todd; Li, Xiaoyuan; Sun, Li;
Wei, Chung Chen; Shirazian, Shahrzad; Liang, Congxin;
Vojtkovsky, Tomas; Nematalla, Asaad S.

PATENT ASSIGNEE(S): Sugan, Inc., USA

SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2001060814 | A2 | 20010823 | WO 2001-US4813 | 20010215 |
| WO 2001060814 | A3 | 20020124 | | |



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-182710P P 20000215
US 2000-216422P P 20000706
US 2000-243532P P 20001027

OTHER SOURCE(S): MARPAT 135:195497

GI



AB The title compds. (I) [wherein R1 = H, halo, (cyclo)alkyl, (hetero)aryl, heteroalicyclic, OH, alkoxy, acyl, (un)substituted amino or carbamoyl, etc.; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (hetero)aryl,

(un)substituted amino, acyl(amino), or sulfamoyl, etc.; R3 = H, halo, alkyl, trihalomethyl, OH, alkoxy, (hetero)aryl, (un)substituted acyl, (acyl)amino, sulfamoyl, or alkylsulfonyl, etc.; R4 = H, halo, alkyl, OH, alkoxy, or (un)substituted amino; R5 and R6 = independently H, alkyl, or acyl; R7 = H, alkyl, (hetero)aryl, or acyl; and their pharmaceutically acceptable salts] were prepd. ~~as protein kinase~~ modulators for the treatment of cellular disorders such as cancer. For example, 5-fluoro-1,3-dihydroindol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide to give II (55%). II exhibited comparable activity against Flk-1 and PDGFR.beta. and inhibited PDGF-dependent receptor phosphorylation in cells with an IC50 value of approx. 0.03 .mu.M. In efficacy expts. against various cancers in mice, II was well tolerated at 80 mg/kg/day, even when dosed continuously for more than 100 days.


IT 356068-93-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of pyrrole substituted 2-indolinone
protein kinase inhibitors by condensation of
dihydroindolones with formylpyrroles for treatment of cancer and other diseases)

RN 356068-93-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 326914-13-0P

RL: ADV (Adverse effect, including toxicity); **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrole substituted 2-indolinone **protein kinase** inhibitors by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)

RN 326914-13-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 280748-39-2P 280748-40-5P 326914-09-4P


326914-10-7P 326914-17-4P 326914-19-6P
342641-15-0P 342641-16-1P 342641-17-2P
342641-18-3P 342641-19-4P 342641-20-7P
342641-21-8P 342641-22-9P 342641-23-0P
342641-24-1P 342641-25-2P 342641-26-3P
342641-27-4P 342641-28-5P 342641-29-6P
342641-30-9P 342641-31-0P 342641-32-1P
342641-33-2P 342641-35-4P 342641-36-5P
342641-37-6P 342641-38-7P 342641-39-8P
342641-40-1P 342641-41-2P 342641-42-3P
342641-43-4P 342641-44-5P 342641-45-6P
342641-46-7P 342641-47-8P 342641-48-9P
342641-49-0P 342641-50-3P 342641-51-4P
342641-52-5P 342641-54-7P 342641-55-8P
342641-56-9P 342641-57-0P 342641-58-1P
342641-59-2P 342641-60-5P 342641-61-6P
342641-62-7P 342641-63-8P 342641-64-9P
342641-65-0P 342641-66-1P 342641-67-2P
342641-68-3P 342641-69-4P 342641-70-7P
342641-71-8P 342641-72-9P 342641-73-0P
342641-74-1P 342641-75-2P 342641-76-3P
342641-77-4P 342641-78-5P 342641-79-6P
342641-80-9P 342641-81-0P 342641-82-1P
342641-83-2P 342641-84-3P 342641-85-4P
342641-87-6P 342641-88-7P 342641-89-8P
342641-91-2P 342641-92-3P 342641-93-4P
342641-94-5P 342641-95-6P 342641-96-7P
342641-97-8P 342641-98-9P 342641-99-0P
342642-00-6P 342642-01-7P 342642-02-8P
342642-03-9P 342642-04-0P 342642-05-1P
342642-06-2P 342642-07-3P 342642-08-4P
342642-09-5P 342642-10-8P 342642-11-9P
342642-12-0P 342642-13-1P 342642-14-2P
342642-15-3P 342642-16-4P 342642-17-5P
346405-32-1P 356068-82-1P 356068-90-1P
356068-91-2P 356068-92-3P 356068-94-5P
356068-95-6P 356068-96-7P 356068-97-8P
356068-99-0P 356069-03-9P 356069-04-0P
356069-05-1P 356069-07-3P 356069-09-5P
356069-12-0P 356069-13-1P 356069-15-3P
356069-16-4P 356069-17-5P 356069-18-6P
356069-19-7P 356069-20-0P 356069-21-1P
356069-22-2P 356069-23-3P 356069-24-4P
356069-25-5P 356069-26-6P 356069-27-7P
356069-28-8P 356069-29-9P 356069-30-2P
356069-31-3P 356069-33-5P 356069-34-6P
356069-35-7P 356069-36-8P 356069-37-9P
356069-38-0P 356069-39-1P 356069-40-4P
356069-41-5P 356069-42-6P 356069-43-7P
356069-44-8P 356069-45-9P 356069-46-0P
356069-47-1P 356069-48-2P 356069-49-3P
356069-50-6P 356069-51-7P 356069-53-9P
356069-55-1P 356069-57-3P 356069-58-4P
356069-59-5P 356069-60-8P 356069-61-9P
356069-62-0P 356069-64-2P 356069-65-3P
356069-66-4P 356069-67-5P 356069-68-6P
356069-69-7P 356069-70-0P 356069-71-1P
356069-72-2P 356069-73-3P 356069-74-4P
356069-75-5P 356069-76-6P 356069-77-7P

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of pyrrole substituted 2-indolinone **protein kinase** inhibitors by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)


RN 280748-39-2 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 280748-40-5 CAPLUS


CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 326914-09-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 326914-10-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 326914-17-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 326914-19-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 342641-15-0 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342641-16-1 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 342641-17-2 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342641-18-3 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-19-4 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342641-20-7 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342641-21-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 342641-22-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 342641-23-0 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 342641-24-1 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-25-2 CAPLUS


CN 1H-Pyrrole-2-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-26-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-27-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 342641-28-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-29-6 CAPLUS
CN 2H-Isoindole-1-carboxamide, 3-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 342641-30-9 CAPLUS

CN 2H-Isoindole-1-carboxamide, 3-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 342641-31-0 CAPLUS

CN 2H-Isoindole-1-carboxamide, 3-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-32-1 CAPLUS

CN 2H-Isoindole-1-carboxamide, N-[2-(diethylamino)ethyl]-3-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 342641-33-2 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-35-4 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-36-5 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-37-6 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-38-7 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-39-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-40-1 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-41-2 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-benzoyl-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-42-3 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-43-4 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-44-5 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-45-6 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(3-hydroxypropyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-46-7 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-47-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-48-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-acetyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(4-hydroxyphenyl)ethyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 342641-49-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-(1-methylethyl)-4-phenyl-(9CI) (CA INDEX NAME)




RN 342641-50-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-4-phenyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 342641-51-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-52-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-N-[3-(4-methyl-1-piperazinyl)propyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-54-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-55-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-56-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-57-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-58-1 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 342641-59-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 342641-60-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-61-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-62-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-64-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-65-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-66-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)




RN 342641-67-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)




RN 342641-68-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-69-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-70-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-71-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-72-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-

ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-73-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-74-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-75-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-76-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-77-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-78-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-79-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-80-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-81-0 CAPLUS

CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-[[[3-(diethylamino)propyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-82-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-83-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 342641-84-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 342641-85-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI)
(CA INDEX NAME)




RN 342641-87-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 342641-88-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-89-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[2-methoxy-5-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-91-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-92-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 342641-93-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[3-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-95-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-96-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-97-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-98-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-[(3-pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-99-0 CAPLUS
 CN Piperazine, 1-[[5-[[1,2-dihydro-4-(2-hydroxyethyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342642-00-6 CAPLUS
 CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-5-[(phenylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342642-01-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342642-02-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342642-03-9 CAPLUS

CN 2H-Isoindole-1-carboxylic acid, 3-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-04-0 CAPLUS

CN 2H-Isoindole-1-carboxylic acid, 3-[[1,2-dihydro-2-oxo-5-[(phenylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-05-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-2-oxo-3-[[4,5,6,7-tetrahydro-3-(4-morpholinylcarbonyl)-2H-isoindol-1-yl]methylene]- (9CI) (CA INDEX NAME)




RN 342642-06-2 CAPLUS


CN Pyrrolidine, 1-[[3-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro-2H-isoindol-1-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 342642-07-3 CAPLUS
 CN 1H-Indole-6-carboxylic acid, 3-[[3-[(dimethylamino)carbonyl]-4,5,6,7-tetrahydro-2H-isoindol-1-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 342642-08-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342642-09-5 CAPLUS
 CN Glycine, N-[[5-[[1,2-dihydro-4-methyl-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-10-8 CAPLUS
 CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-

ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-11-9 CAPLUS

CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 342642-12-0 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 342642-13-1 CAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 342642-14-2 CAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-

ylidene)methyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-15-3 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 342642-16-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342642-17-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 346405-32-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356068-82-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356068-90-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-92-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 356068-94-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356068-95-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-96-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-97-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356068-99-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-03-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356069-04-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-05-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 356069-07-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-09-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-12-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-13-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-15-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-16-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356069-17-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356069-18-6 CAPLUS

CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-82-1

CMF C22 H25 Cl N4 O2




CM 2

CRN 97-67-6

CMF C4 H6 O5

CDES 1:S

Absolute stereochemistry.




RN 356069-19-7 CAPLUS

CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 342641-94-5

CMF C22 H27 F N4 O2




CM 2

CRN 97-67-6

CMF C4 H6 O5

CDES 1:S

Absolute stereochemistry.




RN 356069-20-0 CAPLUS

CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-90-1

CMF C22 H27 Cl N4 O2




CM 2

CRN 97-67-6

CMF C4 H6 O5

CDES 1:S

Absolute stereochemistry.




RN 356069-21-1 CAPLUS

CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 346405-32-1


CMF C22 H25 F N4 O2



CM 2

CRN 97-67-6
 CMF C4 H6 O5
 CDES 1:S


Absolute stereochemistry.



RN 356069-22-2 CAPLUS
 CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(ethylamino)ethyl]-5-
 [(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-
 pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356069-16-4
 CMF C20 H23 F N4 O2




CM 2

CRN 97-67-6
 CMF C4 H6 O5

CDES 1:S

Absolute stereochemistry.



RN 356069-23-3 CAPLUS


CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethyloxidoamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-99-0

CMF C22 H27 F N4 O3

Double bond geometry as shown.




CM 2

CRN 97-67-6

CMF C4 H6 O5

CDES 1:S


Absolute stereochemistry.



RN 356069-24-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-25-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-26-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-27-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-28-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-29-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-30-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-31-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-33-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 356069-32-4
 CMF C22 H24 Br N5 O3

Double bond geometry as shown.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 356069-34-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-35-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-36-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-37-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-38-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-39-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-40-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-41-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-42-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-43-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-44-8 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-45-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[(cyanomethyl)amino]ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-46-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-47-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-48-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-49-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-50-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-51-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-53-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-52-8

CMF C22 H24 F N5 O3


Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 356069-55-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 356069-54-0
CMF C22 H25 N5 O3

Double bond geometry as shown.




CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 356069-57-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-56-2
CMF C23 H24 N6 O3


Double bond geometry as shown.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 356069-58-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-59-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-60-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[(2-cyanoethyl)amino]ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-61-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[(2-cyanoethyl)amino]ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-62-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-64-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-63-1

CMF C22 H24 Cl N5 O3


Double bond geometry as shown.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 356069-65-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-66-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-67-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-68-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-69-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-70-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-71-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-72-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-73-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-74-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-75-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-76-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-77-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 342641-53-6 356069-06-2 356069-08-4

356069-10-8 356069-14-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of pyrrole substituted 2-indolinone **protein kinase** inhibitors by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)


RN 342641-53-6 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 356069-06-2 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356069-08-4 CAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356069-10-8 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-14-2 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L65 ANSWER 9 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:319727 CAPLUS

DOCUMENT NUMBER: 134:316158

TITLE: Oral formulations for camptothecin antitumor compounds

INVENTOR(S): Muggetti, Lorena; Martini, Alessandro; Civaroli, Paola; James, Christopher

PATENT ASSIGNEE(S): Pharmacia + Upjohn S.p.A., Italy

SOURCE: ~~PCT Int. Appl., 30 pp.~~

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2001030351 | A1 | 20010503 | WO 2000-EP9647 | 20001002 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, | | | | |

YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 1999-25127 A 19991022


AB The present invention relates to a semi-solid filling medium which comprises a camptothecin deriv.; a pharmaceutically acceptable carrier matrix which is a polyglycolized glyceride; and an effective thickening-reducing and stabilizing-promoting amt. of one or more pharmaceutically acceptable excipients. For example, a capsule formulation contg. 50 mg of CPT-11 dispersed in a mixt. of Gelucire 44/14 and Epikuron 135F was prepd. showing good dissoln. and stability.

IT 204005-46-9, SU 5416

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral formulations for camptothecin antitumor compds.)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 10 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:208110 CAPLUS

DOCUMENT NUMBER: 134:242681

TITLE: Formulations for parenteral use of estramustine phosphate and amino acids for cancer treatment

INVENTOR(S): Muggetti, Lorena; Colombo, Paolo; Martini, Alessandro; Buzzi, Giovanni

PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2001019372 | A1 | 20010322 | WO 2000-EP8983 | 20000913 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |

PRIORITY APPLN. INFO.: GB 1999-21960 A 19990916

AB A parenteral formulation for cancer treatment comprises estramustine

phosphate, a basic amino acid, and a parenterally acceptable carrier or diluent. The formulation can be administered according to a combined chemotherapy regimen in assocn. with one or more chemotherapeutic agents. The formulation enables the estramustine phosphate to be administered with no side effects at the site of injection. Prepn. of estramustine phosphate N-methyl-glucamine salt in admixt. with arginine (estramustine phosphate/meglumine/arginine in a molar ratio 1:1:2) was presented.


IT 204005-46-9, SU 5416

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combined chemotherapy; formulations for parenteral use of estramustine phosphate and basic amino acids for cancer treatment)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 11 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:208081 CAPLUS

DOCUMENT NUMBER: 134:242666

TITLE: Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins

INVENTOR(S): Muggetti, Lorena; Colombo, Paolo; Martini, Alessandro; Buzzi, Giovanni

PATENT ASSIGNEE(S): Pharmacia & Upjohn S.P.A., Italy

SOURCE: PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2001019339 | A1 | 20010322 | WO 2000-EP7680 | 20000803 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |

PRIORITY APPLN. INFO.: GB 1999-21958 A 19990916

AB A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate and a sulfoalkyl ether cyclodextrin. The formulation can be administered according to a combined chemotherapy regimen in assocn. with one or more chemotherapeutic agents. The formulation also enables estramustine phosphate to be administered with no side effects at the site of injection. A soln. contg.


estramustine phosphate and sulfobutyl ether .beta.-cyclodextrin (1:4.2) was formulated.

IT 204005-46-9, SU 5416

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(parenteral formulations contg. estramustine phosphates and sulfoalkyl ether cyclodextrins and other chemotherapeutic agents)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 12 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:208080 CAPLUS

DOCUMENT NUMBER: 134:242665

TITLE: Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
INVENTOR(S): Muggetti, Lorena; Colombo, Paolo; Martini, Alessandro; Buzzi, Giovanni

PATENT ASSIGNEE(S): Pharmacia & Upjohn S.P.A., Italy

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2001019338 | A1 | 20010322 | WO 2000-EP7679 | 20000803 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |


PRIORITY APPLN. INFO.: GB 1999-21954 A 19990916

AB A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate, a sulfoalkyl ether cyclodextrin and human albumin. The formulation can be administered according to a combined chemotherapy regimen in assocn. with one or more chemotherapeutic agents. The formulation also enables the estramustine phosphate to be administered with no side effects at the site of injection. A soln. contg. estramustine phosphate (Estracyt), sulfobutyl ether .beta.-cyclodextrin, and human albumin (1:1:0.21) was formulated.

IT 204005-46-9, SU 5416

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(parenteral formulations contg. estramustine phosphates and sulfoalkyl ether cyclodextrins and human albumins and chemotherapeutic agents)

RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 13 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:114989 CAPLUS

DOCUMENT NUMBER: 134:168371

TITLE: Formulations for parenteral use of estramustine phosphate and albumin

INVENTOR(S): Muggetti, Lorena; Colombo, Paolo; Martini, Alessandro; Buzzi, Giovanni

PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy

SOURCE: PCT Int. Appl., 14 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2001010446 | A2 | 20010215 | WO 2000-EP7678 | 20000803 |
| WO 2001010446 | A3 | 20010525 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 1999-18779 A 19990809
IT 1999-MI1998 A 19990927

AB A pharmaceutical formulation which comprises a parenterally acceptable carrier or a diluent and estramustine phosphate in admixt. with human albumin, wherein the wt. ratio of estramustine phosphate to human albumin is from about 1:5 to about 1:0.3. The formulation can be administered according to a combined chemotherapy regimen in assocn. with one or more chemotherapeutic agents. The formulation also enables estramustine phosphate to be administered with no side effects at the side of injection. A parenteral soln. contained N-Me glucamine salt of estramustine phosphate 30 mg, and human albumin 25 mg/mL (1:0.8 wt. ratio resp.).


IT 204005-46-9, Su 5416

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(formulations for parenteral use of estramustine phosphate and albumin)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)



L65 ANSWER 14 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:917070 CAPLUS

DOCUMENT NUMBER: 136:214530

TITLE: The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins

AUTHOR(S): Demiroglu, Asuman; Steer, E. Joanna; Heath, Carol; Taylor, Kerry; Bentley, Mark; Allen, Steven L.; Koduru, Prasad; Brody, Judith P.; Hawson, Geoffrey; Rodwell, Robyn; Doody, Mary-Lou; Carnicero, Fernando; Reiter, Andreas; Goldman, John M.; Melo, Junia V.; Cross, Nicholas C. P.

CORPORATE SOURCE: Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London, UK

SOURCE: Blood (2001), 98(13), 3778-3783

CODEN: BLOOAW; ISSN: 0006-4971

PUBLISHER: American Society of Hematology

DOCUMENT TYPE: Journal

LANGUAGE: English


AB This report describes 2 patients with a clin. and hematol. diagnosis of chronic myeloid leukemia (CML) in chronic phase who had an acquired t(8;22)(p11;q11). Anal. by fluorescence in situ hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR) indicated that both patients were neg. for the BCR-ABL fusion, but suggested that the BCR gene was disrupted. Further FISH indicated a breakpoint within fibroblast growth factor receptor 1 (FGFR1), the receptor tyrosine kinase that is known to be disrupted in a distinctive myeloproliferative disorder, most commonly by fusion to ZNF198. RT-PCR confirmed the presence in both cases of an in-frame mRNA fusion between BCR exon 4 and FGFR1 exon 9. Expression of BCR-FGFR1 in the factor-dependent cell line Ba/F3 resulted in interleukin 3-independent clones that grew at a comparable rate to cells transformed with ZNF198-FGFR1. The growth of transformed cells was inhibited by the phosphatidylinositol 3-kinase inhibitor LY294002, the farnesyltransferase inhibitors L744832 and manumycin A, the p38 inhibitors SB202190 and SB203580 but not by the MEK inhibitor PD98059. The growth of BaF3/BCR-FGFR1 and BaF3/ZNF198-FGFR1 was not significantly inhibited by treatment with STI571, but was inhibited by SU5402, a compd. with inhibitory activity against FGFR1. Inhibition with this compd. was assocd. with decreased phosphorylation of ERK1/2 and BCR-FGFR1 or ZNF198-FGFR1, and was dose dependent with an inhibitory concn. of 50% of approx. 5 μ M. As expected, growth of BaF3/BCR-ABL was inhibited by STI571 but not by SU5402. The study demonstrates that the BCR-FGFR1 fusion may occur in patients with apparently typical CML. Patients with constitutively active FGFR1 fusion genes may be amenable to treatment with specific FGFR1 inhibitors.

IT 215543-92-3, SU 5402

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming

activity and specific inhibition of FGFR1 fusion proteins)
RN 215543-92-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 15 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:354377 CAPLUS

DOCUMENT NUMBER: 135:146994

TITLE: Indolinone tyrosine kinase inhibitors block Kit activation and growth of small-cell lung cancer cells

AUTHOR(S): Krystal, Geoffrey W.; Honsawek, Sittisak; Kiewlich, David; Liang, Congxin; Vasile, Stefan; Sun, Li; McMahon, Gerald; Lipson, Kenneth E.

CORPORATE SOURCE: Departments of Internal Medicine and Microbiology/Immunology, McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, Richmond, VA, 23249, USA

SOURCE: Cancer Research (2001), 61(9), 3660-3668
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Six indolinone tyrosine kinase inhibitors were characterized for their ability to inhibit Kit kinase and for their effects on the growth of small-cell lung cancer (SCLC) cell lines. All six compds. were potent inhibitors of Kit kinase in a biochem. assay. A homol. model of compd. binding to the ATP-binding site could account for the increased potency caused by the addn. of a propionate moiety to the indolinone core but not that caused by addn. of a chloride moiety. Although all of the compds. tested were potent in the biochem. assay, several exhibited significantly less potency in cellular kinase assays. Their effects on stem cell factor (SCF)-dependent Kit autophosphorylation and SCLC cell growth were also examd. Inhibition of SCF-stimulated Kit activation and cell growth of the H526 cell line was concn. dependent. At concns. that inhibited SCF-stimulated H526 cell growth, there was little effect on insulin-like growth factor-1-stimulated growth, suggesting that these compds. exhibit reasonable selectivity for inhibition of Kit-mediated proliferation. Higher concns. of the compds. were needed to inhibit serum-stimulated growth. Of the six compds. examd., SU5416 and SU6597 possessed the best cellular potency and, therefore, their effect on the growth of multiple SCLC cell lines in serum-contg. media was examd. In addn. to inhibiting proliferation, these compds. also induced cell death of several SCLC cell lines, but not of normal human diploid fibroblasts, in complete media. These observations suggest that Kit kinase inhibitors such as these may offer a new approach for inhibiting Kit-mediated proliferation of tumors such as SCLC, gastrointestinal stromal tumors, seminomas, and leukemias.

IT 186611-14-3, SU 6663 186611-56-3, SU 5614

204005-46-9, SU 5416 251356-16-8 251356-18-0

RL: BAC (Biological activity or effector, except adverse); BSU


(Biological study, unclassified); PRP (Properties); BIOL (Biological

study)

(indolinone-type tyrosine kinase inhibitors blockade of Kit activation and growth of small-cell lung cancer cells)


RN 186611-14-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-56-3 CAPLUS

CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 251356-16-8 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 251356-18-0 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 16 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:799778 CAPLUS

DOCUMENT NUMBER: 136:112324

TITLE: Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation

AUTHOR(S): Dowlati, Afshin; Haaga, John; Remick, Scot C.; Spiro, Timothy P.; Gerson, Stanton L.; Liu, Lili; Berger, Sosamma J.; Berger, Nathan A.; Willson, James K. V.

CORPORATE SOURCE: Division of Hematology/Oncology, Department of Medicine and Developmental Therapeutics Program, Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH, 44106, USA

SOURCE: Clinical Cancer Research (2001), 7(10), 2971-2976
CODEN: CCREF4; ISSN: 1078-0432

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In the setting of target-based anticancer drug development, it is crit. to establish that the obsd. preclin. activity can be attributed to modulation of the intended target in early phase trials in human subjects. This paradigm of target modulation allows the authors to det. a Phase II or III dose (optimal biochem./biol. modulatory dose) that may not necessarily be the max. tolerated dose. A major obstacle to target-based (often cytostatic) drug development has been obtaining relevant tumor tissue during clin. trials of these novel agents for lab. anal. of the putative marker of drug effect. From 1989 to present, the authors have completed seven clin. trials in which the end point was a biochem. or biol. modulatory dose in human tumor tissues (not surrogate tissue). Eligibility enrollment required that patients have a biopsiable lesion either with computerized tomog. (CT) guidance or direct visualization and consent to sequential (pre and posttreatment) biopsies. A total of 192 biopsies were performed in 107 patients. All but 8 patients had sequential pre and posttreatment biopsies. Seventy-eight (73%) of the 107 patients had liver lesion biopsies. In eight patients, either one or both biopsies contained insufficient viable tumor tissue or no tumor tissue at all for anal. Of a total of 99 patients in whom the authors attempted to obtain paired biopsies, a total of 87 (88%) were successful. Reasons for failure included patient refusal for a second biopsy (n = 2), vasovagal reaction with first biopsy precluding a second biopsy (n = 1), subcapsular hepatic bleeding (n = 1), and most commonly obtaining necrotic tumor, fibrous, or normal tissue in one of the two sequential biopsies (n = 8). This is the first and largest reported series demonstrating that with adequate precautions and experience, sequential tumor biopsies are feasible and safe during early phase clin. trials.


IT 204005-46-9, SU5416

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sequential human tumor biopsies in early phase clin. trials of

anticancer agents for pharmacodynamic evaluation)

RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 17 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:240686 CAPLUS

DOCUMENT NUMBER: 135:2309

TITLE: Inhibition of vascular endothelial growth factor
receptor signaling leads to reversal of tumor
resistance to radiotherapy

AUTHOR(S): Geng, Ling; Donnelly, Edwin; McMahon, Gerald; Lin, P.
Charles; Sierra-Rivera, Elaine; Oshinka, Halina;
Hallahan, Dennis E.

CORPORATE SOURCE: Departments of Radiation Oncology, Vanderbilt
University School of Medicine, Vanderbilt University,
Nashville, TN, 37232, USA

SOURCE: Cancer Research (2001), 61(6), 2413-2419
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Certain refractory neoplasms, such as glioblastoma multiforme (GBM) and melanoma, demonstrate a resistant tumor phenotype in vivo. We obsd. that these refractory tumor models (GBM and melanoma) contain blood vessels that are relatively resistant to radiotherapy. To det. whether the vascular endothelial growth factor receptor-2 (Flk-1/KDR) may be a therapeutic target to improve the effects of radiotherapy, we used the sol. extracellular component of Flk-1 (ExFlk), which blocks vascular endothelial growth factor binding to Flk-1 receptor expressed on the tumor endothelium. Both sFlk-1 and the Flk-1-specific inhibitor SU5416 eliminated the resistance phenotype in GBM and melanoma microvasculature as detd. by both the vascular window and Doppler blood flow methods. Human microendothelial cells and human umbilical vein endothelial cells showed minimal radiation-induced apoptosis. The Flk-1 antagonists sFlk-1 and SU5416 reverted these cell models to apoptosis-prone phenotype. Flk-1 antagonists also reverted GBM and melanoma tumor models to radiation-sensitive phenotype after treatment with 3 Gy. These findings demonstrate that the tumor microenvironment including the survival of tumor-assocd. endothelial cells contributes to tumor blood vessel resistance to therapy.


IT 204005-46-9, SU 5416

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(tumor vascularization inhibitor; inhibition of VEGF receptor signaling
enhances radiation-induced response in tumor blood vessels)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 18 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:169669 CAPLUS

DOCUMENT NUMBER: 134:348057

TITLE: The antiangiogenic **protein kinase** inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

AUTHOR(S): Smolich, Beverly D.; Yuen, Helene A.; West, Kristina A.; Giles, Francis J.; Albitar, Maher; Cherrington, Julie M.

CORPORATE SOURCE: Sugen, South San Francisco, CA, 94080, USA

SOURCE: Blood (2001), 97(5), 1413-1421

CODEN: BLOOAW; ISSN: 0006-4971

PUBLISHER: American Society of Hematology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB SU5416 and SU6668 are potent antiangiogenic small-mol. inhibitors of receptor tyrosine kinases, including those of the vascular endothelial growth factor and platelet-derived growth factor receptor families. The stem cell factor (SCF) receptor, c-kit, is structurally related to these receptors and, although not expressed on mature peripheral blood cells, is expressed in leukemic blasts derived from 60% to 80% of acute myeloid leukemia (AML) patients. The c-kit kinase inhibitory activity of SU5416 and SU6668 was evaluated in MO7E cells, a human myeloid leukemia cell line. Tyrosine autophosphorylation of the receptor, induced by SCF, was inhibited in these cells by SU5416 and SU6668 in a dose-dependent manner (inhibitory concn. of 50% [IC50] 0.1-1 .mu.M). Inhibition of extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation, a signaling event downstream of c-kit activation, was also inhibited in a dose-dependent manner. Both compds. also inhibited SCF-induced proliferation of MO7E cells (IC50 0.1 .mu.M for SU5416; 0.29 .mu.M for SU6668). Furthermore, both SU5416 and SU6668 induced apoptosis in a dose- and time-dependent manner as measured by the increase in activated caspase-3 and the enhanced cleavage of its substrate poly(ADP-ribose) polymerase. These findings with MO7E cells were extended to leukemic blasts from c-kit+ patients. In patient blasts, both SU5416 and SU6668 inhibited SCF-induced phosphorylation of c-kit and ERK1/2 and induced apoptosis. These studies indicate that SU5416 and SU6668 inhibit biol. functions of c-kit in addn. to exhibiting antiangiogenic properties and suggest that the combination of these activities may provide a novel therapeutic approach for the treatment of AML.

IT 204005-46-9, SU5416


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(the antiangiogenic **protein kinase** inhibitors

SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 19 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:905718 CAPLUS

DOCUMENT NUMBER: 136:160779

TITLE: Semaxanib (SUGEN)

AUTHOR(S): Sakamoto, Kathleen M.

CORPORATE SOURCE: Department of Pediatrics and Pathology, UCLA School of
Medicine, Los Angeles, CA, 90095-1752, USA

SOURCE: IDrugs (2001), 4(9), 1061-1067

CODEN: IDRUFN; ISSN: 1369-7056

PUBLISHER: Current Drugs Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. SUGEN (owned by Pharmacia) is developing semaxanib (SU-5416),
the lead in a series of small mol. inhibitors of the flk-1 tyrosine kinase
receptor (flk-1 RTK), for the potential treatment of solid tumors (via
suppression of metastasis and angiogenesis). In July 1999, phase III
trials for colorectal and lung cancer were initiated. In Mar. 2001, phase
III trials were initiated for the compd. as an addn. to a std.
chemotherapy regimen in colorectal cancer; at this time, Pharmacia, as
well as the NCI, was conducting clin. studies for numerous other solid and
hematol. cancers. By Oct. 2000, oral forms of the compd. were also being
evaluated. In July 2000, Pharmacia anticipated US and international
filing in 2001. Taiho and SUGEN have agreed a joint development program
for SUGEN's angiogenesis inhibitors. In August 1998, the USPTO issued
US-05792783 to SUGEN, covering a family of compds., including semaxanib.
The patent claims cover the compds. and compn., as well as methods of use
in a variety of diseases, including cancer. In August 1998, the USPTO
issued US-05792783 to SUGEN, covering a family of compds., including
semaxanib. The patent claims cover the compds. and compn., as well as
methods of use in a variety of diseases, including cancer.

IT 194413-58-6, Semaxanib


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
activity); PKT (Pharmacokinetics); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)

(semaxanib, an inhibitor of the flk-1 tyrosine kinase receptor, for
potential treatment of solid tumors in humans)

RN 194413-58-6 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-,
(3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 20 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:688215 CAPLUS

DOCUMENT NUMBER: 133:252306

TITLE: Preparation of indolinones as **protein kinase** inhibitors.

INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Miller, Todd Anthony; Shirazian, Shahrzad; Wei, Chung Chen; Harris, G. Davis; Xiaoyuan, Li; Liang, Congxin

PATENT ASSIGNEE(S): **Sugen, Inc., USA**

SOURCE: PCT Int. Appl., 245 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2000056709 | A1 | 20000928 | WO 2000-US7704 | 20000322 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| EP 1165513 | A1 | 20020102 | EP 2000-916622 | 20000322 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |

PRIORITY APPLN. INFO.:
US 1999-125945P P 19990324
US 1999-127863P P 19990405
US 1999-131192P P 19990426
US 1999-132243P P 19990503
WO 2000-US7704 W 20000322

OTHER SOURCE(S): MARPAT 133:252306
GI



I


AB Title compds., e.g. [I; m, n = 0, 1; Q = (JR11)m; Q1 = (DR6)n; when n = 1, then A, B, D, E, F = C, N; .ltoreq.3 of A, B, D, E, F = N; when m = 1, then G, H, J, K, L = C, N; .gtoreq.1 and .ltoreq.3 of G, H, J, K, L = N; when n = 0, then A = C, N, B, F = C, N, NH, O, S; E = C, N, O, S; when m = 0, then G = C, N, H, K, L = C, N, NH, O, S; R1-R13 = H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, OH, alkoxy, SH, alkylthiol, aryloxy, amino, etc.; R4R5 or R5R6 or R6R7 or R7R8 = atoms to form a 5-6 membered (hetero)aryl ring; with addnl. provisos], were prepd. Thus, 6-pyridin-3-yl-1,3-dihydroindol-2-one (prepn. given), 4-methoxy-3-thien-2-ylbenzaldehyde, and piperidine were refluxed overnight in EtOH to give 15% 3-(4-methoxy-3-thien-2-ylbenzylidene)-6-pyridin-3-yl-1,3-dihydroindol-2-one. Tested title compds. inhibited HER2 kinase with IC50 = 16.4 .mu.M to .gtoreq.100 .mu.M.

IT 251356-74-8P 295799-29-0P 295799-31-4P
295799-47-2P 295799-51-8P 295799-89-2P
295799-90-5P 295799-97-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indolinones as protein kinase inhibitors)

RN 251356-74-8 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 295799-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-[2-[3-(1-methylethyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 295799-31-4 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[[[1,2-dihydro-4-[2-[3-(1-methylethyl)phenoxy]ethyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)




RN 295799-47-2 CAPLUS

CN 2H-Indol-2-one, 3-[[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 295799-51-8 CAPLUS


CN 2H-Indol-2-one, 3-[[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 295799-89-2 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)(4-methoxyphenyl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 295799-90-5 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,4-dimethoxyphenyl)(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 295799-97-2 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[[[1,2-dihydro-4-[2-[4-(1-methylethyl)phenoxy]ethyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




IT 251356-61-3P 251356-63-5P 251356-65-7P
251356-66-8P 251356-67-9P 251356-68-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of indolinones as **protein kinase**
inhibitors)


RN 251356-61-3 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 251356-63-5 CAPLUS

CN 2H-Indol-2-one, 5-bromo-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 251356-65-7 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 251356-66-8 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 251356-67-9 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 251356-68-0 CAPLUS

CN 2H-Indol-2-one, 5-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 21 OF 70 CAPLUS COPYRIGHT 2002 ACS


ACCESSION NUMBER: 2000:421132 CAPLUS

DOCUMENT NUMBER: 133:43433

TITLE: Preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases.

INVENTOR(S): Corbett, Wendy; Leung, Kin-chun; Mahaney, Paige E.
PATENT ASSIGNEE(S): F. Hoffmann-La Roche, A.G., Switz.
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2000035909 | A1 | 20000622 | WO 1999-EP9673 | 19991209 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| BR 9916223 | A | 20010904 | BR 1999-16223 | 19991209 |
| EP 1149093 | A1 | 20011031 | EP 1999-966933 | 19991209 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| US 6307056 | B1 | 20011023 | US 1999-464466 | 19991215 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | US 1998-112590P | P 19981217 |
| | | | US 1999-149028P | P 19990816 |
| | | | WO 1999-EP9673 | W 19991209 |
| OTHER SOURCE(S): MARPAT 133:43433 | | | | |
| GI | | | | |



AB Title compds. [I; A = (substituted) aryl, heteroaryl; R2 = H, halo, OR4, NR6R7, COR4, CO2R4, cyano, NO2, SO2R4, SO2NR6R7, etc.; R3 = H, OR4, COR4, CO2R4, CONR6R7, halo, cyano, NR6R7, perfluoroalkyl, (substituted) alkyl, etc.; R4 = H, (substituted) alkyl, cycloalkyl, heterocyclyl; R6, R7 = H, (substituted) alkyl, cycloalkyl, COR8, CO2R8, SO2R8, etc.; NR6R7 = (substituted) 3-7 membered ring; R8 = H, (substituted) alkyl, aryl, heteroaryl, cycloalkyl; X = N, CH], were prepd. Thus, (Z)-1,3-dihydro-4-iodo-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one (prepn. given) was heated with phenylboronic acid, Pd(OAc)2, Et3N, and tri-O-tolylphosphine in DMF at 100.degree. for 24 h to give 85% (Z)-1,3-dihydro-4-phenyl-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one. Tested I inhibited SAPK with IC50<0.15 .mu.M.

IT 276251-67-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)

RN 276251-67-3 CAPLUS

CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 22 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:421131 CAPLUS

DOCUMENT NUMBER: 133:43432

TITLE: Preparation of 4-alkynyl-3-(pyrrolylmethylene)-2-oxindoles as inhibitors of cyclin-dependent kinases, in particular CDK2

INVENTOR(S): Chen, Yi; Corbett, Wendy Lea; Dermatakis, Apostolos; Liu, Jin-jun; Luk, Kin-chun; Mahaney, Paige E.; Mischke, Steven-Gregory

PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.

SOURCE: PCT Int. Appl., 170 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2000035908 | A1 | 20000622 | WO 1999-EP9624 | 19991208 |
| W: | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| BR 9916327 | A | 20010918 | BR 1999-16327 | 19991208 |
| EP 1157019 | A1 | 20011128 | EP 1999-963422 | 19991208 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |
| US 6130239 | A | 20001010 | US 1999-464502 | 19991215 |

| | | | | |
|------------------------|----|----------|-----------------|-------------|
| US 6252086 | B1 | 20010626 | US 2000-549864 | 20000414 |
| US 6303793 | B1 | 20011016 | US 2000-566054 | 20000505 |
| PRIORITY APPLN. INFO.: | | | US 1998-112591P | P 19981217 |
| | | | US 1999-149073P | P 19990816 |
| | | | WO 1999-EP9624 | W 19991208 |
| | | | US 1999-464502 | A3 19991215 |

OTHER SOURCE(S): MARPAT 133:43432
GI



AB The title compds. (I) [wherein R1 = H, acyl, carboxy, carbamido, (un)substituted (cyclo)alkyl, or heterocyclcyl; R2 = H, alkoxy, acyl(oxy), carboxy, carbamido, halogen, NO2, CN, sulfamido, perfluoroalkyl, alkyl, etc.; R3 = H, alkoxy, acyl(oxy), carboxy, carbamido, halogen, CN, amino, perfluoroalkyl, alkyl, etc.; X = N or (un)substituted C] and their intermediates and analogs were prepd. by reaction of alkynes with 4-halo-2-oxoindoles. I inhibit cyclin-dependent kinases (CDKs), esp. CDK2, and are useful as anti-proliferative agents in the treatment or control of cell proliferative disorders, in particular breast and colon tumors. For example, Me 4-pentynoate was coupled with (Z)-4-bromo-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-2H-indole-2-one (prepn. given) using (Ph3P)2PdCl2 and CuI as catalysts in DMF and TEA to give (Z)-II in 72% yield. In a CDK2 flash plate assay, II inhibited CDK2 by > 90% at concns. of .ltoreq. 1.0 .mu.M. Representative compds. of the invention were tested in cell-based assays against epithelial breast carcinoma line MDA-MB435 and colon carcinoma line SW480 and gave IC50 values of < 3.5 .mu.M and < 1.0 .mu.M, resp. Formulations for tablets, capsules, and injection soln./emulsion preps. are also included.


IT **275387-68-3P**, (Z)-3-[(4-Acetyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-fluoro-4-iodo-2H-indol-2-one **275387-99-0P**
275388-01-7P 275388-18-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 4-alkynyl-3-(pyrrolylmethylene)-2-oxoindole anti-proliferatives and analogs by reaction of alkynes with the corresponding 4-halo-2-oxoindoles)

RN 275387-68-3 CAPLUS

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-iodo-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 275387-99-0 CAPLUS

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(2S)-2-pyrrolidinylethynyl]-, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 275388-01-7 CAPLUS

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[[(2S,4R)-4-hydroxy-2-pyrrolidinyl]ethynyl]-, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 275388-18-6 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-fluoro-1,2-dihydro-2-oxo-4-[(2S)-2-pyrrolidinylethynyl]-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 275387-69-4P 275387-73-0P 275387-74-1P
275387-77-4P 275387-78-5P 275388-00-6P
275388-02-8P 275388-03-9P 275388-04-0P
275388-10-8P 275388-19-7P 275388-31-3P
275388-32-4P 275388-33-5P 275388-34-6P
275388-35-7P


RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of 4-alkynyl-3-(pyrrolylmethylene)-2-oxoindole
anti-proliferatives and analogs by reaction of alkynes with the
corresponding 4-halo-2-oxoindoles)

RN 275387-69-4 CAPLUS

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-
dihydro-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)ethynyl]-, (3Z)- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 275387-73-0 CAPLUS

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-
dihydro-4-[3-(methylamino)-1-propynyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 275387-74-1 CAPLUS

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[3-(methylamino)-1-propynyl]-, monohydrochloride, (3Z)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275387-77-4 CAPLUS

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(3-hydroxy-3-pyrrolidinyl)ethynyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 275387-78-5 CAPLUS

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(3-hydroxy-3-pyrrolidinyl)ethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275388-00-6 CAPLUS

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(2S)-2-pyrrolidinylethynyl]-, monohydrochloride, (3Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




● HCl

RN 275388-02-8 CAPLUS

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[[(2S, 4R)-4-hydroxy-2-pyrrolidinyl]ethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 275388-03-9 CAPLUS
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[3-(ethylamino)-1-propynyl]-5-fluoro-1,3-dihydro-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 275388-04-0 CAPLUS
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(4-hydroxy-4-piperidiny)ethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275388-10-8 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[4-[3-(ethylamino)-1-propynyl]-5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275388-19-7 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-fluoro-1,2-dihydro-2-oxo-4-[(2S)-2-pyrrolidinylethynyl]-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



● HCl

RN 275388-31-3 CAPLUS
 CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[3-[(2-hydroxypropyl)amino]-1-propynyl]-, monohydrochloride, (3Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl


RN 275388-32-4 CAPLUS
 CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(3R,4S,5R)-4-(ethylamino)-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 275388-33-5 CAPLUS
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(2R)-3-(ethylamino)-2-methyl-2H-pyran-6-yl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 275388-34-6 CAPLUS
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(3R,4S,5R)-4-amino-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 275388-35-7 CAPLUS
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(3S,4S,5R)-4-amino-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 23 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:144722 CAPLUS

DOCUMENT NUMBER: 132:185454

TITLE: Use of anti-angiogenic agents for inhibiting vessel wall injury

INVENTOR(S): Brown, Charles L., III; Gorlin, Steve

PATENT ASSIGNEE(S): Global Vascular Concepts, Inc., USA

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2000010552 | A2 | 20000302 | WO 1999-US19218 | 19990824 |
| WO 2000010552 | A3 | 20001123 | | |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9956871 A1 20000314 AU 1999-56871 19990824

PRIORITY APPLN. INFO.: US 1998-97579P P 19980824
WO 1999-US19218 W 19990824


AB Use of anti-angiogenic agents to inhibit an undesirable response to vessel wall injury, including stent neointima, dialysis graft neointima, vascular graft-induced neointima, and the treatment of benign hypertrophic scar formation as well as the treatment and passivation of unstable atherosclerotic plaques are provided. The invention provides for the use of catheter-based devices for enhancing the local delivery of anti-angiogenic agents into the endothelial tissues of blood vessels of the living body.

IT 204005-46-9, SU5416

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-angiogenic agents for inhibiting vessel wall injury)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



L65 ANSWER 24 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:117197 CAPLUS

DOCUMENT NUMBER: 132:166123

TITLE: 3-Methylidenyl-2-indolinone modulators of
protein kinaseINVENTOR(S): Tang, Peng Cho; Sun, Li; Miller, Todd Anthony; Liang,
Congxin; Tran, Ngoc My; Nguyen, Anh Thi; Nematalla,
Asaad

PATENT ASSIGNEE(S): Sugen, Inc., USA

SOURCE: PCT Int. Appl., 347 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2000008202 | A2 | 20000217 | WO 1999-US17845 | 19990804 |
| WO 2000008202 | A3 | 20000518 | | |
| W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 9954684 | A1 | 20000228 | AU 1999-54684 | 19990804 |
| PRIORITY APPLN. INFO.: | | | US 1998-129256 | A 19980804 |
| | | | US 1998-95470P | P 19980805 |
| | | | US 1998-102178P | P 19980928 |
| | | | US 1999-116107P | P 19990115 |
| | | | WO 1999-US17845 | W 19990804 |
| OTHER SOURCE(S): | MARPAT 132:166123 | | | |
| GI | | | | |



I



II

The title compds. (I) [wherein A = C or N; Q = substituted Ph, pyrrolyl, or indolyl; R0 = H, alkyl, C(O)R19, or C(O)OR19; R1 = H, (un)substituted alkyl, alkoxy, halo, aryl, (CH2)nOC(O)R19, or C(O)NR19; R2 = H, (cyclo)alkyl, (hetero)aryl, heteroalicyclic, trihalomethyl, alkoxy, halo, sulfamido, C(O)OR19, C(O)R19, NHC(O)OR19, (un)substituted amino, etc.; R3 = H, alkyl, trihalomethyl, alkoxy, aryl(oxy), heteroaryl, heteroalicyclic, OH, halo, sulfamido, C(O)R19, (un)substituted amino, etc.; R4 = H, alkyl, alkoxy, or halo; R19 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; n = 1-4] were prepd. as modulators of the activity of receptor tyrosine kinases (RTKs), non-receptor **protein tyrosine kinases** (CTKs), and serine/threonine **protein kinases** (STKs).

Examples include over 200 syntheses and data from seventeen bioassays. For instance, II was prepd. by a 3-step sequence involving: (1) cyclization and redn. of 2,4-dinitrophenylacetic acid with SnCl2.2H2O in EtOH to form 6-amino-2-oxindole, (2) amidation with AcCl in CH2Cl2, and (3) condensation of the amide with 3,5-diisopropyl-4-methoxybenzaldehyde. II was tested for HER-2 kinase activity (IC50 = 6.4 .mu.M), cellular proliferation activity as measured by the incorporation of bromodeoxyuridine (BrdU) driven by HER-2 (IC50 = 9.1 .mu.M) or EGF (IC50 = 11 .mu.M), and antitumor activity as measured by growth of SKOV3 ovarian carcinoma cells (IC50 = 2.6 .mu.M) or A431 human epidermoid carcinoma cells (IC50 = 2.2 .mu.M). The invention compds. are expected to be useful in the prevention and treatment of **protein kinase** related cellular disorders such as cancer, **diabetes**, hepatic cirrhosis, cardiovascular disease, and immunol. disease.

8831-72-0P 258831-76-4P 258831-77-5P

8831-78-6P 258831-79-7P 258831-80-0P

8831-81-1P 258831-82-2P 258831-84-4P

8831-87-7P 258831-89-9P 258831-90-2P

8831-91-3P 258831-92-4P

(Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (or reagent)

mediate; prepn. of 3-methylidenyl-2-indolinones as


kinase modulators for the prevention and

of cancer, **diabetes**, hepatic cirrhosis,

ular disease, and immunol. disease)


APLUS

[2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo-1H-indol-5-yl]ethyl ester (9CI) (CA INDEX NAME)




RN 258831-76-4 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 258831-77-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-carboxy-2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 258831-78-6 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)




RN 258831-79-7 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 258831-80-0 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-carboxy-2-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 258831-81-1 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-carboxy-2-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 258831-82-2 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-carboxy-2-[(1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 258831-84-4 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-carboxy-2-[(6-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 258831-87-7 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-carboxy-4-methyl- (9CI) (CA INDEX NAME)




RN 258831-89-9 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-carboxy-2-[(1,2-dihydro-5-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 258831-90-2 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-carboxy-2-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 258831-91-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-carboxy-2-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 258831-92-4 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-carboxy-2-[[6-(3-ethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)




IT 258830-03-4P 258830-04-5P 258830-17-0P

RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; as **protein kinase** modulators for the prevention and treatment of cancer, **diabetes**, hepatic cirrhosis, cardiovascular disease, and immunol. disease)


RN 258830-03-4 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 258830-04-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 258830-17-0 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[[4-(ethoxycarbonyl)-5-methyl-3-[3-(4-methyl-1-piperazinyl)propyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




IT 245036-29-7P 258831-06-0P 258831-07-1P

RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (target compd.; prepn. of 3-methylidenyl-2-indolinones as **protein kinase** modulators for the prevention and treatment of cancer, **diabetes**, hepatic cirrhosis, cardiovascular disease, and immunol. disease)


RN 245036-29-7 CAPLUS

CN 1H-Indole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 258831-06-0 CAPLUS


CN 1H-Indole-3-propanoic acid, 2-[(5-chloro-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 258831-07-1 CAPLUS

CN 1H-Indole-3-propanoic acid, 2-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-

indol-3-ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




IT 22813-86-1P 215543-92-3P 245036-10-6P
 245036-15-1P 245036-16-2P 245036-17-3P
 245036-28-6P 256657-46-2P 256657-47-3P
 256657-49-5P 256657-51-9P 258829-97-9P
 258829-98-0P 258829-99-1P 258830-00-1P
 258830-01-2P 258830-02-3P 258830-05-6P
 258830-06-7P 258830-07-8P 258830-08-9P
 258830-09-0P 258830-10-3P 258830-11-4P
 258830-12-5P 258830-13-6P 258830-14-7P
 258830-15-8P 258830-16-9P 258830-18-1P
 258830-19-2P 258830-20-5P 258830-21-6P
 258830-22-7P 258830-23-8P 258830-24-9P
 258830-26-1P 258830-28-3P 258830-30-7P
 258830-32-9P 258830-34-1P 258830-36-3P
 258830-37-4P 258830-39-6P 258830-41-0P
 258830-43-2P 258830-45-4P 258830-47-6P
 258830-49-8P 258830-51-2P 258830-53-4P
 258830-55-6P 258830-57-8P 258830-59-0P
 258830-61-4P 258830-63-6P 258830-64-7P
 258830-65-8P 258830-66-9P 258830-68-1P
 258830-69-2P 258830-70-5P 258830-71-6P
 258830-72-7P 258830-73-8P 258830-74-9P
 258830-75-0P 258830-76-1P 258830-77-2P
 258830-78-3P 258830-79-4P 258830-83-0P
 258830-88-5P 258830-92-1P 258830-93-2P
 258830-94-3P 258830-95-4P 258830-96-5P
 258830-97-6P 258830-98-7P 258830-99-8P
 258831-00-4P 258831-01-5P 258831-02-6P
 258831-04-8P 258831-05-9P 258831-08-2P
 258831-09-3P 258831-11-7P 258831-12-8P
 258831-13-9P 258831-14-0P 258831-15-1P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(target compd.; prepn. of 3-methylidenyl-2-indolinones as
protein kinase modulators for the prevention and
 treatment of cancer, **diabetes**, hepatic cirrhosis,
 cardiovascular disease, and immunol. disease)


RN 22813-86-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)- (9CI) (CA INDEX
 NAME)




RN 215543-92-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 245036-10-6 CAPLUS

CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 245036-15-1 CAPLUS

CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-6-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 245036-16-2 CAPLUS

CN 1H-Indole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 245036-17-3 CAPLUS

CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 245036-28-6 CAPLUS

CN 1H-Indole-3-propanamide, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 256657-46-2 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 256657-47-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 256657-49-5 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 256657-51-9 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[6-(3-ethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 258829-97-9 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[6-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 258829-98-0 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 4-(ethoxycarbonyl)-2-[[6-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 258829-99-1 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 258830-00-1 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 258830-01-2 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 258830-02-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 258830-05-6 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-06-7 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-[3-(4-morpholinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-07-8 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-08-9 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-[3-(dimethylamino)propyl]-2-methyl-, ethyl ester (9CI)
(CA INDEX NAME)




RN 258830-09-0 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-[3-(4-morpholinyl)propyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 258830-10-3 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-11-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-morpholinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-12-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-13-6 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[[4-(ethoxycarbonyl)-5-methyl-3-[3-(4-morpholinyl)propyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-14-7 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-6-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-[3-(1-pyrrolidinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-15-8 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-2-methyl-4-[3-(1-pyrrolidinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-16-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[[4-(ethoxycarbonyl)-5-methyl-3-[3-(1-pyrrolidinyl)propyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-18-1 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(1-pyrrolidinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-19-2 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-4-(2-hydroxyethyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-morpholinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-20-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-4-(2-hydroxyethyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(1-pyrrolidinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-21-6 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-[3-(dimethylamino)propyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-22-7 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[[3-[3-(dimethylamino)propyl]-4-(ethoxycarbonyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-23-8 CAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-4-(2-hydroxyethyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-[3-(dimethylamino)propyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-24-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-4-(2-hydroxyethyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-26-1 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-[3-(dimethylamino)propyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 258830-28-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-[3-(dimethylamino)propyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-30-7 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-32-9 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-34-1 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-36-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(6-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-37-4 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-39-6 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-41-0 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-43-2 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-45-4 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-47-6 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[[[1,2-dihydro-5-[[[1-methylethyl)amino]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-49-8 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[[3-[3-(dimethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-51-2 CAPLUS

CN 2H-Indol-2-one, 3-[[[3-[3-(dimethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 258830-53-4 CAPLUS

CN 2H-Indol-2-one, 3-[[[3-[3-(dimethylamino)propyl]-1H-indol-2-yl]methylene]-1,3-dihydro-5-methoxy- (9CI) (CA INDEX NAME)




RN 258830-55-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-methyl-3-[(3-methyl-1H-indol-2-yl)methylene]-
(9CI) (CA INDEX NAME)




RN 258830-57-8 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(3-methyl-1H-indol-2-yl)methylene]-
2-oxo- (9CI) (CA INDEX NAME)




RN 258830-59-0 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(3-methyl-1H-indol-2-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 258830-61-4 CAPLUS


CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-3-[(3-methyl-1H-indol-2-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 258830-63-6 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[(3-methyl-1H-indol-2-yl)methylene]-2-oxo-, compd. with piperidine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 258830-62-5
CMF C19 H14 N2 O3




CM 2


CRN 110-89-4
CMF C5 H11 N



RN 258830-64-7 CAPLUS
CN 2H-Indol-2-one, 5-acetyl-1,3-dihydro-3-[(3-methyl-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 258830-65-8 CAPLUS
CN 2H-Indol-2-one, 5-acetyl-1,3-dihydro-3-(1H-indol-2-ylmethylene)- (9CI) (CA INDEX NAME)




RN 258830-66-9 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo-
(9CI) (CA INDEX NAME)




RN 258830-68-1 CAPLUS

CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-(1H-indol-2-ylmethylene)- (9CI) (CA
INDEX NAME)




RN 258830-69-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo-
(9CI) (CA INDEX NAME)




RN 258830-70-5 CAPLUS

CN 2H-Indol-2-one, 6-chloro-1,3-dihydro-3-(1H-indol-2-ylmethylene)- (9CI)
(CA INDEX NAME)




RN 258830-71-6 CAPLUS


CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(1H-indol-2-ylmethylene)- (9CI)
(CA INDEX NAME)




RN 258830-72-7 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3-(1H-indol-2-ylmethylene)- (9CI) (CA
INDEX NAME)




RN 258830-73-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-4-methyl- (9CI)
(CA INDEX NAME)




RN 258830-74-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-indol-2-yl)methylene]- (9CI)
(CA INDEX NAME)




RN 258830-75-0 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(3-methyl-1H-indol-2-yl)methylene]-
(9CI) (CA INDEX NAME)




RN 258830-76-1 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3-[(3-methyl-1H-indol-2-yl)methylene]-
(9CI) (CA INDEX NAME)




RN 258830-77-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-methyl-3-[(3-methyl-1H-indol-2-yl)methylene]-
(9CI) (CA INDEX NAME)




RN 258830-78-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-5-[(1H-indol-2-ylmethylene)amino]- (9CI) (CA INDEX NAME)




RN 258830-79-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-83-0 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(3-methyl-1H-indol-2-yl)methylene]-
(9CI) (CA INDEX NAME)




RN 258830-88-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N,N-
dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-92-1 CAPLUS
CN 1H-Indole-3-propanoic acid, 2-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 258830-93-2 CAPLUS
CN 1H-Indole-3-propanoic acid, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 258830-94-3 CAPLUS
CN 1H-Indole-3-propanoic acid, 2-[(1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 258830-95-4 CAPLUS
CN 1H-Indole-3-propanoic acid, 2-[(1,2-dihydro-5-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 258830-96-5 CAPLUS
CN 1H-Indole-3-propanoic acid, 2-[(6-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 258830-97-6 CAPLUS
CN 1H-Indole-3-propanoic acid, 2-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 258830-98-7 CAPLUS

CN 1H-Indole-3-propanamide, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 258830-99-8 CAPLUS

CN 2H-Indol-2-one, 3-[[3-[3-(dimethylamino)propyl]-4,5,6,7-tetrahydro-1H-indol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 258831-00-4 CAPLUS

CN 1H-Indole-3-propanamide, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 258831-01-5 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[[4,5,6,7-tetrahydro-3-[3-(4-morpholinyl)propyl]-1H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)




RN 258831-02-6 CAPLUS

CN 1H-Indole-3-propanamide, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro-N-methyl- (9CI) (CA INDEX NAME)




RN 258831-04-8 CAPLUS

CN 1H-Indole-3-propanoic acid, 2-[[[1,2-dihydro-5-[[[(1-methylethyl)amino]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 258831-05-9 CAPLUS

CN 1H-Indole-3-propanoic acid, 2-[[[1,2-dihydro-6-(4-morpholinyl)-2-oxo-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 258831-08-2 CAPLUS

CN 1H-Indole-3-propanamide, 2-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 258831-09-3 CAPLUS

CN 1H-Indole-3-propanamide, 2-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 258831-11-7 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 258831-12-8 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 258831-13-9 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(6-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 258831-14-0 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-5-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 258831-15-1 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



L65 ANSWER 25 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:83373 CAPLUS

DOCUMENT NUMBER: 135:86674

TITLE: The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function

AUTHOR(S): Mendel, Dirk B.; Schreck, Randall E.; West, David C.; Li, Guangmin; Strawn, Laurie M.; Tanciongco, Sheila S.; Vasile, Stefan; Shawver, Laura K.; Cherrington, Julie M.

CORPORATE SOURCE: Sugen, Inc., South San Francisco, CA, 94080, USA

SOURCE: Clinical Cancer Research (2000), 6(12), 4848-4858

CODEN: CCREF4; ISSN: 1078-0432

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB SU5416, a selective inhibitor of the tyrosine kinase activity of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR, is currently in Phase III clin. trials for the treatment of advanced malignancies. In cellular assays, SU5416 inhibits the VEGF-dependent mitogenic/proliferative response of human umbilical vein endothelial cells (HUVECs). In tumor xenograft models, SU5416 inhibits the growth of tumors from a variety of origins by inhibiting tumor angiogenesis. In three different human tumor xenograft models, infrequent (once or twice a week)

administration of SU5416 is efficacious despite the fact that it has a short plasma half-life (30 min), which suggests that SU5416 has long-lasting inhibitory activity in vivo. The goal of the present study was to det. the basis for the prolonged activity of SU5416. The results indicate that a short (3 h) exposure to 5 .mu.M SU5416 (to mimic plasma levels of the compd. as measured in patients who were receiving SU5416 therapy) produced long-lasting (at least 72 h) inhibition of the VEGF-dependent proliferation of HUVECs in culture, which indicate that SU5416 has long-lasting inhibitory activity in vitro as well as in vivo. SU5416 treatment of HUVECs did not affect surface expression of Flk-1/KDR or the affinity of the receptor for VEGF. Instead, the durability of the in vitro activity of SU5416 was shown to be attributable to its long-lasting ability to specifically inhibit VEGF-dependent phosphorylation of Flk-1/KDR and subsequent downstream signaling, although SU5416 is not an irreversible inhibitor of Flk-1/KDR tyrosine kinase activity. The long-lasting inhibition of cellular responses to VEGF was attributable to the accumulation of SU5416 in cells, as shown using radiolabeled compd., such that inhibitory cellular concns. of SU5416 are maintained long after the removal of the compd. from the medium. The long-lasting inhibitory activity of SU5416 in vitro is consistent with the finding that SU5416 has demonstrated evidence of biol. activity in clin. studies when administered twice a week despite a short plasma half-life.


IT 204005-46-9, SU5416

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function in relation to antitumor effects)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 26 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:500184 CAPLUS

DOCUMENT NUMBER: 133:234344

TITLE: DoMCoSAR: A Novel Approach for Establishing the Docking Mode That Is Consistent with the Structure-Activity Relationship. Application to HIV-1 Protease Inhibitors and VEGF Receptor Tyrosine Kinase Inhibitors

AUTHOR(S): Vieth, Michal; Cummins, David J.

CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA

SOURCE: Journal of Medicinal Chemistry (2000), 43(16), 3020-3032

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB DoMCoSAR is a novel approach for statistically detg. the docking mode that is consistent with a structure-activity relationship. The approach establishes the binding mode for the compds. in a chem. series with the assumption that all mols. exhibit the same binding mode. It involves three stages. In the first stage all mols. that belong to a given chem. series are docked to the active site of the protein target. The only bias used in the docking at this stage involves the location of the protein binding site. Coordinates of the common substructure (CS) that results from the unbiased docking are then clustered to establish the major substructure docking modes. In the second stage all mols. are docked to the major docking modes (MDMs) with constraints based on the common substructure. The third stage generates, for the major docking modes, interaction-based descriptors that include electrostatic, VDW, strain, and solvation contributions. The problem of docking mode evaluation is now reduced to the question of which descriptor set is more predictive. To establish a quant. comparison of the descriptor sets assocd. with the major docking modes, we use 50 instances of random 4-fold cross-validation. For each 4-fold cross-validation the predictive squared correlation coeff. (R2) is computed. T-Tests are applied to establish significance of the differences in mean R for one docking mode vs. another. We test the methodol. on two test cases: HIV-1 protease inhibitors (Holloway et al. J. Med. Chem. 1995, 38, 305-317) and vascular endothelial growth factor (VEGF) receptor tyrosine kinase oxoindoles (Sun et al. J. Med. Chem. 1998, 41, 2588-2603). For both test cases there is statistically significant preference for the binding mode consistent with the x-ray structure. The appeal of this methodol. is that researchers gain the objectivity of statistical justification for the selected docking mode. The methodol. is relatively insensitive to subtle variations of the protein structure that include, but are not limited to, side chain and small backbone rearrangement during binding. In addn., predictive models that result from the approach can be used to further optimize chem. series.


IT 15966-93-5 186610-94-6 186611-29-0
186611-37-0 186611-48-3 204005-46-9
204005-54-9 293302-24-6 293302-25-7
293302-26-8 293302-27-9

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(VEGF kinase-inhibitor; DoMCoSAR - novel approach for establishing docking mode that is consistent with structure-activity relationship with application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors)


RN 15966-93-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186610-94-6 CAPLUS


CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-37-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-54-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 293302-24-6 CAPLUS

CN 2H-Indol-2-one, 3-[[3-(3,3-dihydroxypropyl)-4-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 293302-25-7 CAPLUS

CN 2H-Indol-2-one, 3-[[4-(3,3-dihydroxypropyl)-3-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 293302-26-8 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-6-fluoro-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 293302-27-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 27 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:860816 CAPLUS

DOCUMENT NUMBER: 134:141334

TITLE: ~~Biotransformation of the anti-angiogenic compound~~
SU5416

AUTHOR(S): Antonian, Lida; Zhang, Hongbing; Yang, Cheng; Wagner, Greg; Shawver, Laura K.; Shet, Manjunath; Ogilvie, Brian; Madan, Ajay; Parkinson, Andrew

CORPORATE SOURCE: ~~SUGEN, Inc.~~, South San Francisco, CA, 94080, USA
SOURCE: Drug Metabolism and Disposition ~~(2000)~~, 28(12), 1505-1512

PUBLISHER: CODEN: DMDSAI; ISSN: 0090-9556
American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB SU5416 [3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one], an inhibitor of VEGF (vascular endothelial growth factor) receptor tyrosine kinase, Flk-1/KDR (fetal liver kinase 1/kinase insert domain-contg. receptor), also known as VEGF receptor 2 (VEGFR2) is in advanced clin. trials for treatment of **AIDS-related Kaposi's sarcoma** and colorectal and nonsmall cell lung cancers. Since this chem. class has not been studied previously with therapeutic intent, the present study was designed to investigate the in vitro metab. of SU5416 by mouse, rat, dog, monkey, and human liver microsomes and to identify the major metabolites of SU5416. An HPLC procedure was developed and validated to resolve and quantify SU5416 and its metabolites. To evaluate the in vitro metab. of SU5416, pooled liver microsomes from mice, rats, dogs, monkeys, and humans were incubated with SU5416 (25 .mu.M) in the presence of an NADPH-generating system. In the presence of NADPH, mouse, rat, dog, monkey, and human liver microsomes converted SU5416 to at least 12, 9, 9, 7, and 6 polar metabolites, resp. Microsomal metab. of SU5416 showed marked species differences in the levels of different metabolites formed. The overall rate of SU5416 metab. by liver microsomes from the species examd. followed the rank order: monkey .gtoreq. mouse .apprxeq. rat > dog > human. Two major metabolites of SU5416 were

identified, a hydroxymethyl deriv. of SU5416 (M12) and a carboxylic acid deriv. of SU5416 (M6), by spectroscopic methods and comparison with authentic compds. Both of these oxidative metabolites were further metabolized in vivo through glucuronidation. The metabolic fate of SU5416 in microsomes from various species as well as data from in vivo biotransformation in the rat are discussed.


IT 204005-46-9, SU5416

RL: ANT (Analyte); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process)

(biotransformation of anti-angiogenic compd. SU5416)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



IT 280748-38-1, SU 6689 280748-39-2, SU 6595


280748-41-6, SU 9838 324047-04-3 324047-05-4

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)

(biotransformation of anti-angiogenic compd. SU5416)


RN 280748-38-1 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-hydroxy- (9CI) (CA INDEX NAME)




RN 280748-39-2 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 280748-41-6 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-3-[[5-(hydroxymethyl)-3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 324047-04-3 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, [5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 324047-05-4 CAPLUS

CN .beta.-D-Glucopyranuronic acid, 1-[5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrole-2-carboxylate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 28 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:431391 CAPLUS

DOCUMENT NUMBER: 133:246860

TITLE: Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells

AUTHOR(S): Ma, Yongsheng; Carter, Eric; Wang, Xiaomei; Shu, Chang; McMahon, Gerald; Longley, B. Jack

CORPORATE SOURCE: Department of Dermatology, College of Physicians and Surgeons, Columbia University, New York, NY, 10032, USA

SOURCE: Journal of Investigative Dermatology (2000), 114(2),

392-394

CODEN: JIDEAE; ISSN: 0022-202X

PUBLISHER: Blackwell Science, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mastocytosis is a neoplastic disease caused at least in part by somatic mutations of the c-KIT protooncogene resulting in constitutive activation of its protein product, KIT, the receptor tyrosine kinase for stem cell factor. KIT stimulates mast cell proliferation and prevents apoptosis of neoplastic mast cells. To develop potential therapies for mastocytosis we used indolinones, small mols. that inhibit tyrosine kinases. Four indolinone derivs. (SU4984, SU6663, SU6577, and SU5614) inhibited wild-type KIT, but variably inhibited constitutively activated KIT mutants. SU4984, SU6577, and SU5614 were effective against KIT with juxtamembrane activating mutations, whereas only SU6577 could suppress KIT contg. either juxtamembrane or kinase domain activating mutations. Furthermore, SU4984, SU6577, and SU5614 killed neoplastic mast cells expressing a juxtamembrane-mutated KIT, whereas SU4984 and SU6577 killed neoplastic mast cells expressing KIT bearing a kinase domain mutation. These data show a direct correlation between inhibition of constitutively activated KIT and the death of neoplastic mast cells, and point to specific tyrosine kinase inhibitors as a potential therapy aimed directly at a cause of mastocytosis.

IT 186611-14-3, SU 6663 186611-56-3, SU 5614

251356-17-9, SU 6577

RL: BAC (Biological activity or effector, except adverse); BSU


(Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(indolinone derivs. inhibit activated KIT mutants and kill neoplastic mast cells)


RN 186611-14-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-56-3 CAPLUS

CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-17-9 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-6-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 29 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:64436 CAPLUS

DOCUMENT NUMBER: 132:342905

TITLE: Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative

AUTHOR(S): Lanzi, Cinzia; Cassinelli, Giuliana; Pensa, Tiziana; Cassinis, Marco; Gambetta, Romolo A.; Borrello, Maria G.; Menta, Ernesto; Pierotti, Marco A.; Zunino, Franco
CORPORATE SOURCE: Division of Experimental Oncology B, Istituto Nazionale Tumori, Milan, 20133, Italy

SOURCE: International Journal of Cancer (2000), 85(3), 384-390
CODEN: IJCNAB; ISSN: 0020-7136

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Ret-derived oncogenes are frequently and specifically expressed in thyroid tumors. In contrast to the ret receptor, ret oncoproteins are characterized by ligand-independent tyrosine-kinase activity and tyrosine phosphorylation. In this study, novel synthetic arylidene 2-indolinone compds. were evaluated as inhibitors of the ret/ptc1 tyrosine kinase. Four compds. inhibited ret/ptc1 activity in immunokinase assay (IC50 27-42 .mu.M) including one (1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl)methylene]-2H-indol-2-one) (Cpd I) that selectively inhibited the anchorage-independent growth of NIH3T3 transformants expressing the ret/ptc1 gene (NIH3T3ptc1 cells). Following exposure to Cpd I, the transformed phenotype of NIH3T3ptc1 cells was reverted, within 24 h, to a normal fibroblast-like morphol. in adherent-cell culture. In these cells, the constitutive tyrosine phosphorylation of ret/ptc1, of the transducing adaptor protein shc and of a series of co-immunopptd. peptides became much reduced, as demonstrated by immunopptn./Western-blot analyses. Data presented provide addnl. evidence that ret/ptc1 is directly implicated in malignant transformation, and demonstrate the ability of Cpd I to interfere in the signal transduction pathway constitutively activated by the ret/ptc1 oncoprotein. These results confirm the interest of the arylidene 2-indolinone class of tyrosine-kinase inhibitors as tools for the study of ret signaling and the control of cell proliferation in ret- and ret/ptcs-assocd. diseases.

IT 269730-08-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (inhibition of transforming activity of ret/ptc1 oncoprotein by 2-indolinone derivs.)

RN 269730-08-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-5,6-dimethoxy-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 30 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:509842 CAPLUS

DOCUMENT NUMBER: 133:348326

TITLE: Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC

AUTHOR(S): Vajkoczy, Peter; Menger, Michael D.; Goldbrunner, Roland; Ge, Shugang; Annie, T.; Fong, T.; Vollmar, Brigitte; Schilling, Lothar; Ullrich, Axel; Hirth, K. Peter; Tonn, Jorg C.; Schmiedek, Peter; Rempel, Sandra A.

CORPORATE SOURCE: Department of Neurosurgery, Klinikum Mannheim, University of Heidelberg, Mannheim, D-68167, Germany

SOURCE: International Journal of Cancer (2000), 87(2), 261-268
CODEN: IJCNAB; ISSN: 0020-7136

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The solid growth of high-grade glioma appears to be critically dependent on tumor angiogenesis. It remains unknown, however, whether the diffuse infiltration of glioma cells into healthy adjacent tissue is also dependent on the formation of new tumor vessels. Here, the authors analyze the relation between tumor angiogenesis and tumor cell infiltration in an exptl. glioma model. C6 cells were implanted into the dorsal skinfold chamber of nude mice, and tumor angiogenesis was monitored by intravital fluorescence videomicroscopy. Glioma infiltration was assessed by the extent of tumor cell invasion into the adjacent chamber tissue and by expression of SPARC, a cellular marker of glioma invasiveness. To test the hypothesis that glioma angiogenesis and glioma infiltration are codependent, the authors assessed tumor infiltration in both the presence and the absence of the angiogenesis inhibitor SU5416. SU5416 is a selective inhibitor of the VEGF/Flk-I signal-transduction pathway, a crit. pathway implicated in angiogenesis. Control tumors demonstrated both high angiogenic activity and tumor cell invasion accompanied by strong expression of SPARC in invading tumor cells at the tumor-host tissue border. SU5416-treated tumors demonstrated reduced vascular d. and vascular surface in the tumor periphery accompanied by marked inhibition of glioma invasion and decreased SPARC expression. A direct effect of SU5416 on glioma cell motility and invasiveness was excluded by in vitro migration and invasion assays. These results suggest a crucial role for glioma-induced angiogenesis as a prerequisite for diffuse tumor invasion and a possible therapeutic role for anti-angiogenic compds. as inhibitors of both solid and diffuse infiltrative tumor growth.

IT 204005-46-9, SU5416

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(targeting angiogenesis inhibits tumor infiltration and expression of pro-invasive protein SPARC using VEGF/Flk-I signal-transduction pathway inhibitor SU5416)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-

(9CI) (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 31 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:459469 CAPLUS

DOCUMENT NUMBER: 133:144316

TITLE: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent

AUTHOR(S): Mendel, Dirk B.; Laird, A. Douglas; Smolich, Beverly D.; Blake, Robert A.; Liang, Congxin; Hannah, Alison L.; Shaheen, Raymond M.; Ellis, Lee M.; Weitman, Steve; Shawver, Laura K.; Cherrington, Julie M.

CORPORATE SOURCE: SUGEN, Inc., South San Francisco, CA, 94080, USA

SOURCE: Anti-Cancer Drug Design (2000), 15(1), 29-41

CODEN: ACDDEA; ISSN: 0266-9536

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English


AB A review with over 60 refs. Angiogenesis, or the sprouting of new blood vessels, is a central process in the growth of solid tumors. For many cancers, the extent of vascularization of a tumor is a neg. prognostic indicator signifying aggressive disease and increased potential for metastasis. Recent efforts to understand the mol. basis of tumor-assocd. angiogenesis have identified several potential therapeutic targets, including the receptor tyrosine kinases for the angiogenic factor vascular endothelial growth factor (VEGF). Here we review the approach taken at SUGEN, Inc. to discover and develop small mol. inhibitors of receptor tyrosine kinases as anti-angiogenic agents. We focus on SU5416, a selective inhibitor of VEGF receptors that is currently in clin. development for the treatment of advanced malignancies. Its biochem., biol. and pharmacol. properties are reviewed and clin. implications discussed.

IT 204005-46-9, SU5416

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(VEGF receptor tyrosine kinase inhibitors SU5416 development as anti-angiogenesis agent)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 32 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:352846 CAPLUS

DOCUMENT NUMBER: 133:232264

TITLE: The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma

AUTHOR(S): Arasteh, Keikawus; Hannah, Alison

CORPORATE SOURCE: Auguste-Viktoria-Krankenhaus, Berlin, D-12157, Germany

SOURCE: Oncologist (2000), 5(Suppl. 1), 28-31

CODEN: OCOLF6; ISSN: 1083-7159

PUBLISHER: AlphaMed Press

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 33 refs. Kaposi's sarcoma (KS) is the most common neoplasm assocd. with human immunodeficiency virus-1 (HIV-1) infection. KS involves the skin and mucous membranes as well as other organs and can lead to tumor-assocd. edema and ulcerations. Despite therapy with highly active antiviral agents, most patients with HIV-1-related KS eventually develop disseminated disease. In the treatment of KS, a strong rationale exists for the use of agents that inhibit vascular endothelial growth factor (VEGF). Angiogenesis appears to be an important feature of this disease, and recent exptl. studies have demonstrated the role of VEGF and its receptors in the pathogenesis of KS. Thus, therapeutic agents that target the VEGF pathway may be an effective strategy in reducing the tumor growth and edema assocd. with KS. Phase I study results with SU5416, a synthetic low mol.-wt. inhibitor of the VEGF-Flk-1/KDR receptor tyrosine kinase, demonstrate that this agent is well tolerated. Preliminary results show that in a majority of patients with autoimmune deficiency syndrome (AIDS)-related disease, SU5416 clearly has biol. activity (it flattens, shrinks, or dissolves lesions and reduces or resolves edema) or stabilizes the disease. Angiogenesis inhibition with SU5416 is a promising therapeutic approach in treating patients with KS, and further clin. evaluation is currently under way.


IT 204005-46-9, SU5416

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma and treatment with SU5416)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 33 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:725101 CAPLUS

DOCUMENT NUMBER: 132:30444

TITLE: Inhibition of angiogenesis by blocking activation of

the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas

AUTHOR(S): Angelov, Lilyana; Salhia, Bodour; Roncari, Luba; McMahon, Gerald; Guha, Abhijit

CORPORATE SOURCE: Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, ON, M5T 2S8, Can.

SOURCE: Cancer Research (1999), 59(21), 5536-5541
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: AACR Subscription Office

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Neurogenic sarcomas are incurable, common malignant human peripheral nerve tumors subject to local recurrence and systemic metastasis. In this study, the vascularity, vascular endothelial growth factor (VEGF) expression, and effects of inhibiting VEGF receptor on growth of neurogenic sarcomas were examd. Vascularization and VEGF expression were 6.4- and 15-fold higher in tumors than in normal nerves. The small mol. inhibitor (SU5416) of VEGF receptor 2 had no effect on neurogenic sarcoma cell lines in vitro, but the growth of a human tumor explant xenograft model was reduced by 54.8% compared to vehicle. Redn. in tumor growth was due to decreased tumor angiogenesis, leading to redn. of tumor cell proliferation and increased apoptosis. Inhibiting VEGF function may therefore be a useful adjuvant therapy for neurogenic sarcomas.

IT 204005-46-9, SU5416
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiogenesis inhibition by VEGF2 blocking leads to decreased growth of neurogenic sarcomas)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 34 OF 70 .CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:725076 CAPLUS

DOCUMENT NUMBER: 132:44604

TITLE: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis

AUTHOR(S): Shaheen, Raymond M.; Davis, Darren W.; Liu, Wenbiao; Zebrowski, Brian K.; Wilson, Michael R.; Bucana, Corazon D.; McConkey, David J.; McMahon, Gerald; Ellis, Lee M.

CORPORATE SOURCE: Departments of Surgical Oncology, Anderson Cancer Center, The University of Texas M. D., Houston, TX, 77030, USA

SOURCE: Cancer Research (1999), 59(21), 5412-5416
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: AACR Subscription Office
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Increased vascular endothelial growth factor (VEGF) expression is assocd. with colon cancer metastases. We hypothesized that inhibition of VEGF receptor activity could inhibit colon cancer liver metastases. BALB/c mice underwent splenic injection with CT-26 colon cancer cells to generate metastases. Mice received daily i.p. injections of vehicle, tyrosine kinase inhibitor for Flk-1/KDR (SU5416) or tyrosine kinase inhibitor for VEGF, basic fibroblast growth factor, and platelet-derived growth factor receptors (SU6668). SU5416 and SU6668 resp. inhibited metastases (48.1% and 55.3%), microvessel formation (42.0% and 36.2%), and cell proliferation (24.4% and 27.3%) and increased tumor cell (by 2.6- and 4.3-fold) and endothelial cell (by 18.6- and 81.4-fold) apoptosis (P < 0.001). VEGF receptor inhibitors increased endothelial cell apoptosis, suggesting that VEGF may serve as an endothelial survival factor.

IT 204005-46-9, SU 5416

RL: BAC (Biological activity or effector, except adverse); BSU


(Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

{antiangiogenic therapy targeting VEGF receptor tyrosine kinase inhibits liver metastasis of colon cancer and induces tumor and endothelial cell apoptosis}

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 35 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:65738 CAPLUS

DOCUMENT NUMBER: 130:246450

TITLE: ~~SU5416~~ is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types

AUTHOR(S): Fong, T. Annie T.; Shawver, Laura K.; Sun, Li; Tang, Cho; App, Harald; Powell, T. Jeff; Kim, Young H.; Schreck, Randall; Wang, Xueyan; Risau, Werner; Ullrich, Axel; Hirth, K. Peter; McMahon, Gerald

CORPORATE SOURCE: SUGEN, Inc., South San Francisco, CA, 94080, USA

SOURCE: Cancer Res. 59(1), 99-106

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: AACR Subscription Office

DOCUMENT TYPE: Journal

LANGUAGE: English

AB SU5416, a novel synthetic compd., is a potent and selective inhibitor of the Flk-1/KDR receptor tyrosine kinase that is presently under evaluation in Phase I clin. studies for the treatment of human cancers. SU5416 was shown to inhibit vascular endothelial growth factor-dependent mitogenesis of human endothelial cells without inhibiting the growth of a variety of

tumor cells in vitro. In contrast, systemic administration of SU5416 at nontoxic doses in mice resulted in inhibition of s.c. tumor growth of cells derived from various tissue origins. The antitumor effect of SU5416 was accompanied by the appearance of pale white tumors that were resected from drug-treated animals, supporting the antiangiogenic property of this agent. These findings support that pharmacol. inhibition of the enzymic activity of the vascular endothelial growth factor receptor represents a novel strategy for limiting the growth of a wide variety of tumor types.

IT 204005-46-9, SU 5416


RL: BAC (Biological activity or effector, except adverse);

THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(SU5416: selective inhibitor of Flk-1/KDR receptor tyrosine kinase, tumor vascularization and growth)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 36 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:117816 CAPLUS

DOCUMENT NUMBER: 133:37825

TITLE: Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multifluorescence videomicroscopy

AUTHOR(S): Vajkoczy, Peter; Menger, Michael D.; Vollmar, Brigitte; Schilling, Lothar; Schmiedek, Peter; Hirth, K. Peter; Ullrich, Axel; Fong, T. Annie T.

CORPORATE SOURCE: Department of Neurosurgery, Klinikum Mannheim, University of Heidelberg, Mannheim, D-68167, Germany

SOURCE: Neoplasia (New York) (1999), 1(1), 31-41

CODEN: NEOPFL; ISSN: 1522-8002

PUBLISHER: Stockton Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Vascular endothelial growth factor (VEGF) plays a fundamental role in mediating tumor angiogenesis and tumor growth. The direct effect of SU5416, a novel small-mol. inhibitor of the Flk-1-mediated signal transduction pathway of VEGF, on tumor angiogenesis and microhemodynamics of an exptl. glioblastoma was investigated by intravital multifluorescence videomicroscopy. SU5416 treatment suppressed tumor growth. In parallel, SU5416 demonstrated a potent antiangiogenic activity, resulting in redn. of both the total and functional vascular d. of the tumor microvasculature, which indicates an impaired vascularization as well as perfusion failure in the treated tumors. This malperfusion was not compensated for by changes in vessel diam. or recruitment of nonperfused vessels. Analyses of the tumor microcirculation revealed microhemodynamic changes after angiogenesis blockade, such as a higher red cell velocity and blood flow in remnant tumor vessels than in controls. The results demonstrate that the novel antiangiogenic concept of targeting the tyrosine kinase of Flk-1/KDR by means of a small-mol. inhibitor represents

an efficient strategy for controlling growth and progression of angiogenesis-dependent tumors.

IT 204005-46-9, SU 5416


RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); BIOL (Biological study)

(inhibition of glioblastoma growth, angiogenesis, and microcirculation by tyrosine kinase inhibitor SU5416)

RN 204005-46-9 CAPLUS

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 37 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:747592 CAPLUS

DOCUMENT NUMBER: 130:3771

TITLE: Preparation of 3-(hetero)arylmethylidene-2-indolinone derivatives as modulators of protein kinase activity for use in treating cancer.

INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Shawver, Laura Kay; Hirth, Klaus Peter

PATENT ASSIGNEE(S): ~~Sugen~~, Inc., USA

SOURCE: PCT Int. Appl., 269 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------|--|---------------------|-----------------|---------------------|
| WO 9850356 | A1 | 19981112 | WO 1998-US9017 | 19980507 |
| W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | |
| AU 9876842 | A1 | 19981127 | AU 1998-76842 | 19980507 |
| EP 984930 | A1 | 20000315 | EP 1998-924746 | 19980507 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | |
| US 6316429 | B1 | 20011113 | US 1998-74621 | 19980507 |
| JP 2002511852 | T2 | 20020416 | JP 1998-548319 | 19980507 |
| US 6051593 | A | 20000418 | US 1998-99721 | 19980619 |
| US 6313158 | B1 | 20011106 | US 1998-100854 | 19980619 |
| US 6133305 | A | 20001017 | US 1998-161046 | 19980925 |
| US 2001056094 | A1 | 20011227 | US 2000-482198 | 20000112 |
| US 2001007033 | A1 | 20010705 | US 2000-516948 | 20000301 |
| US 2002026053 | A1 | 20020228 | US 2001-916331 | 20010730 |


PRIORITY APPLN. INFO.:

| | | |
|----------------|----|----------|
| US 1997-45838P | P | 19970507 |
| US 1997-46868P | P | 19970508 |
| US 1997-49324P | P | 19970611 |
| US 1997-50412P | P | 19970620 |
| US 1997-50413P | P | 19970620 |
| US 1997-50977P | P | 19970620 |
| US 1997-59336P | P | 19970919 |
| US 1997-59381P | P | 19970919 |
| US 1997-59384P | P | 19970919 |
| US 1997-59544P | P | 19970919 |
| US 1997-59677P | P | 19970919 |
| US 1997-59971P | P | 19970925 |
| US 1997-60194P | P | 19970926 |
| WO 1998-US9017 | W | 19980507 |
| US 1998-99721 | A1 | 19980619 |
| US 1998-161046 | A3 | 19980925 |
| US 2000-516948 | B1 | 20000301 |

OTHER SOURCE(S):

MARPAT 130:3771

GI




AB Title compds. [I; A1-A4 = C, N; when any of A1-A4 = N, then the corresponding R3-R6 = null; R1 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, trihalomethylcarbonyl, OH, CO₂H, trihalomethylsulfonyl, etc.; R2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo; R3-R6 = H, alkyl, trihalomethyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, OH, SH, alkoxy, aryloxy, amino, phosphonyl, guanidinyl, NO₂, halo, (iso)cyanato, etc.; R3R4 or R4R5 or R5R6 = cycloalkyl, aryl, heteroaryl, heteroalicyclic, OCH₂O, OCH₂CH₂O; Q = specified (substituted) (hetero)aryl; Z = O, S], were prepd. Thus, 3-(4-imidazolylmethylidene)-4,6-dimethyl-2-indolinone inhibited CDK2 with IC₅₀ = <0.78 .mu.M.

IT 15966-93-5 186611-30-3 186611-31-4
 186611-33-6 186611-34-7 186611-37-0
 215536-87-1 215536-88-2 215536-91-7
 215537-01-2 215537-24-9 215537-79-4
 215543-92-3 215543-93-4 215543-94-5
 215543-95-6 215543-96-7 215543-97-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (prepn. of 3-(hetero)arylmethylidene-2-indolinone derivs. as modulators of protein kinase activity for use in treating cancer)


RN 15966-93-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-30-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-33-6 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-87-1 CAPLUS

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215536-88-2 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-91-7 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 215537-01-2 CAPLUS

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-24-9 CAPLUS

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-79-4 CAPLUS

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-92-3 CAPLUS


CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-93-4 CAPLUS
CN 2H-Indol-2-one, 3-[(5-acetyl-3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 215543-94-5 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-95-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5,6-dimethoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 215543-96-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-5-[[4-(methoxycarbonyl)benzoyl]amino]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-97-8 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L65 ANSWER 38 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:147306 CAPLUS

DOCUMENT NUMBER: 128:204803

TITLE: Indolinone combinatorial libraries and related

products and methods for the treatment of disease

INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Hirth, Klaus

Peter; Shawver, Laura Kay; et al.

PATENT ASSIGNEE(S): Sugan, Inc., USA; Tang, Peng Cho; Sun, Li; McMahon,

Gerald

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|--|----------|-----------------|----------|
| WO 9807695 | A1 | 19980226 | WO 1997-US14736 | 19970820 |
| W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | |
| CN 1155838 | A | 19970730 | CN 1996-190616 | 19960605 |
| EP 929520 | A1 | 19990721 | EP 1997-939480 | 19970820 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | |

| | | | | |
|-----------------------|----|----------|----------------|----------|
| US 6147106 | A | 20001114 | US 1997-915366 | 19970820 |
| JP 2001503736 | T2 | 20010321 | JP 1998-510973 | 19970820 |
| AU 9741556 | A1 | 19980306 | AU 1997-41556 | 19970821 |
| US 2002022626 | A1 | 20020221 | US 2000-617529 | 20000713 |

PRIORITY APPLN. INFO.:

| | | |
|-----------------|----|----------|
| US 1996-702232 | A | 19960823 |
| US 1996-31585P | P | 19961205 |
| US 1996-31586P | P | 19961205 |
| US 1996-31588P | P | 19961205 |
| US 1996-32546P | P | 19961205 |
| US 1996-32547P | P | 19961205 |
| US 1997-45565P | P | 19970505 |
| US 1997-45566P | P | 19970505 |
| US 1997-45714P | P | 19970505 |
| US 1997-45715P | P | 19970505 |
| US 1997-46843P | P | 19970505 |
| US 1996-45715P | P | 19961205 |
| US 1997-31565P | P | 19970505 |
| US 1997-915366 | A3 | 19970820 |
| WO 1997-US14736 | W | 19970820 |

OTHER SOURCE(S): MARPAT 128:204803
GI



I

AB The invention relates to indolinone derivs. capable of modulating, regulating, and/or inhibiting **protein kinase** signal transduction. The compds. are useful for the treatment of diseases related to unregulated **protein kinase** signal transduction, including cell proliferative diseases such as cancer, **atherosclerosis**, **arthritis**, and restenosis, and metabolic diseases such as **diabetes**. Inhibitors specific to the FLK **protein kinase** can be obtained by adding chem. substituents to the 3-[(indole-3-yl)methylene]-2-indolinone system, in particular at the 1' position of the indole ring. Indolinone compds. that specifically inhibit the FLK and platelet derived growth factor **protein kinases** can harbor a tetrahydroindole or cyclopentano[b]pyrrole moiety. Indolinone compds. that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate **protein kinases**. This invention also features novel hydrosol. indolinone compds. that are tyrosine kinase inhibitors, and related products and methods. Approx. 1200 title compds., such as I, were prepd. by combinatorial condensation of certain (un)substituted indolinones with aldehydes at the 3-position. I gave complete inhibition of MET kinase at chimeric MET receptors in vitro.

IT **203988-42-5P**, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203988-54-9P**, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203988-64-1P**, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203988-74-3P**, 3-[(3,4-Dibromo-2-methylpyrrol-5-


yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone
203988-84-5P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-
[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone
203988-94-7P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-
(morpholinosulfonyl)-2-indolinone 203989-04-2P,
3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-
indolinone 203989-05-3P, 3-[[2,4-Dimethyl-3-
(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone
203989-08-6P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-
[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone
203989-14-4P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-
yl]methylidenyl]-5-iodo-2-indolinone 203989-17-7P,
3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-
[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone
203989-24-6P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-
yl]methylidenyl]-5-bromo-4-methyl-2-indolinone 203989-27-9P,
3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-
[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-
indolinone 203989-35-9P, 3-[[2,4-Dimethyl-3-
(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-
indolinone 203989-40-6P, 3-[[2-(Ethoxycarbonyl)-3-[2-
(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-
5-[(methylamino)sulfonyl]-2-indolinone 203989-52-0P,
3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203989-56-4P
, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-
[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203989-65-5P
, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-
(morpholinosulfonyl)-2-indolinone 203989-68-8P,
3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-
[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-
indolinone 203989-75-7P, 3-[[2,4-Dimethyl-3-
(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone
203989-78-0P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-
[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-
indolinone 203989-88-2P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-
yl)methylidenyl]-5,7-dibromo-2-indolinone 203989-98-4P,
3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone
203990-08-3P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-
bromo-4-methyl-2-indolinone 203990-18-5P, 3-[(2,4-Dimethyl-3-
ethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone
203990-28-7P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-
[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone
203990-38-9P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-
(morpholinosulfonyl)-2-indolinone 203990-48-1P,
3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-
indolinone 203991-62-2P, 3-[(2,4-Dimethylpyrrol-5-
yl)methylidenyl]-5,7-dibromo-2-indolinone 203991-72-4P,
3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone
203991-82-6P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-bromo-4-
methyl-2-indolinone 203991-92-8P, 3-[(2,4-Dimethylpyrrol-5-
yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone
203992-02-3P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203992-12-5P
, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-
indolinone 203992-22-7P, 3-[(2,4-Dimethylpyrrol-5-
yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203994-35-8P,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-
yl]methylidenyl]-5,7-dibromo-2-indolinone 203994-53-0P,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-
yl]methylidenyl]-5-iodo-2-indolinone 203994-72-3P,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-

yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203994-91-6P**,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone
203995-11-3P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-
[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203995-26-0P**
, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203995-36-2P**
, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **203995-39-5P**,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203995-48-6P**,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203995-57-7P**,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203995-66-8P**,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone
203995-75-9P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203995-84-0P**, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203995-93-1P**, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **203996-03-6P**, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203996-13-8P**,
3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203996-23-0P**, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203996-33-2P**, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203996-43-4P**, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203996-53-6P**
, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203996-63-8P**, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **204003-90-7P**
204003-91-8P 204003-96-3P 204003-97-4P
204004-29-5P 204004-86-4P 204004-92-2P
204004-94-4P 204005-03-8P 204005-21-0P
204005-38-9P 204005-39-0P 204005-46-9P
204005-54-9P 204005-56-1P 204005-58-3P
204005-59-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and testing of indolinone combinatorial library as protein kinase inhibitors)

RN 203988-42-5 CAPLUS


CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 203988-54-9 CAPLUS


CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-

dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203988-64-1 CAPLUS

CN 2H-Indol-2-one, 5-bromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 203988-74-3 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203988-84-5 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203988-94-7 CAPLUS

CN Morpholine, 4-[[3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203989-04-2 CAPLUS

CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203989-05-3 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-08-6 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-14-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-17-7 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-24-6 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-27-9 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-35-9 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-40-6 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-52-0 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-56-4 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-65-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-68-8 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-75-7 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-78-0 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-88-2 CAPLUS

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203989-98-4 CAPLUS

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203990-08-3 CAPLUS

CN 2H-Indol-2-one, 5-bromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 203990-18-5 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-28-7 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203990-38-9 CAPLUS

CN Morpholine, 4-[[3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203990-48-1 CAPLUS

CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203991-62-2 CAPLUS


CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203991-72-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203991-82-6 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 203991-92-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203992-02-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-12-5 CAPLUS

CN Morpholine, 4-[[3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203992-22-7 CAPLUS

CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203994-35-8 CAPLUS

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203994-53-0 CAPLUS


CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203994-72-3 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-chloro-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 203994-91-6 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-11-3 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-26-0 CAPLUS

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-36-2 CAPLUS

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-39-5 CAPLUS

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-48-6 CAPLUS


CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-57-7 CAPLUS
 CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)



RN 203995-66-8 CAPLUS
 CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-5-(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-75-9 CAPLUS
 CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-84-0 CAPLUS

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-93-1 CAPLUS

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203996-03-6 CAPLUS

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203996-13-8 CAPLUS


CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203996-23-0 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 203996-33-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203996-43-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203996-53-6 CAPLUS
CN Morpholine, 4-[[3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203996-63-8 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204003-90-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204003-91-8 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-96-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(3,5-bis(1-methylethyl)-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204003-97-4 CAPLUS
CN 1H-Indole-5-propanoic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204004-29-5 CAPLUS

CN 2H-Indol-2-one, 5-amino-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204004-86-4 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(5-amino-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204004-92-2 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204004-94-4 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204005-03-8 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204005-21-0 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1,2,4-trimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 204005-38-9 CAPLUS

CN 2H-Indol-2-one, 5-amino-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-39-0 CAPLUS


CN 2H-Indol-2-one, 5-amino-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 204005-54-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-
methyl- (9CI) (CA INDEX NAME)




RN 204005-56-1 CAPLUS
CN 2H-Indol-2-one, 5-amino-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-
dihydro- (9CI) (CA INDEX NAME)



RN 204005-58-3 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)



RN 204005-59-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



L65 ANSWER 39 OF 70 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:640690 CAPLUS

DOCUMENT NUMBER: 127:314804

TITLE: Assays for KDR/FLK-1 receptor tyrosine kinase inhibitors, and use of the inhibitors for treatment of vasculogenesis- and angiogenesis-related diseases

INVENTOR(S): Hirth, Klaus-P.; McMahon, Gerald; Shawver, Laura K.

PATENT ASSIGNEE(S): Sugen, Inc., USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|----------|
| WO 9734920 | A1 | 19970925 | WO 1997-US3378 | 19970304 |
| W: | AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | |
| AU 9720667 | A1 | 19971010 | AU 1997-20667 | 19970304 |
| PRIORITY APPLN. INFO.: | | | US 1996-621734 | 19960321 |
| | | | WO 1997-US3378 | 19970304 |

AB Processes are disclosed for the identification of compds. and pharmaceutical compns. capable of selectively and potentially inhibiting KDR/FLK-1 tyrosine kinase signal transduction in order to inhibit vasculogenesis and/or angiogenesis. The invention also relates to compds. and compns. identified using the methods of the invention and the use thereof for the treatment of disease relating to inappropriate vasculogenesis and/or angiogenesis. The invention provides an assay cascade comprised of several "filter steps" of increasing selectivity which identify a limited subset of candidate compds. affecting the VEGF receptor on the mol. level.

IT 204005-46-9, SU 5416
RL: BAC (Biological activity or effector, except adverse);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KDR/FLK-1 receptor tyrosine kinase inhibitor identification assay, and
use of compds. for treatment of vasculogenesis- and
angiogenesis-related diseases)
RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)



L65 ANSWER 40 OF 70 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:140244 CAPLUS
DOCUMENT NUMBER: 126:139901
TITLE: Indolinone compounds capable of modulating tyrosine
kinase signal transduction
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugan, Inc., USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 9640116 | A1 | 19961219 | WO 1996-US8903 | 19960605 |
| W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| US 5880141 | A | 19990309 | US 1995-485323 | 19950607 |
| CA 2192797 | AA | 19961219 | CA 1996-2192797 | 19960605 |
| AU 9660441 | A1 | 19961230 | AU 1996-60441 | 19960605 |
| AU 706597 | B2 | 19990617 | | |
| EP 769947 | A1 | 19970502 | EP 1996-918093 | 19960605 |
| EP 769947 | B1 | 20010502 | | |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| BR 9606410 | A | 19971230 | BR 1996-6410 | 19960605 |
| JP 10504323 | T2 | 19980428 | JP 1996-501363 | 19960605 |
| EP 934931 | A2 | 19990811 | EP 1999-103667 | 19960605 |
| EP 934931 | A3 | 19991020 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI | | | | |
| JP 2000026412 | A2 | 20000125 | JP 1999-159567 | 19960605 |
| AT 200863 | E | 20010515 | AT 1996-918093 | 19960605 |
| ES 2159741 | T3 | 20011016 | ES 1996-918093 | 19960605 |
| JP 3231044 | B2 | 20011119 | JP 1997-501363 | 19960605 |

NO 9605377 A 19970212 NO 1996-5377 19961213
PRIORITY APPLN. INFO.: US 1995-485323 A 19950607
EP 1996-918093 A3 19960605
JP 1997-501363 A3 19960605
WO 1996-US8903 W 19960605

OTHER SOURCE(S): MARPAT 126:139901


AB The present invention relates to org. mols. capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Representatives of the 5 different classes of compds. described are SU 4932 [3-(2-chloro-4-hydroxybenzylidenyl)-2-indolinone], SU 4312 [3-(4-dimethylaminobenzylidenyl)-2-indolinone], SU 5416 {3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone}, SU 5204 [3-(2-ethoxybenzylidenyl)-2-indolinone], and SU 4942 [3-(4-bromobenzylidenyl)-2-indolinone]. Diseases which these compds. and their pharmaceutically acceptable prepn.s. may be effective against include arthritis, hepatic cirrhosis, diabetic nephropathy and psoriasis.

IT 15966-93-5P, SU 5408 186610-93-5P, SU 5404
186610-94-6P, SU 5406 186611-14-3P, SU 5402
186611-15-4P, SU 5403 186611-16-5P, SU 5405
186611-17-6P, SU 5407 186611-29-0P, SU 5453
186611-30-3P, SU 5454 186611-31-4P, SU 5455
186611-32-5P, SU 5456 186611-33-6P, SU 5459
186611-34-7P, SU 5460 186611-37-0P, SU 5463
186611-39-2P, SU 5465 186611-48-3P, SU 5477
186611-49-4P, SU 5478 186611-50-7P, SU 5479
186611-54-1P, SU 5613 186611-56-3P, SU 5614
186611-66-5P, SU 5625 186611-67-6P, SU 5626
204005-46-9P, SU 5416

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indolinones capable of modulating tyrosine kinase signal transduction)


RN 15966-93-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186610-93-5 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI)
(CA INDEX NAME)




RN 186610-94-6 CAPLUS

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 186611-14-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 CAPLUS

CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-16-5 CAPLUS

CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 186611-17-6 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-29-0 CAPLUS

CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 CAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-32-5 CAPLUS


CN 2H-Indol-2-one, 3-[(3,5-diiodo-4-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-33-6 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-37-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-39-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-48-3 CAPLUS

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-49-4 CAPLUS

CN 2H-Indol-2-one, 3-[(5-ethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-50-7 CAPLUS

CN 2H-Indol-2-one, 3-[[3,5-dimethyl-4-(1-methylethenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-54-1 CAPLUS


CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 186611-56-3 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-66-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-5-nitro- (9CI) (CA INDEX NAME)



RN 186611-67-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L65 ANSWER 41 OF 70 . CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:746204 CAPLUS

DOCUMENT NUMBER: 126:18783

TITLE: Substituted indolylmethylene-oxindole analogs as tyrosine kinase inhibitors

INVENTOR(S): Battistini, Carlo; Ballinari, Dario; Ermoli, Antonella; Penco, Sergio; Vioglio, Sergio

PATENT ASSIGNEE(S): Pharmacia S.P.A., Italy

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 9632380 | A1 | 19961017 | WO 1996-EP1165 | 19960314 |
| W: JP, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| EP 764152 | A1 | 19970326 | EP 1996-907500 | 19960314 |
| R: DE, ES, FR, GB, IT, SE | | | | |
| JP 10501821 | T2 | 19980217 | JP 1996-530667 | 19960314 |
| US 5849710 | A | 19981215 | US 1996-750208 | 19961204 |
| PRIORITY APPLN. INFO.: | | | GB 1995-7298 | 19950407 |
| | | | WO 1996-EP1165 | 19960314 |

OTHER SOURCE(S): MARPAT 126:18783

GI



II

AB Indol-3-ylmethylene-2-oxindole derivs. I and their pharmaceutically acceptable salts are disclosed [wherein 1 or 2 of R, R1, R2, and R3 = X(CH2)mNH2, X(CH2)mNR4R5, X(CH2)mNHR6, NHC(:NH)NH2, NHC(:NH)NR4R5, NHC(:NH)NHR6, N:CHNH2, N:CHNR4R5, N:CHNHR6, X(CH2)mCOR7, CORa, COR8, YCOY'R9, NHR6, NHR10 group; remaining groups within R and R1-R3 = H, halo,

amino, OH, alkyl, alkoxy, CO₂H, alkoxy carbonyl, alkanoyloxy, cyano, NR₄R₅; X = O, S, NH; m = 1-4; 1 of R₄ and R₅ = H or alkyl, and other = alkyl; or NR₄R₅ forms satd. monoheterocycle; R₆ = alkanoyl, 1- to 3-residue (un)substituted peptidyl; R₇ = OH, amino, alkoxy, NR₄R₅; R_a = amino terminus of 1- to 3-unit peptidyl; R₈ = alkoxy, phenylalkoxy, (CH₂)_nNH₂, (CH₂)_nNR₄R₅, (CH₂)_nNHR₆; n = 1-2; Y, Y' = NH, O; R₉ = Ph, alkyl, phenylalkyl; R₁₀ = mono-, di- or trihydroxyalkyl]. I have tyrosine kinase inhibiting activity, and are useful as antiproliferative, antimetastatic, anticancer, antiatheromatous, anti-Alzheimer, and immunomodulating agents. For example, 2-indolinone reacted with BrCH₂COBr and AlCl₃ to give the 5-(2-bromoacetyl) deriv., which underwent amination with piperidine and then condensation with indole-3-carboxaldehyde, to give title compd. II (FCE 28484). In tests for inhibition of p45 v-abl kinase and K562 leukemia cells in vitro, II had IC₅₀ of 0.78 and 4.82 .mu.M, resp.


IT 184020-79-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (indolylmethylene)oxindole analogs as tyrosine kinase inhibitors)

RN 184020-79-9 CAPLUS

CN Methanimidamide, N'-[2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



L65 ANSWER 42 OF 70 USPATFULL

ACCESSION NUMBER: 2002:67225 USPATFULL

TITLE: Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

INVENTOR(S): Moon, Malcolm Wilson, Kalamazoo, MI, UNITED STATES
Morozowich, Walter, Kalamazoo, MI, UNITED STATES
Gao, Ping, Portage, MI, UNITED STATES
Koenig, Marcel, Burlingame, CA, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2002037878 | A1 | 20020328 |
| APPLICATION INFO.: | US 2001-863819 | A1 | 20010524 (9) |

| | NUMBER | DATE |
|-----------------------|-----------------|---------------|
| PRIORITY INFORMATION: | US 2000-207000P | 20000524 (60) |
| | US 2000-225045P | 20000811 (60) |

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Beth A. Burrous, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109

NUMBER OF CLAIMS: 56

EXEMPLARY CLAIM: 1

LINE COUNT: 4248

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to prodrugs of certain 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that modulate the

activity of **protein kinases** ("PKs"). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 375387-20-5P 375798-46-2P

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 375387-20-5 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-(1-pyrrolidinylmethyl)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-46-2 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(4-methyl-1-piperazinyl)methyl]-, dihydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● 2 HCl


IT 326914-13-0P 375798-54-2P

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 326914-13-0 USPATFULL

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-54-2 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-(hydroxymethyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 375798-45-1P 375798-47-3P 375798-48-4P

375798-49-5P 375798-50-8P 375798-51-9P


375798-52-0P 375798-53-1P 375798-55-3P

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 375798-45-1 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(4-methyl-1-piperazinyl)methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-47-3 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(2-hydroxy-1-pyrrolidinyl)methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-48-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-
[(2-methyl-1-pyrrolidinyl)methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-49-5 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-
[[2-(methoxymethyl)-1-pyrrolidinyl]methyl]-, (3Z)- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.




RN 375798-50-8 USPATFULL

CN L-Proline, 1-[[[(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-
2-oxo-1H-indol-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 375798-51-9 USPATFULL

CN 2H-Indol-2-one, 1-[(3,5-dimethyl-1-piperazinyl)methyl]-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-52-0 USPATFULL

CN 2H-Indol-2-one, 1-[[bis(2-methoxyethyl)amino]methyl]-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-53-1 USPATFULL

CN Pyridinium, 1-[[[(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-1-yl]methyl]-, chloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● Cl⁻

RN 375798-55-3 USPATFULL
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



L65 ANSWER 43 OF 70 USPATFULL
ACCESSION NUMBER: 2002:61304 USPATFULL
TITLE: 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
INVENTOR(S): Moon, Malcolm Wilson, Kalamazoo, MI, UNITED STATES
Morozowich, Walter, Kalamazoo, MI, UNITED STATES
Gao, Ping, Portage, MI, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2002035140 | A1 | 20020321 |
| APPLICATION INFO.: | US 2001-863905 | A1 | 20010524 (9) |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 2000-207000P | 20000524 (60) |
| | US 2000-225045P | 20000811 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | Beth A. Burrous, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109 | |
| NUMBER OF CLAIMS: | 21 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 2979 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-

ylmethylidene)-2-indolinone derivatives that modulate the activity of **protein kinases** ("PKs"). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT **375387-20-5P 375798-46-2P**

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 375387-20-5 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-(1-pyrrolidinylmethyl)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-46-2 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(4-methyl-1-piperazinyl)methyl]-, dihydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● 2 HCl


IT **326914-13-0P 375798-54-2P**

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 326914-13-0 USPATFULL

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-54-2 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-(hydroxymethyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 375798-45-1P 375798-47-3P 375798-48-4P

375798-49-5P 375798-50-8P 375798-51-9P


375798-52-0P 375798-53-1P 375798-55-3P

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 375798-45-1 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(4-methyl-1-piperazinyl)methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-47-3 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(2-hydroxy-1-pyrrolidinyl)methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-48-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(2-methyl-1-pyrrolidinyl)methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-49-5 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[[2-(methoxymethyl)-1-pyrrolidinyl]methyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 375798-50-8 USPATFULL

CN L-Proline, 1-[[[(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 375798-51-9 USPATFULL

CN 2H-Indol-2-one, 1-[(3,5-dimethyl-1-piperazinyl)methyl]-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-52-0 USPATFULL

CN 2H-Indol-2-one, 1-[[bis(2-methoxyethyl)amino]methyl]-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-53-1 USPATFULL

CN Pyridinium, 1-[[[(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-1-yl]methyl]-, chloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● Cl⁻

RN 375798-55-3 USPATFULL
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



L65 ANSWER 44 OF 70 USPATFULL
ACCESSION NUMBER: 2002:55041 USPATFULL
TITLE: Mannich base prodrugs of 3-(pyrrol-2-ylmethylydene)-2-indolinone derivatives
INVENTOR(S): Moon, Malcolm Wilson, Kalamazoo, MI, UNITED STATES
Morozowich, Walter, Kalamazoo, MI, UNITED STATES
Gao, Ping, Portage, MI, UNITED STATES
Tang, Peng Cho, Moraga, CA, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2002032204 | A1 | 20020314 |
| APPLICATION INFO.: | US 2001-863804 | A1 | 20010524 (9) |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 2000-207000P | 20000524 (60) |
| | US 2000-225045P | 20000811 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | Beth A. Burrous, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109 | |
| NUMBER OF CLAIMS: | 36 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 3353 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of **protein kinases** ("PKs"). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 375387-20-5P 375798-46-2P

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 375387-20-5 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-(1-pyrrolidinylmethyl)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-46-2 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(4-methyl-1-piperazinyl)methyl]-, dihydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● 2 HCl


IT 326914-13-0P 375798-54-2P

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 326914-13-0 USPATFULL

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-54-2 USPTAFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-(hydroxymethyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 375798-45-1P 375798-47-3P 375798-48-4P

375798-49-5P 375798-50-8P 375798-51-9P


375798-52-0P 375798-53-1P 375798-55-3P

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 375798-45-1 USPTAFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(4-methyl-1-piperazinyl)methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-47-3 USPTAFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-[(2-hydroxy-1-pyrrolidinyl)methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-48-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-
[(2-methyl-1-pyrrolidinyl)methyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-49-5 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-1-
[[2-(methoxymethyl)-1-pyrrolidinyl]methyl]-, (3Z)- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.




RN 375798-50-8 USPATFULL

CN L-Proline, 1-[[[(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-
2-oxo-1H-indol-1-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 375798-51-9 USPATFULL

CN 2H-Indol-2-one, 1-[(3,5-dimethyl-1-piperazinyl)methyl]-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-52-0 USPATFULL

CN 2H-Indol-2-one, 1-[[bis(2-methoxyethyl)amino]methyl]-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 375798-53-1 USPATFULL

CN Pyridinium, 1-[[[(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-1-yl]methyl]-, chloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● Cl⁻

RN 375798-55-3 USPATFULL

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



L65 ANSWER 45 OF 70 USPATFULL

ACCESSION NUMBER: 2002:48648 USPATFULL

TITLE: 2-indolinone derivatives as modulators of
protein kinase activity

INVENTOR(S): Tang, Peng Cho, Moraga, CA, UNITED STATES
Sun, Li, Foster City, CA, UNITED STATES
McMahon, Gerald, Kenwood, CA, UNITED STATES
Harris, G. Davis, JR., San Francisco, CA, UNITED STATES

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 2002028840 | A1 | 20020307 |
| APPLICATION INFO.: | US 2001-899550 | A1 | 20010706 (9) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1999-293518, filed on 15 Apr 1999, GRANTED, Pat. No. US 6316635 | | |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 1998-82056P | 19980416 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | Beth A. Burrous, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109 | |
| NUMBER OF CLAIMS: | 30 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 2811 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel imidazoly 2-indolinones and physiologically acceptable salts and prodrugs thereof which modulate the activity of **protein kinases** and therefore are expected to be useful in the prevention and treatment of **protein kinase** related cellular disorders such as **cancer**.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5P, SU 5408 186610-93-5P, SU 5404
186610-94-6P, SU 5406 186611-14-3P, SU 5402
186611-15-4P, SU 5403 186611-16-5P, SU 5405
186611-17-6P, SU 5407 186611-29-0P, SU 5453
186611-30-3P, SU 5454 186611-31-4P, SU 5455
186611-32-5P, SU 5456 186611-33-6P, SU 5459
186611-34-7P, SU 5460 186611-37-0P, SU 5463
186611-39-2P, SU 5465 186611-48-3P, SU 5477
186611-49-4P, SU 5478 186611-50-7P, SU 5479
186611-54-1P, SU 5613 186611-56-3P, SU 5614
186611-66-5P, SU 5625 186611-67-6P, SU 5626
204005-46-9P, SU 5416

(prepn. of indolinones capable of modulating tyrosine kinase signal transduction)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186610-93-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI)
(CA INDEX NAME)




RN 186610-94-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 186611-14-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-16-5 USPATFULL

CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 186611-17-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-29-0 USPATFULL

CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-32-5 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-diiodo-4-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-33-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-39-2 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-48-3 USPATFULL

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-49-4 USPATFULL

CN 2H-Indol-2-one, 3-[(5-ethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-50-7 USPATFULL

CN 2H-Indol-2-one, 3-[[3,5-dimethyl-4-(1-methylethenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-54-1 USPATFULL

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 186611-56-3 USPATFULL

CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-66-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-5-nitro- (9CI) (CA INDEX NAME)




RN 186611-67-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 204005-46-9 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L65 ANSWER 46 OF 70 USPATFULL

ACCESSION NUMBER: 2002:43684 USPATFULL

TITLE: Novel 3-(substituted) -2- indolinones compounds and use thereof as inhibitors of **protein kinase** activityINVENTOR(S): Tang, Peng Cho, Moraga, CA, UNITED STATES
Sun, Li, Foster City, CA, UNITED STATES
McMahon, Gerald, Kenwood, CA, UNITED STATES

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 2002026053 | A1 | 20020228 |
| APPLICATION INFO.: | US 2001-916331 | A1 | 20010730 (9) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 2000-516948, filed on 1 Mar 2000, ABANDONED Division of Ser. No. US 1998-161046, filed on 25 Sep 1998, GRANTED, Pat. No. US 6133305 | | |

| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 1997-60194P | 19970926 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | Beth A. Burrous, FOLEY & LARDNER, Washington Harbour, 3000 K Street N.W., Suite 500, Washington, DC, 20007-5109 | |
| NUMBER OF CLAIMS: | 20 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 5540 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel 3-(substituted)-2-indolinones compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of **protein kinases** and therefore are expected to be useful in the prevention and treatment of **protein kinase** related disorders such as **cancer**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5 186611-30-3 186611-31-4

186611-33-6 186611-34-7 186611-37-0

215536-87-1 215536-88-2 215536-91-7

215537-01-2 215537-24-9 215537-79-4


215543-92-3 215543-93-4 215543-94-5

215543-95-6 215543-96-7 215543-97-8

(prepn. of 3-(hetero)arylmethylidene-2-indolinone derivs. as modulators of protein kinase activity for use in treating cancer)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-33-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-87-1 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215536-88-2 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-91-7 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 215537-01-2 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-24-9 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-79-4 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-92-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-93-4 USPATFULL

CN 2H-Indol-2-one, 3-[(5-acetyl-3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 215543-94-5 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215543-95-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5,6-dimethoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 215543-96-7 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-5-[[4-(methoxycarbonyl)benzoyl]amino]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-97-8 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



L65 ANSWER 47 OF 70 USPATFULL

ACCESSION NUMBER: 2002:37906 USPATFULL

TITLE: Indolinone combinatorial libraries and related products and methods for the treatment of disease

INVENTOR(S): Tang, Peng Cho, Moraga, CA, UNITED STATES

Sun, LI, Foster City, CA, UNITED STATES

McMahon, Gerald, San Francisco, CA, UNITED STATES

Hirth, Klaus Peter, San Francisco, CA, UNITED STATES

Shawver, Laura Kay, San Francisco, CA, UNITED STATES

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 2002022626 | A1 | 20020221 |
| APPLICATION INFO.: | US 2000-617529 | A1 | 20000713 (9) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1997-915366, filed on 20 Aug 1997, GRANTED, Pat. No. US 6147106 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | APPLICATION | | |
| LEGAL REPRESENTATIVE: | BETH A BURROUS, FOLEY & LARDNER, WASHINGTON HARBOUR, 30000 K STREET, N.W., WASHINGTON, DC, 20007-5109 | | |
| NUMBER OF CLAIMS: | 17 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 42 Drawing Page(s) | | |
| LINE COUNT: | 7888 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting **protein kinase** signal transduction. Such compounds are useful for the treatment of diseases related to unregulated **protein kinase** signal transduction, including cell proliferative diseases such as **cancer, atherosclerosis, arthritis** and restenosis and metabolic diseases such as **diabetes**. The present invention features indolinone compounds

that potentially inhibit **protein kinases** and related products and methods. Inhibitors specific to the FLK **protein kinase** can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1' position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor **protein kinases** can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety. Indolinone compounds that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate **protein kinases**. This invention also features novel hydrosoluble indolinone compounds that are tyrosine kinase inhibitors and related products and methods.


CAS INDEXING IS AVAILABLE FOR THIS PATENT:

IT **203988-42-5P**, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203988-54-9P**, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203988-64-1P**, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203988-74-3P**, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203988-84-5P**, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203988-94-7P**, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203989-04-2P**, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **203989-05-3P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone **203989-08-6P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone **203989-14-4P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone **203989-17-7P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone **203989-24-6P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone **203989-27-9P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone **203989-35-9P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203989-40-6P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203989-52-0P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203989-56-4P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203989-65-5P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203989-68-8P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203989-75-7P**, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone **203989-78-0P**, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone **203989-88-2P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203989-98-4P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203990-08-3P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203990-18-5P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203990-28-7P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-


[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone
203990-38-9P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203990-48-1P,
3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203991-62-2P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203991-72-4P,
3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203991-82-6P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203991-92-8P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203992-02-3P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203992-12-5P,
3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203992-22-7P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203994-35-8P,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203994-53-0P,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203994-72-3P,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203994-91-6P,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203995-11-3P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203995-26-0P,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203995-36-2P,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203995-39-5P,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203995-48-6P,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203995-57-7P,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203995-66-8P,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203995-75-9P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203995-84-0P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203995-93-1P,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203996-03-6P,
3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203996-13-8P, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203996-23-0P, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203996-33-2P,
3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203996-43-4P, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203996-53-6P, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203996-63-8P,
3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 204003-90-7P 204003-91-8P 204003-96-3P
204003-97-4P 204004-29-5P 204004-86-4P
204004-92-2P 204004-94-4P 204005-03-8P
204005-21-0P 204005-38-9P 204005-39-0P
204005-46-9P 204005-54-9P 204005-56-1P
204005-58-3P 204005-59-4P

(prepn. and testing of indolinone combinatorial library as protein kinase inhibitors)


RN 203988-42-5 USPATFULL
CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203988-54-9 USPATFULL
CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203988-64-1 USPATFULL
CN 2H-Indol-2-one, 5-bromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 203988-74-3 USPATFULL
CN 1H-Indole-5-sulfonamide, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203988-84-5 USPATFULL
CN 1H-Indole-5-sulfonamide, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203988-94-7 USPATFULL

CN Morpholine, 4-[[3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203989-04-2 USPATFULL

CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203989-05-3 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-08-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-14-4 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-17-7 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-24-6 USPATFULL


CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 203989-27-9 USPATFULL


CN 1H-Pyrrole-3-propanoic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-

indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-35-9 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[(methoxycarbonyl)indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-40-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-5-[(methoxycarbonyl)indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-52-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-56-4 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-65-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-68-8 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-75-7 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-78-0 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-88-2 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203989-98-4 USPATFULL

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203990-08-3 USPATFULL

CN 2H-Indol-2-one, 5-bromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 203990-18-5 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-28-7 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203990-38-9 USPATFULL

CN Morpholine, 4-[[3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203990-48-1 USPATFULL

CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203991-62-2 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203991-72-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203991-82-6 USPATFULL

CN 2H-Indol-2-one, 5-bromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 203991-92-8 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203992-02-3 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-12-5 USPATFULL

CN Morpholine, 4-[[3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203992-22-7 USPATFULL

CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203994-35-8 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203994-53-0 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203994-72-3 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-chloro-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203994-91-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-11-3 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-26-0 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-36-2 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-39-5 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-48-6 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-57-7 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-66-8 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-75-9 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-84-0 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-93-1 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203996-03-6 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203996-13-8 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203996-23-0 USPATFULL

CN 2H-Indol-2-one, 5-bromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 203996-33-2 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203996-43-4 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203996-53-6 USPATFULL

CN Morpholine, 4-[[3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203996-63-8 USPATFULL

CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204003-90-7 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204003-91-8 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204003-96-3 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[[3,5-bis(1-methylethyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204003-97-4 USPATFULL

CN 1H-Indole-5-propanoic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204004-29-5 USPATFULL

CN 2H-Indol-2-one, 5-amino-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204004-86-4 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5-amino-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204004-92-2 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204004-94-4 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204005-03-8 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204005-21-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1,2,4-trimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 204005-38-9 USPATFULL

CN 2H-Indol-2-one, 5-amino-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-39-0 USPATFULL

CN 2H-Indol-2-one, 5-amino-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-46-9 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-54-9 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 204005-56-1 USPATFULL

CN 2H-Indol-2-one, 5-amino-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-58-3 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-59-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



L65 ANSWER 48 OF 70 USPATFULL

ACCESSION NUMBER: 2001:237974 USPATFULL

TITLE: 3-(Cycloalkanoheteroarylidenyl)-2-Indolinone
Protein Tyrosine Kinase InhibitorsINVENTOR(S): Tang, Peng Cho, Moraga, CA, United States
Sun, Li, Foster City, CA, United States
McMahon, Gerald, Kenwood, CA, United States

NUMBER KIND DATE

Searched by Barb O'Bryen, STIC 308-4291

PATENT INFORMATION: US 2001056094 A1 20011227
US 6350754 B2 20020226
APPLICATION INFO.: US 2000-482198 A1 20000112 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-99721, filed on 19 Jun
1998, GRANTED, Pat. No. US 6051593


| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 1997-50413P | 19970620 (60) |
| | US 1997-59544P | 19970919 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | BETH A. BURROUS, FOLEY & LARDNER, WASHINGTON HARBOUR, 3000 K STREET, N.W., STE. 500, WASHINGTON, DC, 20007-5109 | |
| NUMBER OF CLAIMS: | 26 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 3325 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to novel 3-(cycloalkano-heteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of **protein tyrosine kinases** and therefore to be useful in the prevention and treatment of **protein tyrosine kinase** related cellular disorders such as **cancer**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5 186611-30-3 186611-31-4
186611-33-6 186611-34-7 186611-37-0
215536-87-1 215536-88-2 215536-91-7
215537-01-2 215537-24-9 215537-79-4
215543-92-3 215543-93-4 215543-94-5
215543-95-6 215543-96-7 215543-97-8
(prepn. of 3-(hetero)arylmethylidene-2-indolinone derivs. as modulators
of protein kinase activity for use in treating cancer)
RN 15966-93-5 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-33-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-87-1 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215536-88-2 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-91-7 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 215537-01-2 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-24-9 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-79-4 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-92-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-93-4 USPATFULL

CN 2H-Indol-2-one, 3-[(5-acetyl-3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 215543-94-5 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215543-95-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5,6-dimethoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 215543-96-7 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[4-(methoxycarbonyl)benzoyl]amino]-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-97-8 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



L65 ANSWER 49 OF 70 USPATFULL

ACCESSION NUMBER:

2001:171157 USPATFULL

TITLE:

3-(4'-bromobenzylidene)-2-indolinone and analogues thereof for the treatment of disease

INVENTOR(S):

Tang, Peng Cho, Moraga, CA, United States
Sun, Li, Foster City, CA, United States
McMahon, Gerald, Kenwood, CA, United States

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 2001027207 | A1 | 20011004 |
| APPLICATION INFO.: | US 2001-765619 | A1 | 20010122 (9) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1998-212494, filed on 15 Dec 1998, GRANTED, Pat. No. US 6225335 | | |
| | Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995, GRANTED, Pat. No. US 5880141 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | APPLICATION | | |
| LEGAL REPRESENTATIVE: | Beth A. Burrous, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109 | | |
| NUMBER OF CLAIMS: | 10 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 3391 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5P, SU 5408 186610-93-5P, SU 5404

186610-94-6P, SU 5406 186611-14-3P, SU 5402

186611-15-4P, SU 5403 186611-16-5P, SU 5405

186611-17-6P, SU 5407 186611-29-0P, SU 5453

186611-30-3P, SU 5454 186611-31-4P, SU 5455

186611-32-5P, SU 5456 186611-33-6P, SU 5459

186611-34-7P, SU 5460 186611-37-0P, SU 5463

186611-39-2P, SU 5465 186611-48-3P, SU 5477

186611-49-4P, SU 5478 186611-50-7P, SU 5479

186611-54-1P, SU 5613 186611-56-3P, SU 5614


186611-66-5P, SU 5625 186611-67-6P, SU 5626

204005-46-9P, SU 5416

(prepn. of indolinones capable of modulating tyrosine kinase signal transduction)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186610-93-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI)
(CA INDEX NAME)




RN 186610-94-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 186611-14-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-16-5 USPATFULL

CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 186611-17-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-29-0 USPATFULL

CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-32-5 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-diiodo-4-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-33-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-39-2 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-48-3 USPATFULL

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-49-4 USPATFULL

CN 2H-Indol-2-one, 3-[(5-ethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-50-7 USPATFULL

CN 2H-Indol-2-one, 3-[[3,5-dimethyl-4-(1-methylethenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-54-1 USPATFULL

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 186611-56-3 USPATFULL

CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-66-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-5-nitro- (9CI) (CA INDEX NAME)




RN 186611-67-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 204005-46-9 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L65 ANSWER 50 OF 70 USPATFULL

ACCESSION NUMBER: 2001:105414 USPATFULL

TITLE: Novel 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activityINVENTOR(S): Tang, Peng Cho, Moraga, CA, United States
Sun, Li, Foster City, CA, United States
McMahon, Gerald, Kenwood, CA, United States

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 2001007033 | A1 | 20010705 |
| APPLICATION INFO.: | US 2000-516948 | A1 | 20000301 (9) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1998-161046, filed on 25 Sep 1998, PENDING | | |


| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 1997-60194P | 19970926 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | BETH A BURROUS, FOLEY & LARDNER WASHINGTON HARBOUR, 3000 K STREET, N.W., WASHINGTON, DC, 20007-5109 | |
| NUMBER OF CLAIMS: | 20 | |

EXEMPLARY CLAIM: 1
LINE COUNT: 4626
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to novel 3-(substituted)-2-indolinones compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of **protein kinases** and therefore are expected to be useful in the prevention and treatment of **protein kinase** related disorders such as **cancer**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 15966-93-5 186611-30-3 186611-31-4
186611-33-6 186611-34-7 186611-37-0
215536-87-1 215536-88-2 215536-91-7
215537-01-2 215537-24-9 215537-79-4
215543-92-3 215543-93-4 215543-94-5
215543-95-6 215543-96-7 215543-97-8
(prepn. of 3-(hetero)arylmethylidene-2-indolinone derivs. as modulators of protein kinase activity for use in treating cancer)
RN 15966-93-5 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-30-3 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-33-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-87-1 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215536-88-2 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-91-7 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 215537-01-2 USPATFULL


CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 215537-24-9 USPATFULL


CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)

dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-79-4 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-92-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-93-4 USPATFULL

CN 2H-Indol-2-one, 3-[(5-acetyl-3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 215543-94-5 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215543-95-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5,6-dimethoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 215543-96-7 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[[4-(methoxycarbonyl)benzoyl]amino]-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-97-8 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



L65 ANSWER 51 OF 70 USPATFULL

ACCESSION NUMBER: 2001:202612 USPATFULL

TITLE: Bicyclic **protein kinase** inhibitors

INVENTOR(S): Tang, Peng Cho, Moraga, CA, United States

PATENT ASSIGNEE(S): Sun, Li, Foster City, CA, United States
McMahon, Gerald, Kenwood, CA, United States
Sugen, Inc., South San Francisco, CA, United States
(U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|---------------|------|--------------|
| PATENT INFORMATION: | US 6316429 | B1 | 20011113 |
| APPLICATION INFO.: | US 1998-74621 | | 19980507 (9) |

| | NUMBER | DATE |
|-----------------------|---------------------|---------------|
| PRIORITY INFORMATION: | US 1997-45838P | 19970507 (60) |
| | US 1997-59677P | 19970919 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Raymond, Richard L. | |
| ASSISTANT EXAMINER: | Truong, Tamthom N. | |
| LEGAL REPRESENTATIVE: | Foley & Lardner | |
| NUMBER OF CLAIMS: | 10 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 3756 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to novel 3-idene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of **protein kinases** and therefore are expected to be useful in the prevention and treatment of **protein kinase** related cellular disorders such as **cancer**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5 186611-30-3 186611-31-4
186611-33-6 186611-34-7 186611-37-0
215536-87-1 215536-88-2 215536-91-7
215537-01-2 215537-24-9 215537-79-4
215543-92-3 215543-93-4 215543-94-5
215543-95-6 215543-96-7 215543-97-8
(prepn. of 3-(hetero)arylmethylidene-2-indolinone derivs. as modulators of protein kinase activity for use in treating cancer)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-33-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-87-1 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215536-88-2 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-91-7 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 215537-01-2 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-24-9 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-79-4 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-92-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-93-4 USPATFULL

CN 2H-Indol-2-one, 3-[(5-acetyl-3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 215543-94-5 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215543-95-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5,6-dimethoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 215543-96-7 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[4-(methoxycarbonyl)benzoyl]amino]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-97-8 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



L65 ANSWER 52 OF 70 USPATFULL
ACCESSION NUMBER: 2001:197055 USPATFULL
TITLE: Bioavailability of 3-heteroarylidenyl-2-indolinones
active as **protein tyrosine kinase**
inhibitors
INVENTOR(S): Tang, Peng Cho, Moraga, CA, United States
Sun, Li, Foster City, CA, United States
McMahon, Gerald, Kenwood, CA, United States
PATENT ASSIGNEE(S): Sugan, Inc., Redwood City, CA, United States (U.S.
corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6313158 | B1 | 20011106 |
| APPLICATION INFO.: | US 1998-100854 | | 19980619 (9) |


| | NUMBER | DATE |
|-----------------------|--------------------|---------------|
| PRIORITY INFORMATION: | US 1997-50412P | 19970620 (60) |
| | US 1997-59336P | 19970919 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Shah, Mukund J. | |
| ASSISTANT EXAMINER: | McKenzie, Thomas C | |
| LEGAL REPRESENTATIVE: | Foley & Lardner | |
| NUMBER OF CLAIMS: | 21 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 3273 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel 3-heteroarylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which have improved hydrosolubility and which are expected to modulate the activity of **protein tyrosine kinases** and therefore should be useful in the prevention and treatment of **protein tyrosine kinase** related cellular disorders such as **cancer**.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5 186611-30-3 186611-31-4
186611-33-6 186611-34-7 186611-37-0
215536-87-1 215536-88-2 215536-91-7
215537-01-2 215537-24-9 215537-79-4
215543-92-3 215543-93-4 215543-94-5
215543-95-6 215543-96-7 215543-97-8
(prepn. of 3-(hetero)arylmethylidene-2-indolinone derivs. as modulators
of protein kinase activity for use in treating cancer)
RN 15966-93-5 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-33-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-87-1 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215536-88-2 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-91-7 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 215537-01-2 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-24-9 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-79-4 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-92-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-93-4 USPATFULL

CN 2H-Indol-2-one, 3-[(5-acetyl-3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 215543-94-5 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215543-95-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5,6-dimethoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 215543-96-7 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[4-(methoxycarbonyl)benzoyl]amino]-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-97-8 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



L65 ANSWER 53 OF 70 USPATFULL

ACCESSION NUMBER: 2001:185487 USPATFULL

TITLE: 4-aryloxindoles

INVENTOR(S): Corbett, Wendy Lea, Randolph, NJ, United States
Luk, Kin-Chun, North Caldwell, NJ, United States
Mahaney, Paige E., Montclair, NJ, United States

PATENT ASSIGNEE(S): Hoffman-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6307056 | B1 | 20011023 |
| APPLICATION INFO.: | US 1999-464466 | | 19991215 (9) |

| | NUMBER | DATE |
|-----------------------|-----------------|---------------|
| PRIORITY INFORMATION: | US 1998-112590P | 19981217 (60) |
| | US 1999-149028P | 19990816 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: Johnston, George W., Rocha-Tramaloni, Patricia S.
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 3094

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are 4-aryloxindoles that inhibit or modulate **protein kinases**, in particular JNK **protein kinases**. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are useful as anti-inflammatory agents, particularly useful in the treatment of rheumatoid **arthritis**. Also disclosed are pharmaceutical compositions containing the foregoing compounds, as well as methods for the treatment and/or control of

inflammation, particularly in the treatment or control of rheumatoid arthritis, using said compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 276251-67-3P

(prepn. of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)

RN 276251-67-3 USPATFULL

CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L65 ANSWER 54 OF 70 USPATFULL

ACCESSION NUMBER: 2001:179279 USPATFULL

TITLE: 4-alkenyl-and 4-alkynyloxindoles

INVENTOR(S): Chen, Yi, Nutley, NJ, United States

Dermatakis, Apostolos, North Brunswick, NJ, United States

Liu, Jin-Jun, Warren, NJ, United States

Luk, Kin-Chun, North Caldwell, NJ, United States

PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 6303793 | B1 | 20011016 |
| APPLICATION INFO.: | US 2000-566054 | | 20000505 (9) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1999-464502, filed on 15 Dec 1999, now patented, Pat. No. US 6130239 | | |

| | NUMBER | DATE |
|-----------------------|-----------------|---------------|
| PRIORITY INFORMATION: | US 1998-112591P | 19981217 (60) |
| | US 1999-149073P | 19990816 (60) |

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Aulakh, C. S.

LEGAL REPRESENTATIVE: Johnston, George W., Rocha-Tramaloni, Patricia S.

NUMBER OF CLAIMS: 3

EXEMPLARY CLAIM: 1

LINE COUNT: 4113

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula ##STR1##

and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, a, b, and X are as defined herein. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular **cancer**, more particularly, the treatment or control of breast and colon **tumors**. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 275387-68-3P, (Z)-3-[(4-Acetyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-fluoro-4-iodo-2H-indol-2-one 275387-99-0P
275388-01-7P 275388-18-6P

(prepn. of 4-alkynyl-3-(pyrrolylmethylene)-2-oxoindole anti-proliferatives and analogs by reaction of alkynes with the corresponding 4-halo-2-oxoindoles)

RN 275387-68-3 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-iodo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 275387-99-0 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(2S)-2-pyrrolidinylethynyl]-, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 275388-01-7 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[[[(2S,4R)-4-hydroxy-2-pyrrolidinyl]ethynyl]-, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 275388-18-6 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-fluoro-1,2-dihydro-2-oxo-4-[(2S)-2-pyrrolidinylethynyl]-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 275387-69-4P 275387-73-0P 275387-74-1P

275387-77-4P 275387-78-5P 275388-00-6P

275388-02-8P 275388-03-9P 275388-04-0P

275388-10-8P 275388-19-7P 275388-31-3P

275388-32-4P 275388-33-5P 275388-34-6P

275388-35-7P


(prepn. of 4-alkynyl-3-(pyrrolylmethylene)-2-oxoindole

anti-proliferatives and analogs by reaction of alkynes with the corresponding 4-halo-2-oxoindoles)

RN 275387-69-4 USPATFULL


CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)ethynyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 275387-73-0 USPATFULL
 CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[3-(methoxymethyl)-1-propynyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 275387-74-1 USPATFULL
 CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[3-(methylamino)-1-propynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl


RN 275387-77-4 USPATFULL
 CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(3-hydroxy-3-pyrrolidinyl)ethynyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 275387-78-5 USPATFULL
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(3-hydroxy-3-pyrrolidinyl)ethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 275388-00-6 USPATFULL
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(2S)-2-pyrrolidinylethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 275388-02-8 USPATFULL
 CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[[[(2S,4R)-4-hydroxy-2-pyrrolidinyl]ethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



● HCl

RN 275388-03-9 USPATFULL
 CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[3-(ethylamino)-1-propynyl]-5-fluoro-1,3-dihydro-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 275388-04-0 USPATFULL
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(4-hydroxy-4-piperidinyl)ethynyl]-, monohydrochloride, (3Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 275388-10-8 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[4-[3-(ethylamino)-1-propynyl]-5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275388-19-7 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-fluoro-1,2-dihydro-2-oxo-4-[(2S)-2-pyrrolidinylethynyl]-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




● HCl

RN 275388-31-3 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[3-[(2-hydroxypropyl)amino]-1-propynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275388-32-4 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(3R,4S,5R)-4-(ethylamino)-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 275388-33-5 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(2R)-3-(ethylamino)-2-methyl-2H-pyran-6-yl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 275388-34-6 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(3R,4S,5R)-4-(ethylamino)-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI)
(CA INDEX NAME)

amino-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 275388-35-7 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(3S,4S,5R)-4-amino-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 275388-09-5P

(prepn. of 4-alkynyl-3-(pyrrolylmethylene)-2-oxoindole anti-proliferatives and analogs by reaction of alkynes with the corresponding 4-halo-2-oxoindoles)

RN 275388-09-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(5-fluoro-1,2-dihydro-4-iodo-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L65 ANSWER 55 OF 70 USPATFULL
 ACCESSION NUMBER: 2001:98105 USPATFULL
 TITLE: 4-alkenyl- and 4-alkynyloxindoles
 INVENTOR(S): Chen, Yi, Nutley, NJ, United States
 Dermatakis, Apostolos, North Brunswick, NJ, United States
 Luk, Kin-Chun, North Caldwell, NJ, United States
 PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 6252086 | B1 | 20010626 |
| APPLICATION INFO.: | US 2000-549864 | | 20000414 (9) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1999-464502, filed on 15 Dec 1999, now patented, Pat. No. US 6130239, issued on 10 Oct 2000 | | |

| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 1998-112591P | 19981217 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Higel, Floyd D. | |
| LEGAL REPRESENTATIVE: | Johnston, George W., Rocha-Tramaloni, Patricia S. | |
| NUMBER OF CLAIMS: | 24 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 4328 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula ##STR1##

and the pharmaceutically acceptable salts thereof. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular **cancer**, more particularly, the treatment or control of breast and colon **tumors**. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **275387-68-3P**, (Z)-3-[(4-Acetyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-fluoro-4-iodo-2H-indol-2-one **275387-99-0P**


275388-01-7P 275388-18-6P

(prepn. of 4-alkynyl-3-(pyrrolylmethylene)-2-oxindole anti-proliferatives and analogs by reaction of alkynes with the corresponding 4-halo-2-oxindoles)

RN **275387-68-3 USPATFULL**

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-iodo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 275387-99-0 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(2S)-2-pyrrolidinylethynyl]-, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 275388-01-7 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[[(2S,4R)-4-hydroxy-2-pyrrolidinyl]ethynyl]-, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 275388-18-6 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-fluoro-1,2-dihydro-2-oxo-4-[(2S)-2-pyrrolidinylethynyl]-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 275387-69-4P 275387-73-0P 275387-74-1P
275387-77-4P 275387-78-5P 275388-00-6P
275388-02-8P 275388-03-9P 275388-04-0P
275388-10-8P 275388-19-7P 275388-31-3P
275388-32-4P 275388-33-5P 275388-34-6P
275388-35-7P

(prepn. of 4-alkynyl-3-(pyrrolylmethylene)-2-oxoindole
anti-proliferatives and analogs by reaction of alkynes with the
corresponding 4-halo-2-oxoindoles)

RN 275387-69-4 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)ethynyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 275387-73-0 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[3-(methylamino)-1-propynyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 275387-74-1 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[3-(methylamino)-1-propynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275387-77-4 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(3-hydroxy-3-pyrrolidinyl)ethynyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 275387-78-5 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(3-hydroxy-3-pyrrolidinyl)ethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275388-00-6 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(2S)-2-pyrrolidinyldethynyl]-, monohydrochloride, (3Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




● HCl

RN 275388-02-8 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[[[(2S,4R)-4-hydroxy-2-pyrrolidinyl]ethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 275388-03-9 USPATFULL
 CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[3-(ethylamino)-1-propynyl]-5-fluoro-1,3-dihydro-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 275388-04-0 USPATFULL
 CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(4-hydroxy-4-piperidiny)ethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275388-10-8 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[4-[3-(ethylamino)-1-propynyl]-5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275388-19-7 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-fluoro-1,2-dihydro-2-oxo-4-[(2S)-2-pyrrolidinylethynyl]-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




● HCl

RN 275388-31-3 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[3-[(2-hydroxypropyl)amino]-1-propynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275388-32-4 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(3R,4S,5R)-4-(ethylamino)-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 275388-33-5 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(2R)-3-(ethylamino)-2-methyl-2H-pyran-6-yl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 275388-34-6 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(3R,4S,5R)-4-amino-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 275388-35-7 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(3S,4S,5R)-4-amino-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 275388-09-5P

(prepn. of 4-alkynyl-3-(pyrrolylmethylene)-2-oxoindole
anti-proliferatives and analogs by reaction of alkynes with the
corresponding 4-halo-2-oxoindoles)

RN 275388-09-5 USPTFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(5-fluoro-1,2-dihydro-4-iodo-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L65 ANSWER 56 OF 70 USPTFULL

ACCESSION NUMBER: 2001:75421 USPTFULL

TITLE: Methods of preventing and treating neurological
disorders with compounds that modulate the function of
the C-RET receptor **protein tyrosine**
kinase

INVENTOR(S): Clary, Douglas, San Francisco, CA, United States

PATENT ASSIGNEE(S): Sugen, Inc., Redwood City, CA, United States (U.S.
corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6235769 | B1 | 20010522 |
| APPLICATION INFO.: | US 1998-109883 | | 19980702 (9) |

| | NUMBER | DATE |
|-----------------------|----------------------|---------------|
| PRIORITY INFORMATION: | US 1997-51715P | 19970703 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Criares, Theodore J. | |
| LEGAL REPRESENTATIVE: | Foley & Lardner | |
| NUMBER OF CLAIMS: | 14 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 2371 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates in part to a method of preventing or treating an abnormal condition caused by an aberration in the function of the C-RET receptor, and specifically to the treatment and prevention of neurodegenerative disorders by administering a pharmaceutical composition that modulates the function of the C-RET receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 204003-90-7 204003-91-8 204003-96-3

204003-97-4

(study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases, and screening method)


RN 204003-90-7 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204003-91-8 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204003-96-3 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[[3,5-bis(1-methylethyl)-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-97-4 USPATFULL

CN 1H-Indole-5-propanoic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



L65 ANSWER 57 OF 70 USPATFULL

ACCESSION NUMBER: 2001:63712 USPATFULL

TITLE: 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease

INVENTOR(S): Tang, Peng Cho, Moraga, CA, United States
Sun, Li, Foster City, CA, United StatesPATENT ASSIGNEE(S): McMahon, Gerald, Kenwood, CA, United States
Sugen, Inc., Red City, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 6225335 | B1 | 20010501 |
| APPLICATION INFO.: | US 1998-212494 | | 19981215 (9) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1996-659191, filed on 5 Jun 1996, now patented, Pat. No. US 5883113 | | |
| | Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995, now patented, Pat. No. US 5880141 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Raymond, Richard L. | | |
| LEGAL REPRESENTATIVE: | Foley & Lardner | | |
| NUMBER OF CLAIMS: | 19 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 4036 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5P, SU 5408 186610-93-5P, SU 5404
186610-94-6P, SU 5406 186611-14-3P, SU 5402
186611-15-4P, SU 5403 186611-16-5P, SU 5405
186611-17-6P, SU 5407 186611-29-0P, SU 5453
186611-30-3P, SU 5454 186611-31-4P, SU 5455
186611-32-5P, SU 5456 186611-33-6P, SU 5459
186611-34-7P, SU 5460 186611-37-0P, SU 5463
186611-39-2P, SU 5465 186611-48-3P, SU 5477
186611-49-4P, SU 5478 186611-50-7P, SU 5479
186611-54-1P, SU 5613 186611-56-3P, SU 5614
186611-66-5P, SU 5625 186611-67-6P, SU 5626
204005-46-9P, SU 5416

(prepn. of indolinones capable of modulating tyrosine kinase signal transduction)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186610-93-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI)
(CA INDEX NAME)




RN 186610-94-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 186611-14-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-16-5 USPATFULL

CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 186611-17-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-29-0 USPATFULL

CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-32-5 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-diiodo-4-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-33-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-39-2 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-48-3 USPATFULL

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-49-4 USPATFULL

CN 2H-Indol-2-one, 3-[(5-ethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-50-7 USPATFULL

CN 2H-Indol-2-one, 3-[[3,5-dimethyl-4-(1-methylethenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-54-1 USPATFULL

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 186611-56-3 USPATFULL

CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-66-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-5-nitro- (9CI) (CA INDEX NAME)




RN 186611-67-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 204005-46-9 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L65 ANSWER 58 OF 70 USPATFULL

ACCESSION NUMBER: 2000:153739 USPATFULL

TITLE: Indolinone combinatorial libraries and related products and methods for the treatment of disease

INVENTOR(S): Tang, Peng Cho, Moraga, CA, United States

Sun, Li, Foster City, CA, United States

McMahon, Gerald, San Francisco, CA, United States

Hirth, Klaus Peter, San Francisco, CA, United States

Shawver, Laura Kay, San Francisco, CA, United States

PATENT ASSIGNEE(S): Sugan, Inc., South San Francisco, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|--|------|--------------|
| PATENT INFORMATION: | US 6147106 | | 20001114 |
| APPLICATION INFO.: | US 1997-915366 | | 19970820 (8) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Stockton, Laura L. | | |
| NUMBER OF CLAIMS: | 15 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 42 Drawing Figure(s); 24 Drawing Page(s) | | |
| LINE COUNT: | 5935 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting **protein kinase** signal transduction. Such compounds are useful for the treatment of diseases related to unregulated **protein kinase** signal transduction, including cell proliferative diseases such as **cancer, atherosclerosis, arthritis** and restenosis and metabolic diseases such as **diabetes**. The present invention features indolinone compounds that potentially inhibit **protein kinases** and related products and methods. Inhibitors specific to the FLK **protein kinase** can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1' position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor **protein kinases** can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety. Indolinone compounds that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate **protein kinases**. This invention also features novel hydrosoluble indolinone compounds that are tyrosine kinase inhibitors and related products and methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 203988-42-5P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203988-54-9P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203988-64-1P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203988-74-3P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203988-84-5P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203988-94-7P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203989-04-2P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203989-05-3P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203989-08-6P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203989-14-4P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203989-17-7P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203989-24-6P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203989-27-9P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203989-35-9P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203989-40-6P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203989-52-0P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203989-56-4P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203989-65-5P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203989-68-8P, 3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203989-75-7P, 3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203989-78-0P, 3-[[2-(Ethoxycarbonyl)-

3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **203989-88-2P**,
3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203989-98-4P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203990-08-3P**,
3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203990-18-5P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203990-28-7P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203990-38-9P**, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203990-48-1P**,
3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **203991-62-2P**, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203991-72-4P**,
3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203991-82-6P**, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203991-92-8P**, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203992-02-3P**, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203992-12-5P**,
3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203992-22-7P**, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **203994-35-8P**,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203994-53-0P**,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203994-72-3P**,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203994-91-6P**,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203995-11-3P**, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203995-26-0P**,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203995-36-2P**,
3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **203995-39-5P**,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203995-48-6P**,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203995-57-7P**,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203995-66-8P**,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203995-75-9P**, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203995-84-0P**, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203995-93-1P**,
3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone **203996-03-6P**,
3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone **203996-13-8P**, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone **203996-23-0P**, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone **203996-33-2P**,
3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone **203996-43-4P**, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone **203996-53-6P**, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone **203996-63-8P**

, 3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone

204003-90-7P 204003-91-8P 204003-96-3P

204003-97-4P 204004-29-5P 204004-86-4P

204004-92-2P 204004-94-4P 204005-03-8P

204005-21-0P 204005-38-9P 204005-39-0P


204005-46-9P 204005-54-9P 204005-56-1P

204005-58-3P 204005-59-4P

(prepn. and testing of indolinone combinatorial library as protein kinase inhibitors)


RN 203988-42-5 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203988-54-9 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203988-64-1 USPATFULL

CN 2H-Indol-2-one, 5-bromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 203988-74-3 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203988-84-5 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)




RN 203988-94-7 USPATFULL

CN Morpholine, 4-[[3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203989-04-2 USPATFULL

CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203989-05-3 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-08-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-14-4 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-17-7 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-24-6 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-27-9 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-35-9 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-40-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-52-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-56-4 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-65-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-68-8 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-75-7 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-78-0 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-88-2 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203989-98-4 USPATFULL

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203990-08-3 USPATFULL

CN 2H-Indol-2-one, 5-bromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 203990-18-5 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-28-7 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203990-38-9 USPATFULL

CN Morpholine, 4-[[3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203990-48-1 USPATFULL

CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203991-62-2 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203991-72-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203991-82-6 USPATFULL

CN 2H-Indol-2-one, 5-bromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 203991-92-8 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203992-02-3 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-12-5 USPATFULL

CN Morpholine, 4-[[3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203992-22-7 USPATFULL

CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203994-35-8 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203994-53-0 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203994-72-3 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-chloro-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203994-91-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-11-3 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-26-0 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-36-2 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-39-5 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-48-6 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-57-7 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-66-8 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[[1,2-dihydro-5-
[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-,
2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-75-9 USPATFULL

1H-Pyrrole-2,4-dicarboxylic acid, 5-[[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-84-0 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-93-1 USPATFULL

CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203996-03-6 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203996-13-8 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203996-23-0 USPATFULL

CN 2H-Indol-2-one, 5-bromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 203996-33-2 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203996-43-4 USPATFULL

CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203996-53-6 USPATFULL

CN Morpholine, 4-[[3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203996-63-8 USPATFULL

CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204003-90-7 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204003-91-8 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204003-96-3 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[[3,5-bis(1-methylethyl)-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204003-97-4 USPATFULL

CN 1H-Indole-5-propanoic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204004-29-5 USPATFULL

CN 2H-Indol-2-one, 5-amino-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204004-86-4 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5-amino-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204004-92-2 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204004-94-4 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204005-03-8 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204005-21-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1,2,4-trimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 204005-38-9 USPATFULL

CN 2H-Indol-2-one, 5-amino-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-39-0 USPATFULL

CN 2H-Indol-2-one, 5-amino-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-46-9 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-54-9 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 204005-56-1 USPATFULL

CN 2H-Indol-2-one, 5-amino-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-58-3 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-59-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)



L65 ANSWER 59 OF 70 USPATFULL

ACCESSION NUMBER: 2000:138391 USPATFULL

TITLE: 3-(substituted)-2-indolinones compounds and use thereof
as inhibitors of **protein kinase**
activityINVENTOR(S): Tang, Peng Cho, Moraga, CA, United States
Sun, Li, Foster City, CA, United StatesPATENT ASSIGNEE(S): McMahon, Gerald, Kenwood, CA, United States
Sugen, Inc., Redwood City, CA, United States (U.S.
corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6133305 | | 20001017 |
| APPLICATION INFO.: | US 1998-161046 | | 19980925 (9) |

| | NUMBER | DATE |
|-----------------------|-------------------|---------------|
| PRIORITY INFORMATION: | US 1997-60194P | 19970926 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | McKane, Joseph K. | |
| ASSISTANT EXAMINER: | Oswecki, Jane C. | |
| LEGAL REPRESENTATIVE: | Lyon & Lyon LLP | |
| NUMBER OF CLAIMS: | 27 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 4998 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel 3-(substituted)-2-indolinones compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of **protein kinases** and therefore are expected to be useful in the prevention and treatment of **protein kinase** related disorders such as **cancer**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5 186611-30-3 186611-31-4

186611-33-6 186611-34-7 186611-37-0

215536-87-1 215536-88-2 215536-91-7

215537-01-2 215537-24-9 215537-79-4


215543-92-3 215543-93-4 215543-94-5

215543-95-6 215543-96-7 215543-97-8

(prepn. of 3-(hetero)arylmethylidene-2-indolinone derivs. as modulators
of protein kinase activity for use in treating cancer)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-33-6 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-87-1 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215536-88-2 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-91-7 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 215537-01-2 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-24-9 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-79-4 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-92-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-93-4 USPATFULL

CN 2H-Indol-2-one, 3-[(5-acetyl-3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 215543-94-5 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215543-95-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5,6-dimethoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 215543-96-7 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-5-[[4-(methoxycarbonyl)benzoyl]amino]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-97-8 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



L65 ANSWER 60 OF 70 USPATFULL

ACCESSION NUMBER: 2000:134906 USPATFULL

TITLE: 4-Alkenyl- and 4-alkynyloxindoles

INVENTOR(S): Chen, Yi, Nutley, NJ, United States

Corbett, Wendy Lea, Randolph, NJ, United States

Dermatakis, Apostolos, North Brunswick, NJ, United States

Liu, Jin-Jun, Warren, NJ, United States

Luk, Kin-Chun, North Caldwell, NJ, United States

Mahaney, Paige E., Montclair, NJ, United States

Mischke, Steven Gregory, Florham Park, NJ, United States

PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6130239 | | 20001010 |
| APPLICATION INFO.: | US 1999-464502 | | 19991215 (9) |

| | NUMBER | DATE |
|-----------------------|-----------------|---------------|
| PRIORITY INFORMATION: | US 1998-112591P | 19981217 (60) |
| | US 1999-149073P | 19990816 (60) |

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Aulakh, Charanjit S.

LEGAL REPRESENTATIVE: Johnston, George W., Rocha-Tramaloni, Patricia S.

NUMBER OF CLAIMS: 42

EXEMPLARY CLAIM: 1

LINE COUNT: 4523

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the

formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, a, b, and X are as defined herein. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular **cancer**, more particularly, the treatment or control of breast and colon **tumors**. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 275387-68-3P, (Z)-3-[(4-Acetyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-fluoro-4-iodo-2H-indol-2-one 275387-99-0P


275388-01-7P 275388-18-6P

(prepn. of 4-alkynyl-3-(pyrrolylmethylene)-2-oxoindole anti-proliferatives and analogs by reaction of alkynes with the corresponding 4-halo-2-oxoindoles)

RN 275387-68-3 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-iodo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 275387-99-0 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(2S)-2-pyrrolidinylethynyl]-, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 275388-01-7 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[[[(2S,4R)-4-hydroxy-2-pyrrolidinyl]ethynyl]-, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 275388-18-6 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-fluoro-1,2-dihydro-2-oxo-4-[(2S)-2-pyrrolidinylethynyl]-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 275387-69-4P 275387-73-0P 275387-74-1P

275387-77-4P 275387-78-5P 275388-00-6P

275388-02-8P 275388-03-9P 275388-04-0P

275388-10-8P 275388-19-7P 275388-31-3P

275388-32-4P 275388-33-5P 275388-34-6P


275388-35-7P

(prepn. of 4-alkynyl-3-(pyrrolylmethylene)-2-oxoindole anti-proliferatives and analogs by reaction of alkynes with the corresponding 4-halo-2-oxoindoles)

RN 275387-69-4 USPATFULL


CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)ethynyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 275387-73-0 USPATFULL
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[3-(methylamino)-1-propynyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 275387-74-1 USPATFULL
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[3-(methylamino)-1-propynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl


RN 275387-77-4 USPATFULL
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(3-hydroxy-3-pyrrolidinyl)ethynyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 275387-78-5 USPATFULL
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(3-hydroxy-3-pyrrolidinyl)ethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 275388-00-6 USPATFULL
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(2S)-2-pyrrolidinylethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 275388-02-8 USPATFULL
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[[[(2S,4R)-4-hydroxy-2-pyrrolidinyl]ethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 275388-03-9 USPATFULL
CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[3-(ethylamino)-1-propynyl]-5-fluoro-1,3-dihydro-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275388-04-0 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[(4-hydroxy-4-piperidinyl)ethynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275388-10-8 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[4-[3-(ethylamino)-1-propynyl]-5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 275388-19-7 USPATFULL
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-fluoro-1,2-dihydro-2-oxo-4-[(2S)-2-pyrrolidinylethynyl]-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



● HCl

RN 275388-31-3 USPATFULL
 CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-5-fluoro-1,3-dihydro-4-[3-[(2-hydroxypropyl)amino]-1-propynyl]-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 275388-32-4 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(3R,4S,5R)-4-(ethylamino)-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 275388-33-5 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(2R)-3-(ethylamino)-2-methyl-2H-pyran-6-yl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 275388-34-6 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(3R,4S,5R)-4-

amino-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 275388-35-7 USPATFULL

CN 2H-Indol-2-one, 3-[(4-acetyl-1H-pyrrol-2-yl)methylene]-4-[(3S,4S,5R)-4-amino-3,5-dihydroxy-1-hexynyl]-5-fluoro-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 275388-09-5P

(prepn. of 4-alkynyl-3-(pyrrolylmethylene)-2-oxoindole anti-proliferatives and analogs by reaction of alkynes with the corresponding 4-halo-2-oxoindoles)

RN 275388-09-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-(5-fluoro-1,2-dihydro-4-iodo-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L65 ANSWER 61 OF 70 USPATFULL
ACCESSION NUMBER: 2000:134905 USPATFULL
TITLE: 3-(cyclohexanoheteroarylidenyl)-2-indolinone
protein tyrosine **kinase** inhibitors
INVENTOR(S): Tang, Peng Cho, Moraga, CA, United States
Sun, Li, Foster City, CA, United States
McMahon, Gerald, Kenwood, CA, United States
PATENT ASSIGNEE(S): Sugan, Inc., Redwood City, CA, United States (U.S.
corporation)

| | NUMBER | KIND | DATE |
|---------------------|---------------|------|--------------|
| PATENT INFORMATION: | US 6130238 | | 20001010 |
| APPLICATION INFO.: | US 1998-99842 | | 19980619 (9) |

| | NUMBER | DATE |
|-----------------------|-----------------|---------------|
| PRIORITY INFORMATION: | US 1997-50977P | 19970620 (60) |
| | US 1997-59544P | 19970919 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Richter, Johann | |
| ASSISTANT EXAMINER: | Dolan, John F. | |
| LEGAL REPRESENTATIVE: | Lyon & Lyon LLP | |
| NUMBER OF CLAIMS: | 20 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 5643 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel 3-(cyclohexanoheteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of **protein** tyrosine **kinases** and therefore to be useful in the prevention and treatment of **protein** tyrosine **kinase** related cellular disorders such as **cancer**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5 186611-30-3 186611-31-4

186611-33-6 186611-34-7 186611-37-0

215536-87-1 215536-88-2 215536-91-7

215537-01-2 215537-24-9 215537-79-4


215543-92-3 215543-93-4 215543-94-5

215543-95-6 215543-96-7 215543-97-8

(prepn. of 3-(hetero)arylmethylidene-2-indolinone derivs. as modulators of protein kinase activity for use in treating cancer)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-33-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-87-1 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215536-88-2 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-91-7 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 215537-01-2 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-24-9 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-79-4 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-92-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-93-4 USPATFULL

CN 2H-Indol-2-one, 3-[(5-acetyl-3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 215543-94-5 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215543-95-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5,6-dimethoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 215543-96-7 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-5-[[4-(methoxycarbonyl)benzoyl]amino]-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-97-8 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



L65 ANSWER 62 OF 70 USPATFULL

ACCESSION NUMBER: 2000:47250 USPATFULL

TITLE: 3-(cycloalkanoheteroarylidenyl)-2-indolinone
protein tyrosine kinase inhibitorsINVENTOR(S): Tang, Peng Cho, Moraga, CA, United States
Sun, Li, Foster City, CA, United States
McMahon, Gerald, Kenwood, CA, United States

PATENT ASSIGNEE(S): Sugan, Inc., Redwood City, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|---------------|------|--------------|
| PATENT INFORMATION: | US 6051593 | | 20000418 |
| APPLICATION INFO.: | US 1998-99721 | | 19980619 (9) |

| | NUMBER | DATE |
|-----------------------|----------------|---------------|
| PRIORITY INFORMATION: | US 1997-59544P | 19970919 (60) |
| | US 1997-50413P | 19970620 (60) |

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Richter, Johann

ASSISTANT EXAMINER: Oswecki, Jane C.

LEGAL REPRESENTATIVE: Lyon & Lyon LLP

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

LINE COUNT: 3421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel 3-(cycloalkanoheteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of **protein tyrosine kinases** and therefore to be useful in the prevention and treatment of **protein tyrosine kinase** related

cellular disorders such as cancer.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5 186611-30-3 186611-31-4
186611-33-6 186611-34-7 186611-37-0
215536-87-1 215536-88-2 215536-91-7
215537-01-2 215537-24-9 215537-79-4
215543-92-3 215543-93-4 215543-94-5
215543-95-6 215543-96-7 215543-97-8

(prepn. of 3-(hetero)arylmethylidene-2-indolinone derivs. as modulators of protein kinase activity for use in treating cancer)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-33-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-87-1 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215536-88-2 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215536-91-7 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 215537-01-2 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-24-9 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-79-4 USPATFULL

CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-92-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 215543-93-4 USPATFULL

CN 2H-Indol-2-one, 3-[(5-acetyl-3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 215543-94-5 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215543-95-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5,6-dimethoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 215543-96-7 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-5-[[4-(methoxycarbonyl)benzoyl]amino]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-97-8 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[[[5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



L65 ANSWER 63 OF 70 USPATFULL

ACCESSION NUMBER: 1999:99576 USPATFULL

TITLE: Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases

INVENTOR(S): Mohammadi, Moosa, New York, NY, United States
Schlessinger, Joseph, New York, NY, United States
Hubbard, Stevan R., Riverdale, NY, United States

PATENT ASSIGNEE(S): Sugen, Inc., Redwood City, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|-----------------|------|--------------|
| PATENT INFORMATION: | US 5942428 | | 19990824 |
| APPLICATION INFO.: | US 1996-701191 | | 19960821 (8) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Teng, Sally P. | | |
| LEGAL REPRESENTATIVE: | Lyon & Lyon LLP | | |


NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 31042

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Crystals of the tyrosine kinase domain of cytoplasmic tyrosine kinases and receptor tyrosine kinases that undergo ligand-mediated receptor dimerization are provided. In particular, crystals of a mutant of the tyrosine kinase domain of fibroblast growth factor receptor 1 (FLGK), alone and in complex with a non-hydrolyzable adenosine triphosphate analogue, are provided. Also provided are the high resolution three dimensional structures of crystalline FLGK, both alone and in co-complex with the adenosine triphosphate analogue, as determined by X-ray diffraction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **186611-14-3D**, complex with fibroblast growth factor receptor 1
(crystal structures of a protein tyrosine kinase)
RN 186611-14-3 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



L65 ANSWER 64 OF 70 USPATFULL

ACCESSION NUMBER: 1999:37134 USPATFULL
TITLE: 3-(4'-dimethylaminobenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease
INVENTOR(S): Tang, Peng Cho, Moraga, CA, United States
Sun, Li, Foster City, CA, United States
McMahon, Gerald, Kenwood, CA, United States
PATENT ASSIGNEE(S): Sugan, Inc., Redwood City, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 5886020 | | 19990323 |
| APPLICATION INFO.: | US 1996-655226 | | 19960605 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Raymond, Richard L. | | |
| LEGAL REPRESENTATIVE: | Lyon & Lyon LLP | | |
| NUMBER OF CLAIMS: | 45 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 4065 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT **15966-93-5P 186610-93-5P 186610-94-6P**

186610-95-7P 186611-14-3P 186611-15-4P
186611-16-5P 186611-17-6P 186611-29-0P
186611-30-3P 186611-31-4P 186611-37-0P
186611-39-2P 186611-48-3P

(prepn. of 3-benzylidene-2-indolinones as tyrosine kinase activity
modulators)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186610-93-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI)
(CA INDEX NAME)




RN 186610-94-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 186610-95-7 USPATFULL

CN 2H-Indol-2-one, 3-[(4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 186611-14-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-16-5 USPATFULL

CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 186611-17-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-29-0 USPATFULL

CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-39-2 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-48-3 USPATFULL
 CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




L65 ANSWER 65 OF 70 USPATFULL
 ACCESSION NUMBER: 1999:34018 USPATFULL
 TITLE: 3-(2'-alkoxybenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease
 INVENTOR(S): Tang, Peng Cho, Moraga, CA, United States
 Sun, Li, Foster City, CA, United States
 McMahon, Gerald, Kenwood, CA, United States
 PATENT ASSIGNEE(S): Sugan, Inc., Redwood City, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|--|---|------|--------------|
| PATENT INFORMATION: | US 5883116 | | 19990316 |
| APPLICATION INFO.: | US 1996-655224 | | 19960605 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Raymond, Richard L. | | |
| LEGAL REPRESENTATIVE: | Lyon & Lyon LLP | | |
| NUMBER OF CLAIMS: | 26 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 3816 | | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | | |
| AB | The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 15966-93-5P, SU 5408 186610-93-5P, SU 5404
 186610-94-6P, SU 5406 186611-14-3P, SU 5402
 186611-15-4P, SU 5403 186611-16-5P, SU 5405
 186611-17-6P, SU 5407 186611-29-0P, SU 5453
 186611-30-3P, SU 5454 186611-31-4P, SU 5455
 186611-37-0P, SU 5463 186611-39-2P, SU 5465
 186611-48-3P, SU 5477 204005-46-9P
 (3-(2-alkoxybenzylidene)-2-indolinones and their analogs for modulating tyrosine kinase signal transduction)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186610-93-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 186610-94-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-14-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-16-5 USPATFULL

CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 186611-17-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-29-0 USPATFULL

CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-39-2 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-48-3 USPATFULL

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-46-9 USPATFULL
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)



L65 ANSWER 66 OF 70 USPATFULL
ACCESSION NUMBER: 1999:34015 USPATFULL
TITLE: 3-(4'-Bromobenzylidene)-2-indolinone and analogues
thereof for the treatment of disease
INVENTOR(S): Tang, Peng Cho, Moraga, CA, United States
Sun, Li, Foster City, CA, United States
McMahon, Gerald, Kenwood, CA, United States
PATENT ASSIGNEE(S): Sugan, Inc., Redwood City, CA, United States (U.S.
corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 5883113 | | 19990316 |
| APPLICATION INFO.: | US 1996-659191 | | 19960605 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Raymond, Richard L. | | |
| LEGAL REPRESENTATIVE: | Lyon & Lyon LLP | | |
| NUMBER OF CLAIMS: | 27 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 3833 | | |


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to organic molecules capable of modulating
tyrosine kinase signal transduction in order to regulate, modulate
and/or inhibit abnormal cell proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5P, SU 5408 186610-93-5P, SU 5404
186610-94-6P, SU 5406 186611-14-3P, SU 5402
186611-15-4P, SU 5403 186611-16-5P, SU 5405
186611-17-6P, SU 5407 186611-29-0P, SU 5453
186611-30-3P, SU 5454 186611-31-4P, SU 5455
186611-37-0P, SU 5463 186611-48-3P, SU 5477
204005-46-9P, SU 5416
(prepn. of 3-benzylidene-2-indolinones as tyrosine kinase activity
modulators)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186610-93-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 186610-94-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-14-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-16-5 USPATFULL

CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 186611-17-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-29-0 USPATFULL

CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-48-3 USPATFULL

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-46-9 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L65 ANSWER 67 OF 70 USPATFULL

ACCESSION NUMBER: 1999:30822 USPATFULL

TITLE: Benzylidene-Z-indoline compounds for the treatment of disease

INVENTOR(S): Tang, Peng Cho, Moraga, CA, United States

Sun, Li, Foster City, CA, United States

McMahon, Gerald, Kenwood, CA, United States

PATENT ASSIGNEE(S): Sugan, Inc., Redwood City, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---------------------|------|--------------|
| PATENT INFORMATION: | US 5880141 | | 19990309 |
| APPLICATION INFO.: | US 1995-485323 | | 19950607 (8) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Raymond, Richard L. | | |
| LEGAL REPRESENTATIVE: | Lyon & Lyon LLP | | |
| NUMBER OF CLAIMS: | 7 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 2475 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5P, SU 5408 186610-93-5P, SU 5404

186610-94-6P, SU 5406 186611-14-3P, SU 5402

186611-15-4P, SU 5403 186611-16-5P, SU 5405

186611-17-6P, SU 5407 186611-29-0P, SU 5453

186611-30-3P, SU 5454 186611-31-4P, SU 5455

186611-32-5P, SU 5456 186611-33-6P, SU 5459

186611-34-7P, SU 5460 186611-37-0P, SU 5463

186611-39-2P, SU 5465 186611-48-3P, SU 5477

186611-49-4P, SU 5478 186611-50-7P, SU 5479

186611-54-1P, SU 5613 186611-56-3P, SU 5614


186611-66-5P, SU 5625 186611-67-6P, SU 5626

204005-46-9P, SU 5416

(prepn. of indolinones capable of modulating tyrosine kinase signal transduction)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186610-93-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI)
(CA INDEX NAME)




RN 186610-94-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 186611-14-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-16-5 USPATFULL

CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 186611-17-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-29-0 USPATFULL

CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-32-5 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-diiodo-4-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-33-6 USPATFULL

CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-39-2 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-48-3 USPATFULL

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-49-4 USPATFULL

CN 2H-Indol-2-one, 3-[(5-ethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-50-7 USPATFULL

CN 2H-Indol-2-one, 3-[[3,5-dimethyl-4-(1-methylethenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-54-1 USPATFULL

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 186611-56-3 USPATFULL

CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-66-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-5-nitro- (9CI) (CA INDEX NAME)




RN 186611-67-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 204005-46-9 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L65 ANSWER 68 OF 70 USPATFULL

ACCESSION NUMBER: 1998:157314 USPATFULL

TITLE: Substituted indolylmethylene-oxindole analogues as tyrosine kinase inhibitors

INVENTOR(S): Battistini, Carlo, Novate Milanese, Italy
Ballinari, Dario, S. Donato Milanese, Italy
Ermoli, Antonella, Buccinasco, Italy
Penco, Sergio, Milan, Italy

PATENT ASSIGNEE(S): Vioglio, Sergio, Cusano Milanino, Italy
Pharmacia & Upjohn S.p.A., Milan, Italy (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------------------|
| PATENT INFORMATION: | US 5849710 | | 19981215 |
| | WO 9632380 | | 19961017 |
| APPLICATION INFO.: | US 1996-750208 | | 19961204 (8) |
| | WO 1996-EP1165 | | 19960314 |
| | | | 19961204 PCT 371 date |
| | | | 19961204 PCT 102(e) date |

| | NUMBER | DATE |
|-----------------------|--------------|----------|
| PRIORITY INFORMATION: | GB 1995-7298 | 19950407 |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Oswecki, Jane C.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 1106

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to indol-3-ylmethylene-2-oxindole derivatives which are useful as tyrosine kinase inhibitors. The compounds are suitable for use as anti-proliferative agents, anti-metastatic agents, anti-cancer agents, and in the control of angiogenesis and in inhibiting the development of atheromatous and an immunomogulating agents.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 184020-79-9P

(prepn. of (indolylmethylene)oxindole analogs as tyrosine kinase inhibitors)

RN 184020-79-9 USPATFULL

CN Methanimidamide, N'-[2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



L65 ANSWER 69 OF 70 USPATFULL

ACCESSION NUMBER: 1998:138936 USPATFULL

TITLE: 3-(2'-halobenzylidenyl)-2-indolinone compounds for the treatment of disease

INVENTOR(S): Tang, Peng Cho, Moraga, CA, United States

Sun, Li, Foster City, CA, United States

McMahon, Gerald, Kenwood, CA, United States

PATENT ASSIGNEE(S): Sugan, Inc., Redwood City, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 5834504 | | 19981110 |
| APPLICATION INFO.: | US 1996-655225 | | 19960605 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Raymond, Richard L. | | |
| LEGAL REPRESENTATIVE: | Lyon & Lyon LLP | | |
| NUMBER OF CLAIMS: | 24 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 3662 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5P 186610-93-5P 186610-94-6P
186611-14-3P 186611-15-4P 186611-16-5P
186611-29-0P 186611-30-3P 186611-31-4P
186611-37-0P 186611-39-2P 186611-48-3P
204005-03-8P 204005-46-9P

(prepn. of 3-benzylidene-2-indolinones and analogs as tyrosine kinase
signal transduction modulators)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186610-93-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI)
(CA INDEX NAME)




RN 186610-94-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 186611-14-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-16-5 USPATFULL

CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 186611-29-0 USPATFULL

CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-39-2 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-48-3 USPATFULL

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-03-8 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 204005-46-9 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



L65 ANSWER 70 OF 70 USPATFULL

ACCESSION NUMBER: 1998:95556 USPATFULL

TITLE: 3-heteroaryl-2-indolinone compounds for the treatment of disease

INVENTOR(S): Tang, Peng Cho, Moraga, CA, United States

Sun, Li, Foster City, CA, United States

McMahon, Gerald, Kenwood, CA, United States

PATENT ASSIGNEE(S): Sugan, Inc., Redwood City, CA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 5792783 | | 19980811 |
| APPLICATION INFO.: | US 1996-655223 | | 19960605 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995 | | |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Raymond, Richard L. | | |
| LEGAL REPRESENTATIVE: | Lyon & Lyon LLP | | |
| NUMBER OF CLAIMS: | 28 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 3788 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 15966-93-5P 186610-93-5P 186610-94-6P
186611-14-3P 186611-15-4P 186611-16-5P
186611-17-6P 186611-29-0P 186611-30-3P
186611-31-4P 186611-37-0P 186611-39-2P
186611-48-3P 186611-56-3P 186611-67-6P
204005-46-9P

(prepn. of 3-(hetero)arylmethylene-2-indolinones as tyrosine kinase signal transduction modulators)


RN 15966-93-5 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186610-93-5 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI)
(CA INDEX NAME)




RN 186610-94-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-14-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 USPATFULL

CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-16-5 USPATFULL

CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 186611-17-6 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-29-0 USPATFULL

CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-31-4 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-37-0 USPATFULL

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-39-2 USPATFULL

CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-48-3 USPATFULL

CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-56-3 USPATFULL

CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-67-6 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 204005-46-9 USPATFULL

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



FILE 'HOME' ENTERED AT 15:04:58 ON 30 APR 2002